Pharmaceutical compositions of anti-CD20 / anti-CD3 bispecific antibodies and methods of use

By adding appropriate amounts of buffering agents, tonicity agents and surfactants to the anti-CD20/anti-CD3 bispecific antibody drug composition to control the pH range, the adsorption loss problem of antibodies during storage and administration is solved, ensuring the drug's Stability and therapeutic effects.

CN119013300APending Publication Date: 2024-11-22F HOFFMANN LA ROCHE & CO AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033318.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-13
Filing Date
2023-04-12
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing anti-CD20/anti-CD3 bispecific antibody pharmaceutical compositions are prone to loss due to protein adsorption during storage and administration, especially at low concentrations of treatment efficacy, and high viscosity problems may occur at high concentrations.

Method used

Using an anti-CD20/anti-CD3 bispecific antibody containing about 1 mg/ml to 25 mg/ml, a buffer of 10 mM to 50 mM, a tonic agent of ≥200 mM, a 0mM to 15 mM methionine and ≥0.2 mg/ml The liquid pharmaceutical composition of the surfactant has a pH range of about 5.0 to about 6.0, ensuring antibody stability and preventing adsorption loss.

Benefits of technology

Effectively maintain the stability and activity of anti-CD20/anti-CD3 bispecific antibodies, ensure that patients receive the expected dose of antibodies, reduce protein loss during storage and administration, and improve therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005077099870000411
    Figure BDA0005077099870000411
  • Figure BDA0005077099870000872
    Figure BDA0005077099870000872
  • Figure BDA0005077099870000881
    Figure BDA0005077099870000881
Patent Text Reader

Abstract

The present invention relates to pharmaceutical compositions of anti-CD20 / anti-CD3 bispecific antibodies and methods of use thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a pharmaceutical composition of an anti-CD20 / anti-CD3 bispecific antibody and a method of using the same. Background Art

[0002] One of the major challenges in the development of biotech therapeutics is protein stability, which must be maintained in the multiple process steps involved in the entry of therapeutics into the market. In addition, protein stability must be maintained during storage and during administration to patients. Therapeutic antibodies can be formulated in aqueous carriers to be administered to subjects, for example, by intravenous or subcutaneous administration. During the storage, handling and administration of such pharmaceutical compositions, it is necessary to mitigate the loss of therapeutic antibodies, which may occur through degradation and surface adsorption, such as protein adsorption to the surface of filters, storage tanks, pipelines, syringes, intravenous fluid bags and other containers. Both low-concentration and high-concentration formulations are faced with their own challenges in research and development and manufacturing processes. For example, low concentrations are greatly affected by surface adsorption, while high concentrations may show high viscosity.

[0003] In cases where a pharmaceutical composition contains a relatively low concentration of a therapeutic protein, protein loss may be significantly increased by these factors, resulting in reduced therapeutic efficacy of the pharmaceutical composition.

[0004] Therefore, there is a need in the art to develop pharmaceutical formulations in which anti-CD20 / anti-CD3 bispecific antibodies (e.g., low-dose anti-CD20 / anti-CD3 bispecific antibodies, such as low-dose anti-CD20 / anti-CD3 T cell engaging bispecific antibodies, such as glofitamab) are stable and protected from loss due to adsorption. Summary of the invention

[0005] The present invention relates to pharmaceutical compositions of anti-CD20 / anti-CD3 bispecific antibodies (e.g., anti-CD20 / anti-CD3 T cell engaging bispecific antibodies (TCBs), such as Gefituzumab, RO7082859, or RG6026) and methods of using the same. The disclosed compositions and related methods solve the problem of delivering anti-CD20 / anti-CD3 bispecific antibodies (e.g., anti-CD20 / anti-CD3 TCBs, such as Gefituzumab) formulated at low concentrations, ensuring that patients receive the intended dose of anti-CD20 / anti-CD3 bispecific antibodies (e.g., anti-CD20 / anti-CD3 TCBs, such as Gefituzumab) with little or no protein loss during storage and administration.

[0006] In one aspect, the invention features a liquid pharmaceutical composition comprising:

[0007] about 1 mg / ml to 25 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody;

[0008] about 10 mM to 50 mM buffer;

[0009] Tonicity agent of about ≥200 mM;

[0010] about 0 mM to 15 mM methionine; and

[0011] About ≥ 0.2 mg / ml of surfactant;

[0012] The pH is in the range of about 5.0 to about 6.0,

[0013] Wherein the anti-CD20 / anti-CD3 bispecific antibody comprises:

[0014] a) at least one antigen binding domain that specifically binds to CD20, comprising:

[0015] A heavy chain variable region comprising:

[0016] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;

[0017] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and

[0018] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO:3;

[0019] and a light chain variable region comprising:

[0020] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4;

[0021] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and

[0022] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and

[0023] b) at least one antigen binding domain that specifically binds to CD3, comprising:

[0024] A heavy chain variable region comprising:

[0025] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9;

[0026] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and

[0027] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO: 11; and a light chain variable region comprising:

[0028] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;

[0029] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and

[0030] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14.

[0031] In one embodiment, the concentration of the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) is in the range of about 1 mg / ml to 5 mg / ml. In one embodiment, the concentration of the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) is in the range of about 0.9 mg / ml to 1.1 mg / ml. In one embodiment, the concentration of the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) is about 1 mg / ml.

[0032] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprises:

[0033] a) at least one antigen binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8; and

[0034] b) at least one antigen binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence of SEQ ID NO: 15 and a light chain variable region sequence of SEQ ID NO: 16.

[0035] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprises:

[0036] a) a first Fab molecule that specifically binds to CD3, in particular CD3ε; and

[0037] The variable domains VL and VH of the Fab light chain and Fab heavy chain are replaced with each other;

[0038] b) a second Fab molecule and a third Fab molecule, which specifically binds to CD20, wherein in the constant domain CL of the second Fab molecule and the third Fab molecule, the amino acid at position 124 is substituted by lysine (K) (according to Kabat numbering), and the amino acid at position 123 is substituted by lysine (K) or arginine (R), in particular by arginine (R) (according to Kabat numbering), and wherein in the constant domain CH1 of the second Fab molecule and the third Fab molecule, the amino acid at position 147 is substituted by glutamic acid (E) (EU numbering), and the amino acid at position 213 is substituted by glutamic acid (E) (EU numbering); and

[0039] c) The Fc domain is composed of a first subunit and a second subunit that are capable of stable association.

[0040] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody is Gefituzumab.

[0041] In one embodiment, the buffer is a histidine buffer, optionally a histidine HCl buffer. In one embodiment, the concentration of the buffer is about 15mM to 25mM. In one embodiment, the concentration of the buffer is about 20mM. In one embodiment, the buffer provides a pH of about 5.2 to about 5.8.

[0042] In one embodiment, the tonicity agent is selected from the group consisting of salt, sugar and amino acid. In one embodiment, the tonicity agent is sucrose or sodium chloride. In one embodiment, the tonicity agent is sucrose at a concentration of about 200 mM or more. In one embodiment, the tonicity agent is sucrose at a concentration of about 200 mM to 280 mM. In one embodiment, the tonicity agent is sucrose at a concentration of about 240 mM.

[0043] In one embodiment, the concentration of methionine is about 5 mM to 15 mM.

[0044] In one embodiment, the concentration of methionine is about 10 mM. In one embodiment, the concentration of the surfactant is about 0.2 mg / ml to 0.8 mg / ml. In one embodiment, the surfactant is polysorbate 20 or poloxamer 188. In one embodiment, the surfactant is polysorbate 20 at a concentration of 0.2 mg / ml to 0.8 mg / ml. In one embodiment, the surfactant is polysorbate 20 at a concentration of about 0.5 mg / ml.

[0045] In one embodiment, the liquid pharmaceutical composition comprises:

[0046] About 1 mg / ml to 5 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprising:

[0047] a) at least one antigen binding domain that specifically binds to CD20,

[0048] It comprises: a heavy chain variable region comprising:

[0049] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;

[0050] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and

[0051] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO:3;

[0052] and a light chain variable region comprising:

[0053] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4;

[0054] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and

[0055] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and

[0056] b) at least one antigen binding domain that specifically binds to CD3,

[0057] It comprises: a heavy chain variable region comprising:

[0058] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9;

[0059] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and

[0060] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO:11;

[0061] as well as

[0062] A light chain variable region comprising:

[0063] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;

[0064] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and

[0065] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14;

[0066] About 15 mM to 25 mM histidine buffer;

[0067] about 200mM to 280mM sucrose;

[0068] about 0 mM to 15 mM methionine; and

[0069] About 0.2mg / ml to 0.8mg / ml of PS20,

[0070] The pH is from about 5 to about 6.

[0071] In one embodiment, the liquid pharmaceutical composition comprises:

[0072] About 1 mg / ml of Gefituzumab;

[0073] About 20 mM histidine buffer;

[0074] About 240 mM sucrose;

[0075] about 10 mM methionine; and

[0076] About 0.5mg / ml of PS20,

[0077] The pH was about 5.5.

[0078] In one embodiment, the present invention provides use of the liquid pharmaceutical composition of any one of the preceding aspects and embodiments for preparing a medicament useful for treating a cell proliferative disorder.

[0079] In another aspect, the invention features the pharmaceutical composition of any of the preceding aspects and embodiments for use in treating or delaying progression of a cell proliferative disorder in a subject in need thereof.

[0080] In another aspect, the invention features a pharmaceutical composition of any one of the foregoing aspects and embodiments for use in treating a cell proliferative disorder or delaying progression thereof in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of any one of the foregoing aspects and embodiments.

[0081] In certain embodiments, the cell proliferative disorder is cancer.

[0082] Another aspect of the present invention relates to the invention as described herein.

[0083] Unless the context clearly suggests otherwise, each embodiment can be combined. Each embodiment can be applied to each aspect of the invention, unless the context clearly suggests otherwise.

[0084] Specific embodiments of the invention will become apparent from the following more detailed description of certain preferred embodiments and the claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0085] The application file contains at least one drawing executed in color. Copies of this patent or patent application with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0086] Figure 1 A to Figure 1 N: Schematic diagram showing the configuration of an exemplary anti-CD20 / anti-CD3 bispecific antibody.

[0087] Figure 2 : Schematic diagram showing the structure of Gefituzumab.

[0088] Figure 3 : Formulation development GLP Tox and entry into human studies. Surfactant content of formulations F1 to F5, initially compared after 6 weeks storage at 5°C, 25°C or 40°C.

[0089] Figure 4 A to Figure 4 C: Formulation development GLP Tox and entry into human studies, Size Exclusion Chromatography (SEC) of Formulations F1 to F5, initial comparison after 6 weeks storage at 5°C, 25°C or 40°C. Figure 4 A: Main peak, Figure 4 B: high molecular weight (HMW); Figure 4 C. Low molecular weight (LMW).

[0090] Figure 5 A to Figure 5 C: Formulation development GLP Tox and entry into human studies, ion exchange chromatography (IEC) of formulations F1 to F5, initial comparison after 6 weeks storage at 5°C, 25°C or 40°C. Figure 5 A: Main peak, Figure 5 B. HMW; Figure 5 C. LMW.

[0091] Figure 6 : Formulation development - Results of analysis of Formulation F1 up to 84 weeks. F1 = 5 mg / ml RO7022859 (ie, Gefitumab), 20 mM histidine HCl pH 5.5, 240 mM sucrose, 10 mM methionine, 0.05% (w / v) polysorbate 20.

[0092] Figure 7 A to Figure 7 B: Formulation development GLP Tox and entry into human studies, huCD20 binding of formulations F1 to F5, initial comparison after 3 and 6 weeks storage at 5°C, 25°C or 40°C ( Figure 7 A) and huCD3 binding of formulations F1 to F5, initially versus after 3 and 6 weeks storage at 5°C, 25°C or 40°C ( Figure 7 B).

[0093] Figure 8 A to Figure 8 B: Phase III and commercial formulation development studies. Size exclusion (SE)-HPLC % HMWS ( Figure 8 A) and ion exchange (IE)-HPLC% acidic region ( Figure 8 B) as a function of protein concentration.

[0094] Fig. 9 A to Fig. 9 B: Phase III and commercial formulation development studies. After 6 weeks of storage at 40°C, SE-HPLC % HMWS ( Fig. 9 A) and % acidic region ( Fig. 9 B) as a function of pH and stabilizer (methionine) addition.

[0095] Fig.10 : Phase III and commercial formulation development studies. Gefituzumab SE-HPLC % HMWS (including visible particle formation) and IE-HPLC % acidic zone as a function of tonicity agent after 26 weeks of storage at 25°C.

[0096] Fig.11 A to Fig.11 B: Phase III and commercial formulation development studies. Gefituzumab SE-HPLC % HMWS (including visible particle formation) after 7 days of shaking at 25°C ( Fig.11 A) and IE-HPLC% acidic region ( Fig.11 B) as a function of surfactant.

[0097] Fig.12 : Phase III and commercial formulation development studies. Gefituzumab PS20 content [mg / ml] and visible particle formation as a function of protein concentration initially and after 104 weeks of storage at 5°C.

[0098] Fig.13 : Long-term stability data: Example of the effect of PS20 content on stability of Gefituzumab DP batches (stored at 2°C-8°C). DETAILED DESCRIPTION

[0099] The present invention relates to pharmaceutical compositions of anti-CD20 / anti-CD3 bispecific antibodies and methods of use thereof. The disclosed compositions and related methods solve the problem of delivering anti-CD20 / anti-CD3 bispecific antibodies formulated at low concentrations, ensuring that patients receive the intended dose of anti-CD20 / anti-CD3 bispecific antibodies with little or no loss of bispecific antibodies during storage and administration.

[0100] I. General Technology

[0101] Unless otherwise noted, the implementation of the present invention will adopt the conventional techniques of molecular biology (including recombinant technology), microbiology, cell biology, biochemistry and immunology, which are within the technical scope of the art. Such techniques are fully explained in the following documents, such as "Molecular Cloning: A Laboratory Manual", the 2nd edition (Sambrook et al., 1989); "Oligonucleotide Synthesis" (MJ Gait compiles, 1984); "Animal Cell Culture" (RI Freshney compiles, 1987); "Methods in Enzymology" (Academic Press, Inc.); "Current Protocols in Molecular Biology" (FM Ausubel et al. compiles, 1987, and regularly updated); "PCR: The Polymerase Chain Reaction" (Mullis et al. compiles, 1994); "A Practical Guide to Molecular Cloning" (Perbal Bernard V., 1988); "Phage Display: A Laboratory Manual" (Barbas et al., 2001).

[0102] II. Definitions

[0103] Unless otherwise defined below, the terms used herein are generally as used in the art.

[0104] Unless otherwise indicated, the term "cluster of differentiation 20" or "CD20" as used herein refers to any native CD20 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). CD20 (also known as B lymphocyte antigen CD20, B lymphocyte surface antigen B1, Leu-16, Bp35, BM5 and LF5; the human protein is characterized in the UniProt database entry P11836) is a hydrophobic transmembrane protein of approximately 35 kD expressed on pre-B and mature B lymphocytes (Valentine, MA et al., J. Biol. Chem. 264 (1989) 11282-11287; Tedder, TF et al., Proc. Natl. Acad. Sci. USA 85 (1988) 208-212; Stamenkovic, I. et al., J. Exp. Med. 167 (1988) 1975-1980; Einfeld, DA et al., EMBO J.7 (1988) 711-717; Tedder, TF et al., J.Immunol.142 (1989) 2560-2568). The corresponding human gene is transmembrane 4 domain, subfamily A member 1, also known as MS4A1. This gene encodes a member of the transmembrane 4A gene family. Members of this new protein family are characterized by common structural features and similar intron / exon splicing boundaries, and exhibit unique expression patterns in hematopoietic cells and non-lymphoid tissues. This gene encodes a B lymphocyte surface molecule that plays a role in the development and differentiation of B cells into plasma cells. This family member is located at 11q12 in a cluster of family members. The term encompasses "full-length" unprocessed CD20, as well as any form of CD20 produced by processing in the cell. The term also encompasses naturally occurring variants of CD20, such as splice variants or allelic variants. Alternative splicing of this gene produces two transcript variants encoding the same protein. In one embodiment, CD20 is human CD20.

[0105] The terms "anti-CD20 antibody" and "antibody that binds to CD20" refer to an antibody that is capable of binding to CD20 with sufficient affinity such that the antibody is useful as a diagnostic and / or therapeutic agent targeting CD20. In one embodiment, the extent of binding of the anti-CD20 antibody to unrelated, non-CD20 proteins is less than about 10% of the extent of binding of the antibody to CD20, as measured, for example, by radioimmunoassay (RIA). In certain embodiments, the antibody that binds to CD20 has a binding affinity of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10 -8 M or smaller, e.g. 10-8 M to 10 -13 M, for example 10 -9 M to 10 -13 The dissociation constant (K D In certain embodiments, the anti-CD20 antibody binds to an epitope of CD20 that is conserved in CD20 from different species.

[0106] "Type II anti-CD20 antibody" refers to an anti-CD20 antibody having the binding properties and biological activity of a Type II anti-CD20 antibody, as described in Cragg et al., Blood 103 (2004) 2738-2743; Cragg et al., Blood 101 (2003) 1045-1052, Klein et al., mAbs 5 (2013), 22-33, and summarized in Table 1 below.

[0107] Table 1. Type I and Type II anti-CD20 antibodies

[0108] Type I Anti-CD20 Antibodies Type II anti-CD20 antibodies Binds to class I CD20 epitope Binds to class II CD20 epitope Localization of CD20 to lipid rafts Does not localize CD20 to lipid rafts High CDC* Low CDC* ADCC activity* ADCC activity* Complete binding capacity to B cells About half binding capacity for B cells Weak homopolymerization Homopolymerization Low cell death induction Strong cell death induction

[0109] *If IgG1 isotype

[0110] Examples of type II anti-CD20 antibodies include, e.g., obinutuzumab (GA101), tositumomab (B1), humanized B-Ly1 antibody IgG1 (a chimeric humanized IgG1 antibody as disclosed in WO 2005 / 044859), 11B8 IgG1 (as disclosed in WO 2004 / 035607), and AT80 IgG1.

[0111] Examples of type I anti-CD20 antibodies include, e.g., rituximab, ofatumumab, veltuzumab, ocaratuzumab, ocrelizumab, PRO131921, ublituximab, HI47 IgG3 (ECACC, hybridoma), 2C6 IgG1 (as disclosed in WO 2005 / 103081), 2F2 IgG1 (as disclosed in WO 2004 / 035607 and WO 2005 / 103081), and 2H7 IgG1 (as disclosed in WO 2004 / 056312).

[0112] Unless otherwise indicated, "CD3" refers to any native CD3 from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys) and rodents (e.g., mice and rats). The term encompasses "full-length" unprocessed CD3, as well as any form of CD3 produced by processing in cells. The term also encompasses naturally occurring variants of CD3, such as splice variants or allelic variants. In one embodiment, CD3 is human CD3, in particular the epsilon subunit (CD3 epsilon) of human CD3. The amino acid sequence of human CD3 epsilon is shown in UniProt (www.uniprot.org) accession number P07766 (version 144) or NCBI (www.ncbi.nlm.nih.gov / ) RefSeq NP_000724.1. The amino acid sequence of cynomolgus monkey [Macaca fascicularis] CD3 epsilon is shown in NCBI GenBank No. BAB71849.1.

[0113] The terms "anti-CD20 / anti-CD3 antibody," "anti-CD20 / anti-CD3 bispecific antibody," and "bispecific antibody that binds to CD20 and CD3" refer to a bispecific antibody that is capable of binding to both CD20 and CD3 with sufficient affinity such that the antibody can be used as a diagnostic and / or therapeutic agent targeting CD20 and / or CD3. In one embodiment, the extent of binding of the bispecific antibody that binds to CD20 and CD3 to unrelated, non-CD3 proteins and / or non-CD20 proteins is less than about 10% of the binding of the antibody to CD3 and / or CD20, as measured by, for example, a radioimmunoassay (RIA). In certain embodiments, the anti-CD20 / anti-CD3 bispecific antibody is expressed at ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10 - 8 M or smaller, e.g. 10 -8 M to 10 -13 M, for example 10 -9 M to 10 -13 The dissociation constant (K D) binds to each of CD20 and / or CD3. In certain embodiments, the bispecific antibody that binds to CD20 and CD3 binds to a CD3 epitope conserved in CD3 from different species and / or a CD20 epitope conserved in CD20 from different species. An example of an anti-CD20 / anti-CD3 bispecific antibody is Gefituzumab (WHO Drug Information (International Nonproprietary Name of Medicinal Substances), Recommended INN: List83, 2020, Vol. 34, No. 1, p. 39, also referred to as anti-CD20 / anti-CD3 T cell engagement bispecific antibody (TCB), CD20-TCB, RO7082859 or RG6026; CAS No.: 2229047-91-8).

[0114] As used herein, the term "amino acid mutation" means that amino acid substitution, deletion, insertion and modification are covered. Any combination of substitution, deletion, insertion and modification can be performed to obtain the final construct, provided that the final construct has the desired characteristics, such as reduced binding to Fc receptors. Amino acid sequence deletions and insertions include amino terminal and / or carboxyl terminal deletions and insertions of amino acids. Specific amino acid mutations are amino acid substitutions. For the purpose of changing the binding characteristics of, for example, Fc regions, non-conservative amino acid substitutions, i.e., replacing one amino acid with another amino acid having different structural and / or chemical properties, are particularly preferred. Amino acid substitutions include substitutions with non-natural amino acids or with amino acid derivatives of twenty naturally occurring standard amino acids (e.g., 4-hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine). Amino acid mutations can be produced using genetic or chemical methods well known in the art. Genetic methods can include site-directed mutagenesis, PCR, gene synthesis, etc. It is also useful to envision methods for changing amino acid side chain groups by methods other than genetic engineering (such as chemical modification). Various names can be used herein to indicate the same amino acid mutation. For example, substitution of proline at position 329 of the Fc region with glycine can be represented as 329G, G329, G 329 , P329G or Pro329Gly.

[0115] "Affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., a receptor) and its binding partner (e.g., a ligand). Unless otherwise indicated, as used herein, "binding affinity" refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., a receptor and a ligand). The affinity of a molecule X for its partner Y can generally be expressed in terms of the dissociation constant (K D ) indicates that the dissociation constant is the sum of the dissociation rate constant and the association rate constant (k off and k on). Therefore, equivalent affinities can include different rate constants as long as the ratio of the rate constants remains the same. Affinity can be measured by well-established methods known in the art. A particular method for measuring affinity is surface plasmon resonance (SPR).

[0116] An "affinity matured" antibody is one with one or more alterations in one or more hypervariable regions (HVRs) which result in an improvement in the affinity of the antibody for antigen, compared to a parent antibody which does not possess such alterations.

[0117] As used herein, the term "antigen binding portion" refers to a polypeptide molecule that specifically binds to an antigenic determinant. In one embodiment, the antigen binding portion is capable of directing the entity to which it is connected (e.g., a cytokine or a second antigen binding portion) to a target site, such as to a specific type of tumor cell or tumor stroma with an antigenic determinant. The antigen binding portion includes antibodies and fragments thereof as further defined herein. Preferred antigen binding portions include an antigen binding domain of an antibody, which includes an antibody heavy chain variable region and an antibody light chain variable region. In certain embodiments, the antigen binding portion may include an antibody constant region as further defined herein and known in the art. Available heavy chain constant regions include any of the following five isotypes: α, δ, ε, γ or μ. Available light chain constant regions include any of the following two isotypes: κ and λ.

[0118] "Binding", "specific binding" or "specific for" means that the binding is selective for the antigen and can be distinguished from unwanted or non-specific interactions. The ability of an antigen binding moiety to bind to a specific antigenic determinant can be determined by enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to those skilled in the art, such as surface plasmon resonance (SPR) technology. Instrumental analysis) (Liljeblad et al., Glyco J. 17, 323-329 (2000))) and traditional binding assays (Heeley, Endocr Res. 28, 217-229 (2002)). In one embodiment, the extent of binding of the antigen-binding portion to an unrelated protein is less than about 10% of the extent of binding of the antigen-binding portion to the antigen, as measured, for example, by SPR. In certain embodiments, the antigen-binding portion that binds to the antigen, or an antigen-binding molecule comprising the antigen-binding portion, has a dissociation constant (K D ): ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM or ≤0.001 nM (e.g., 10 -8 M or smaller, for example, from 10 -8 M to 10 -13 M, for example, from 10 -9M to 10 -13 M).

[0119] "Decreased binding", e.g., reduced binding to an Fc receptor, refers to a decrease in affinity for the corresponding interaction, as measured, e.g., by SPR. For clarity, the term also includes a decrease in affinity to zero (or below the detection limit of the analytical method), i.e., complete elimination of the interaction. Conversely, "increased binding" refers to an increase in binding affinity for the corresponding interaction.

[0120] As used herein, the term "antigen binding molecule" in its broadest sense refers to a molecule that specifically binds to an antigenic determinant. Examples of antigen binding molecules are immunoglobulins and their derivatives, such as fragments thereof.

[0121] As used herein, the term "antigenic determinant" is synonymous with "antigen" and "epitope", and refers to a site on a polypeptide macromolecule (e.g., a continuous stretch of amino acids or a conformational configuration consisting of different regions of non-continuous amino acids), to which an antigen-binding portion binds, thereby forming an antigen-binding portion-antigen complex. Useful antigenic determinants can be found, for example, on the surface of tumor cells, on the surface of virus-infected cells, on the surface of other diseased cells, in free matter in serum and / or in the extracellular matrix (ECM). Unless otherwise indicated, the protein (e.g., CD3) referred to herein as an antigen can be any natural form of protein from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). In a specific embodiment, the antigen is a human protein. When referring to a specific protein herein, the term encompasses "full length", unprocessed protein, and any form of protein produced by intracellular processing. The term also encompasses naturally occurring protein variants, such as splice variants or allelic variants. An exemplary human protein that can be used as an antigen is CD3, in particular the epsilon subunit of CD3 (for human sequences, see UniProt No. P07766 (Release 130), NCBI RefSeq No. NP_000724.1; or for cynomolgus monkey [Macacafascicularis] sequences, UniProt No. Q95LI5 (Release 49), NCBI GenBank No. BAB71849.1). In certain embodiments, the T cell activating bispecific antigen binding molecules described herein bind to an epitope of CD3 or a target cell antigen that is conserved in CD3 or a target cell antigen from different species.

[0122] As used herein, the term "polypeptide" refers to a molecule consisting of monomers (amino acids) linearly connected by amide bonds (also referred to as peptide bonds). The term "polypeptide" refers to any chain with two or more amino acids, rather than the specific length of the product. Therefore, peptides, dipeptides, tripeptides, oligopeptides, "proteins", "amino acid chains" or any other terms used to refer to chains with two or more amino acids are included in the definition of "polypeptide", and the term "polypeptide" can be used instead of any of these terms, or can be used interchangeably with any of these terms. The term "polypeptide" is also intended to refer to the post-expression modification product of the polypeptide, and the post-expression modification includes but is not limited to glycosylation, acetylation, phosphorylation, amidation, derivatization with known protection / blocking groups, proteolytic cleavage, or modification with non-naturally occurring amino acids. The polypeptide can be derived from a natural biological source or produced by recombinant technology, and is not necessarily translated from a specified nucleic acid sequence. It can be generated in any way, including by chemical synthesis. The size of a polypeptide of the invention can be about 3 or more, 5 or more, 10 or more, 20 or more, 25 or more, 50 or more, 75 or more, 100 or more, 200 or more, 500 or more, 1,000 or more, or 2,000 or more amino acids. Polypeptides can have a defined three-dimensional structure, but they do not necessarily have such a structure. Polypeptides with a defined three-dimensional structure are referred to as folded; and polypeptides that do not have a defined three-dimensional structure, but can adopt a large number of different conformations, are referred to as unfolded.

[0123] An "isolated" polypeptide or variant or derivative thereof means a polypeptide that is not in its natural environment. No particular level of purification is required. For example, an isolated polypeptide can be removed from the polypeptide's native or natural environment. Recombinantly produced polypeptides and proteins expressed in host cells are considered isolated for purposes of the present invention, as are native or recombinant polypeptides that have been separated, fractionated, or partially or substantially purified by any suitable technique.

[0124] "Percent (%) amino acid sequence identity" relative to a reference polypeptide sequence is defined as the percentage of amino acid residues in the candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence, after aligning the candidate sequence with the reference polypeptide sequence and introducing gaps (if necessary) to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for determining percent amino acid sequence identity can be achieved in various ways within the skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithm required to achieve maximum alignment over the full length of the compared sequences. However, for the purposes of this article, the sequence comparison computer program ALIGN-2 is used to generate amino acid sequence identity values. The ALIGN-2 sequence comparison computer program is written by Genentech, Inc., and the source code has been submitted to the US Copyright Office, Washington DC, 20559, with user documentation, where it is registered with U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or can be compiled from the source code. The ALIGN-2 program should be compiled to be used in The operating system includes digital V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and are unchanged. When ALIGN-2 is used to compare amino acid sequences, the amino acid sequence identity % (which can be alternatively expressed as a given amino acid sequence A having or comprising a certain amino acid sequence identity % with or for a given amino acid sequence B) of a given amino acid sequence A is calculated as follows:

[0125] Multiply 100 by the fraction X / Y

[0126] Where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be understood that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not be equal to the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values ​​used herein are obtained using the ALIGN-2 computer program as described in the preceding paragraph.

[0127] The term "antibody" herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen-binding activity.

[0128] The terms "full length antibody," "intact antibody," and "whole antibody" are used interchangeably herein to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.

[0129] "Antibody fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody and binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, diabodies, linear antibodies, single-chain antibody molecules (e.g., scFv), and multispecific antibodies formed by antibody fragments. The term "antibody fragment" as used herein also encompasses single domain antibodies.

[0130] The term "immunoglobulin molecule" refers to a protein with the structure of a naturally occurring antibody. For example, the IgG class immunoglobulin is a heterotetrameric glycoprotein of about 150,000 daltons, which is composed of two light chains and two heavy chains bonded by disulfide bonds. From the N-terminal to the C-terminal, each heavy chain has a variable region (VH) (also referred to as a variable heavy chain domain or a heavy chain variable domain), followed by three constant domains (CH1, CH2 and CH3) (also referred to as a heavy chain constant region). Similarly, from the N-terminal to the C-terminal, each light chain has a variable region (VL) (also referred to as a variable light chain domain or a light chain variable domain), followed by a constant light chain (CL) domain (also referred to as a light chain constant region). The heavy chains of immunoglobulins can be assigned to one of five categories: called α (IgA), δ (IgD), ε (IgE), γ (IgG) or μ (IgM), some of which can be further divided into subclasses, such as γ1 (IgG1), γ2 (IgG2), γ3 (IgG3), γ4 (IgG4), α1 (IgA1) and α2 (IgA2). The light chains of immunoglobulins can be assigned to one of two types based on the amino acid sequence of their constant domains: called kappa (κ) and lambda (λ). Immunoglobulins are essentially composed of two Fab molecules and an Fc domain connected by the immunoglobulin hinge region.

[0131] The term "antigen binding domain" refers to a portion of an antibody that includes a region that specifically binds to and is complementary to part or all of an antigen. The antigen binding domain can be provided by, for example, one or more antibody variable domains (also referred to as antibody variable regions). Preferably, the antigen binding domain includes an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH).

[0132] The term "variable region" or "variable domain" refers to the domain of an antibody heavy chain or light chain that participates in the binding of an antibody to an antigen. The variable domains of the heavy and light chains of natural antibodies (VH and VL, respectively) generally have similar structures, wherein each domain comprises four conserved framework regions (FRs) and three hypervariable regions (HVRs). See, e.g., Kindt et al., Kuby Immunology, 6th edition, WH Freeman and Co., p. 91 (2007). A single VH or VL domain may be sufficient to confer antigen binding specificity.

[0133] A "human antibody" is an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody produced by a human or human cell, or derived from a non-human antibody using a full repertoire of human antibodies or other human antibody coding sequences. This definition of a human antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues.

[0134] A "humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will substantially comprise at least one, usually two, variable domains, wherein all or substantially all HVRs (e.g., CDRs) correspond to HVRs of non-human antibodies, and all or substantially all FRs correspond to FRs of human antibodies. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. An antibody in "humanized form," such as a non-human antibody, refers to an antibody that has undergone humanization.

[0135] As used herein, the term "hypervariable region" or "HVR" refers to the regions of an antibody variable domain that are hypervariable in sequence ("complementarity determining regions" or "CDRs") and / or form structurally defined loops ("hypervariable loops") and / or contain antigen contact residues ("antigen contact points"). Typically, an antibody comprises six HVRs: three in VH (H1, H2, H3) and three in VL (L1, L2, L3). Exemplary HVRs herein include:

[0136] (a) Hypervariable loops occurring at the following amino acid residues: 26 to 32 (L1), 50 to

[0137] 52 (L2), 91 to 96 (L3), 26 to 32 (H1), 53 to 55 (H2) and 96 to 101 (H3)

[0138] (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987));

[0139] (b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed. Public Health

[0140] Service, National Institutes of Health, Bethesda, MD (1991));

[0141] (c) Antigenic contact points occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al.

[0142] et al., J. Mol. Biol. 262:732-745 (1996); and

[0143] (d) a combination of (a), (b) and / or (c) comprising HVR amino acid residues 46-56 (L2),

[0144] 47-56(L2), 48-56(L2), 49-56(L2), 26-35(H1), 26-35b(H1), 49-65

[0145] (H2), 93-102(H3) and 94-102(H3).

[0146] Unless otherwise indicated, HVR residues and other residues in the variable domain (eg, FR residues) are numbered herein according to Kabat et al., supra.

[0147] "Framework" or "FR" refers to the variable domain residues other than the hypervariable region (HVR) residues. The FR of the variable domain is usually composed of the following four FR domains: FR1, FR2, FR3 and FR4. Therefore, HVR and FR sequences usually appear in the following sequence in VH (or VL): FR1-H1 (L1)-FR2-H2 (L2)-FR3-H3 (L3)-FR4.

[0148] "People's common framework" is such a framework, which represents the most commonly present amino acid residues in the selection of human immunoglobulin VL or VH framework sequences. In general, the selection of human immunoglobulin VL or VH sequences comes from a subgroup of variable domain sequences. In general, the subgroup of sequences is such as Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), Volumes 1 to 3. In one embodiment, for VL, the subgroup is such as subgroup κI in Kabat et al. (supra). In one embodiment, for VH, the subgroup is such as subgroup III in Kabat et al. (supra).

[0149] For the purposes of this article, "acceptor human framework" is a framework that includes an amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework as defined below. The acceptor human framework "derived from" a human immunoglobulin framework or a human consensus framework may include an amino acid sequence identical to the human immunoglobulin framework or a human consensus framework, or it may include amino acid sequence changes. In some embodiments, the number of amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical to the VL human immunoglobulin framework sequence or a human consensus framework sequence in sequence.

[0150] The "class" of an antibody refers to the type of constant domain or constant region possessed by the heavy chain of the antibody. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and some of these antibodies can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.

[0151] As used herein, the term IgG "isotype" or "subclass" refers to any subclass of immunoglobulins defined by the chemical and antigenic characteristics of the immunoglobulin constant region.

[0152] The term "Fc domain" or "Fc region" herein is used to define the C-terminal region of an immunoglobulin heavy chain, which contains at least a portion of a constant region. The term includes a native sequence Fc region and a variant Fc region. Although the boundaries of the IgG heavy chain Fc region may be slightly different, the human IgG heavy chain Fc region is generally defined as extending from Cys226 or from Pro230 to the carboxyl terminus of the heavy chain. However, the antibody produced by the host cell can undergo post-translational cleavage of one or more (particularly one or two) amino acids from the C-terminus of the heavy chain. Therefore, the antibody produced by the host cell by expressing a specific nucleic acid molecule encoding a full-length heavy chain may include a full-length heavy chain, or the antibody may include a cleavage variant of the full-length heavy chain (also referred to herein as "a cleaved variant heavy chain"). This may be the case where the last two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, EU numbering). Therefore, the C-terminal lysine (Lys447) or C-terminal glycine (Gly446) and lysine (K447) of the Fc region may or may not exist. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is numbered according to the EU numbering system (also referred to as the EU index), as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Edition, Public Health Service, National Institutes of Health, Bethesda, MD, 1991 (see also above). As used herein, the "subunit" of the Fc domain refers to one of the two polypeptides forming the dimeric Fc domain, i.e., a polypeptide comprising the C-terminal constant region of an immunoglobulin heavy chain, which is capable of stabilizing self-association. For example, the subunit of the IgG Fc domain comprises IgG CH2 and IgG CH3 constant domains.

[0153] "Modifications that promote the association of the first and second subunits of the Fc domain" are manipulations of the peptide backbone or post-translational modifications of the Fc domain subunits that reduce or prevent the association of a polypeptide comprising the Fc domain subunit with the same polypeptide to form a homodimer. As used herein, modifications that promote association particularly include separate modifications to each of the two Fc domain subunits (i.e., the first and second subunits of the Fc domain) that are desired to associate, wherein the modifications complement each other to promote the association of the two Fc domain subunits. For example, modifications that promote association may change the structure or charge of one or both of the Fc domain subunits so as to make their association sterically or electrostatically favorable, respectively. Thus, (heterologous) dimerization occurs between a polypeptide comprising the first Fc domain subunit and a polypeptide comprising the second Fc domain subunit, which may be different in the sense that the additional components (e.g., antigen binding moieties) fused to each subunit are inconsistent. In some embodiments, modifications that promote association include amino acid mutations, particularly amino acid substitutions, in the Fc domain. In a specific embodiment, the modifications promoting association comprise individual amino acid mutations, in particular amino acid substitutions, of each of the two subunits of the Fc domain.

[0154] "Activating Fc receptors" are Fc receptors that, upon engagement by the Fc region of an antibody, result in signaling events that stimulate cells bearing the receptor to perform effector functions. Activating Fc receptors include FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa (CD32), and FcαRI (CD89).

[0155] When used in relation to antibodies, the term "effector function" refers to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), cytokine secretion, immune complex-mediated antigen uptake by antigen-presenting cells, downregulation of cell surface receptors (e.g., B cell receptor), and B cell activation.

[0156] As used herein, the term "effector cell" refers to a population of lymphocytes that display effector moiety receptors (e.g., cytokine receptors) and / or Fc receptors on their surfaces, through which they bind to the effector moiety (e.g., cytokine) and / or Fc region of an antibody and contribute to the destruction of a target cell (e.g., a tumor cell). Effector cells may, for example, mediate cytotoxicity or phagocytosis. Effector cells include, but are not limited to, effector T cells, such as CD8 + Cytotoxic T cells, CD4 +Helper T cells, γδ T cells, NK cells, lymphokine-activated killer (LAK) cells and macrophages / monocytes.

[0157] As used herein, the terms "engineered", "engineered" and "engineered" are considered to include any manipulation of the peptide backbone, or post-translational modification of a naturally occurring or recombinant polypeptide or fragment thereof. Engineering includes modifications to the amino acid sequence, glycosylation pattern or side chain groups of individual amino acids, and combinations of these methods. "Engineering", particularly with the prefix "glyco-", and the term "glycosylation engineering", includes metabolic engineering of the glycosylation machinery of the cell, including genetic manipulation of the oligosaccharide synthesis pathway to achieve altered glycosylation of glycoproteins expressed in the cell. In addition, glycosylation engineering includes the effects of mutations and the cellular environment on glycosylation. In one embodiment, glycosylation engineering is a change in glycosyltransferase activity. In a specific embodiment, engineering results in altered glucosaminyltransferase activity and / or fucosyltransferase activity. Glycosylation engineering can be used to obtain "host cells with increased GnTIII activity" (e.g., host cells that have been manipulated to express increased levels of one or more polypeptides having β(1,4)-N-acetylglucosaminyltransferase III (GnTIII) activity), "host cells with increased ManII activity" (e.g., host cells that have been manipulated to express increased levels of one or more polypeptides having α-mannosidase II (ManII) activity), or "host cells with reduced α(1,6) fucosyltransferase activity" (e.g., host cells that have been manipulated to express reduced levels of α(1,6) fucosyltransferase).

[0158] The terms "host cell", "host cell line" and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acids have been introduced, including progeny of such cells. Host cells include "transformants" and "transformed cells", which include primary transformed cells and progeny derived from the primary transformed cells, regardless of the number of passages. Progeny may not be completely consistent with the nucleic acid content of the parent cell, but may contain mutations. This article includes mutant progeny with the same function or biological activity as screened or selected in the original transformed cells. Host cells are any type of cell system that can be used to generate proteins for the present invention. In one embodiment, the host cell is engineered to allow the production of antibodies with modified oligosaccharides. In certain embodiments, the host cell has been manipulated to express increased levels of one or more polypeptides with β (1,4) -N- acetylglucosaminyltransferase III (GnTIII) activity. In certain embodiments, the host cell has been further manipulated to express increased levels of one or more polypeptides with α-mannosidase II (ManII) activity. Host cells include cultured cells, for example cultured mammalian cells, such as CHO cells, BHK cells, NSO cells, SP2 / 0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or hybridoma cells, yeast cells, insect cells and plant cells, to name a few, and also include cells in transgenic animals, transgenic plants or cultured plant or animal tissues.

[0159] As used herein, the term "polypeptide having GnTIII activity" refers to a polypeptide capable of catalyzing the addition of an N-acetylglucosamine (GlcNAc) residue in a β-1,4 linkage to a β-linked mannoside of a trimannosyl core of an N-linked oligosaccharide. According to the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB), this includes fusion polypeptides that exhibit an enzymatic activity similar but not necessarily identical to the activity of β(1,4)-N-acetylglucosaminyltransferase III (also known as β-1,4-mannosyl-glycoprotein 4-β-N-acetylglucosaminyl-transferase (EC 2.4.1.144)), as measured in a specific bioassay, with or without dose dependence. Where dose dependence does exist, it need not be the same as GnTIII, but rather substantially similar in dose dependence in a given activity compared to GnTIII (i.e., the candidate polypeptide will exhibit greater activity or no more than about 25 times the activity, preferably no more than about ten times the activity, and most preferably no more than about three times the activity relative to GnTIII). In certain embodiments, the polypeptide having GnTIII activity is a fusion polypeptide comprising the catalytic domain of GnTIII and the Golgi localization domain of a heterologous Golgi resident polypeptide. In particular, the Golgi localization domain is the localization domain of mannosidase II or GnTI, most particularly the localization domain of mannosidase II. Alternatively, the Golgi localization domain is selected from the group consisting of the localization domain of mannosidase I, the localization domain of GnTII, and the localization domain of α1,6 core fucosyltransferase. Methods for generating such fusion polypeptides and using them to produce antibodies with increased effector function are disclosed in WO 2004 / 065540, US Provisional Patent Application No. 60 / 495,142, and US Patent Application Publication No. 2004 / 0241817, the entire contents of which are expressly incorporated herein by reference.

[0160] As used herein, the term "Golgi localization domain" refers to an amino acid sequence of a Golgi resident polypeptide that is responsible for anchoring the polypeptide to a location within the Golgi complex. Generally, the localization domain comprises the amino terminal "tail" of the enzyme.

[0161] As used herein, the term "polypeptide having ManII activity" refers to a polypeptide capable of catalyzing the hydrolysis of terminal 1,3- and 1,6-linked α-D-mannose residues in branched GlcNAcMan5GlcNAc2 mannose intermediates of N-linked oligosaccharides. According to the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB), this includes polypeptides that exhibit an enzymatic activity similar to, but not necessarily identical to, the activity of Golgi α-mannosidase II (also known as mannosyl oligosaccharide 1,3-1,6-α-mannosidase II (EC 3.2.1.114)).

[0162] Antibody-dependent cell-mediated cytotoxicity (ADCC) is an immune mechanism that causes immune effector cells to lyse antibody-coated target cells. Target cells are cells that are specifically bound by the protein portion of the N-terminus of the Fc region, usually via the antibody or fragment thereof comprising the Fc region. As used herein, the term "increased / reduced ADCC" is defined as the increase / reduction of the number of target cells lysed by the ADCC mechanism defined above at a given antibody concentration in the culture medium surrounding the target cells within a given time, and / or the reduction / increase of the antibody concentration necessary for the lysis of a given number of target cells by the ADCC mechanism in the culture medium surrounding the target cells within a given time. The increase / reduction of ADCC is relative to the use of the same standard production, purification, formulation and storage methods (such methods are known to those skilled in the art), produced by the same type of host cells but not yet engineered by the same antibody-mediated ADCC. For example, the increase of antibody-mediated ADCC produced by a host cell engineered to have a changed glycosylation pattern (e.g., expressing glycosyltransferases, GnTIII or other glycosyltransferases) by the methods described herein is relative to the same antibody-mediated ADCC produced by the same type of non-engineered host cells.

[0163] "Antibodies with increased / decreased antibody-dependent cell-mediated cytotoxicity (ADCC)" means antibodies with increased / decreased ADCC, as determined by any suitable method known to those of ordinary skill in the art. One recognized in vitro ADCC assay is as follows:

[0164] 1) The assay uses target cells known to express the target antigen recognized by the antigen binding region of the antibody;

[0165] 2) The assay uses human peripheral blood mononuclear cells (PBMCs) isolated from the blood of randomly selected healthy donors as effector cells;

[0166] 3) The assay was performed according to the following protocol:

[0167] i) PBMCs were isolated using standard density centrifugation procedures and centrifuged at 5 × 10 6 The cells were suspended in RPMI cell culture medium at a density of 10 cells / ml;

[0168] ii) Target cells were grown by standard tissue culture methods, harvested from the exponential growth phase, with cell viability above 90%, washed in RPMI cell culture medium, and treated with 100 μCi 51 Cr labeling, the cells were washed twice with cell culture medium and then incubated at 10 5 Resuspend in cell culture medium at a density of 10 cells / ml;

[0169] iii) Transfer 100 μl of the final target cell suspension to a 96-well microtiter plate.

[0170] In each hole of the fixed plate;

[0171] iv) the antibody was serially diluted from 4000 ng / ml to 0.04 ng / ml in cell culture medium, and then 50 μl of the resulting antibody solution was added to the target cells in a 96-well microtiter plate, and various antibody concentrations covering the entire concentration range were tested in triplicate;

[0172] v) For the maximum release (MR) control, three additional wells in the plate containing the labeled target cells received 50 μl of a 2% (v / v) non-ionic detergent (Nonidet, Sigma, St. Louis) in water instead of the antibody solution (point iv above);

[0173] vi) For spontaneous release (SR) controls, three additional wells in the plate containing labeled target cells received 50 μl of RPMI cell culture medium instead of antibody solution (see above).

[0174] Point iv);

[0175] vii) the 96-well microtiter plate was then centrifuged at 50×g for 1 minute and incubated at 4° C. for 1 hour;

[0176] viii) 50 μl of PBMC suspension (point i above) was added to each well to obtain an effector:target cell ratio of 25:1, and the plate was placed in a 5% CO2 atmosphere and 37°C incubator for 4 hours;

[0177] ix) harvesting the cell-free supernatant from each well and quantifying the experimentally released radioactivity (ER) using a gamma counter;

[0178] x) calculating the specific lysis percentage at each antibody concentration according to the formula (ER-MR) / (MR-SR)×100, wherein ER is the average quantitative radioactivity of the antibody concentration (see point ix above), MR is the average quantitative radioactivity of the MR control (see point v above) (see point ix above), and SR is the average quantitative radioactivity of the SR control (see point vi above) (see point ix above);

[0179] 4) "Increased / decreased ADCC" is defined as an increase / decrease in the maximum percentage of specific lysis observed within the above-tested antibody concentration range, and / or a decrease / increase in the antibody concentration required to achieve half of the maximum percentage of specific lysis observed within the above-tested antibody concentration range. The increase / decrease in ADCC is relative to ADCC measured using the above assay mediated by the same antibody produced by the same type of host cell but not engineered using the same standard production, purification, formulation and storage methods known to those skilled in the art.

[0180] The term "monoclonal antibody" as used herein refers to an antibody obtained from a substantially homogeneous antibody population, that is, except for possible variant antibodies (e.g., containing naturally occurring mutations or produced during the production of monoclonal antibody preparations, such variants are usually present in small amounts), the individual antibodies comprising the population have identity and / or bind to the same epitope. Contrary to the polyclonal antibody preparations that generally include different antibodies for different determinants (epitopes), each monoclonal antibody in the monoclonal antibody preparation is directed to a single determinant on the antigen. Therefore, the modifier "monoclonal" represents that the feature of the antibody is obtained from a substantially homogeneous antibody population, and should not be interpreted as requiring antibody to be produced by any ad hoc method. For example, the monoclonal antibody to be used according to the present invention can be prepared by a variety of techniques, including but not limited to hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of human immunoglobulin loci, such methods and other exemplary methods for preparing monoclonal antibodies are described herein.

[0181] A "naked antibody" refers to an antibody that is not conjugated to a heterologous moiety (eg, a cytotoxic moiety) or a radiolabel. Naked antibodies can be present in pharmaceutical preparations.

[0182] "Natural antibodies" refer to naturally occurring immunoglobulin molecules with different structures. For example, natural IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, consisting of two identical light chains and two identical heavy chains bonded by disulfide bonds. From the N-terminus to the C-terminus, each heavy chain has a variable region (VH), also referred to as a variable heavy chain domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from the N-terminus to the C-terminus, each light chain has a variable region (VL), also referred to as a variable light chain domain or a light chain variable domain, followed by a constant light chain (CL) domain. The light chain of an antibody can be classified into one of two types based on the amino acid sequence of its constant domain, which are called kappa (κ) and lambda (λ).

[0183] As used herein, the terms "first", "second", "third", etc., with respect to antigen binding parts or domains are used to facilitate distinction when there is more than one of each type of part or domain. Unless explicitly stated, the use of these terms is not intended to confer a particular order or orientation.

[0184] The terms "multi-specific" and "bispecific" refer to the ability of an antigen binding molecule to specifically bind to at least two different antigenic determinants. Typically, a bispecific antigen binding molecule comprises two antigen binding sites, each of which is specific for a different antigenic determinant. In certain embodiments, a bispecific antigen binding molecule is capable of simultaneously binding to two antigenic determinants, particularly two antigenic determinants expressed on two different cells.

[0185] As used herein, the term "valence" or "titer" means that there is a specific number of antigen binding sites in an antigen binding molecule. Therefore, the term "monovalently binds to an antigen" means that there is one (and no more than one) antigen binding site specific for an antigen in an antigen binding molecule.

[0186] "Antigen binding site" refers to the site of an antigen binding molecule that provides interaction with an antigen, i.e., one or more amino acid residues. For example, the antigen binding site of an antibody comprises amino acid residues from the complementarity determining region (CDR). Natural immunoglobulin molecules typically have two antigen binding sites, and Fab molecules typically have a single antigen binding site.

[0187] As used herein, "activating T cell antigen" refers to an antigenic determinant expressed by T lymphocytes, particularly cytotoxic T lymphocytes, which can induce or enhance T cell activation when interacting with an antigen binding molecule. Specifically, the interaction of an antigen binding molecule with an activating T cell antigen can induce T cell activation by triggering the signal transduction cascade of a T cell receptor complex. An exemplary activating T cell antigen is CD3. In a particular embodiment, the activating T cell antigen is CD3, particularly the epsilon subunit of CD3 (for human sequences, see UniProt numbering P07766 (version 130), NCBI RefSeq numbering NP_000724.1; or for cynomolgus monkey [Macaca fascicularis] sequences, UniProt numbering Q95LI5 (version 49), NCBI GenBank numbering BAB71849.1).

[0188] As used herein, "T cell activation" refers to one or more cellular responses of T lymphocytes, particularly cytotoxic T lymphocytes, selected from: proliferation, differentiation, cytokine secretion, cytotoxic effector molecule release, cytotoxic activity, and expression of activation markers. The T cell activation therapeutic agents used in the present invention are capable of inducing T cell activation. Suitable assays for measuring T cell activation are known in the art as described herein.

[0189] As used herein, "target cell antigen" refers to an antigenic determinant present on the surface of a target cell, which is, for example, a cell in a tumor (such as a cancer cell or a cell of a tumor stroma). In a specific embodiment, the target cell antigen is CD20, particularly human CD20 (see UniProt No. P11836).

[0190] As used herein, "B cell antigen" refers to an antigenic determinant present on the surface of B lymphocytes, particularly malignant B lymphocytes (in this case, the antigen is also referred to as a "malignant B cell antigen").

[0191] As used herein, "T cell antigen" refers to an antigenic determinant present on the surface of T lymphocytes, particularly cytotoxic T lymphocytes.

[0192] "Fab molecule" refers to a protein composed of the VH and CH1 domains of the heavy chain ("Fab heavy chain") and the VL and CL domains of the light chain ("Fab light chain") of an immunoglobulin.

[0193] "Fusion" means that the components (eg, Fab molecule and Fc domain subunit) are linked by peptide bonds, either directly or via one or more peptide linkers.

[0194] An "effective amount" of an agent refers to the amount necessary to cause a physiological change in the cells or tissues to which the agent is administered.

[0195] A "therapeutically effective amount" of an agent (e.g., a pharmaceutical composition) refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or preventive result. A therapeutically effective amount of an agent, for example, eliminates, reduces, delays, minimizes, or prevents the adverse effects of a disease.

[0196] "Therapeutic agent" means an active ingredient, e.g., a pharmaceutical composition, which is administered to a subject in an attempt to alter the natural course of the disease in the subject being treated, and may be used either prophylactically or during clinical pathology. "Immunotherapeutic agent" means a therapeutic agent administered to a subject in an attempt to restore or enhance the subject's immune response to, e.g., a tumor.

[0197] The term "pharmaceutical composition" refers to a preparation that is in a form that permits the biological activity of the active ingredients contained in the preparation to be effective, and that contains no additional components that are unacceptably toxic to a subject to which the composition would be administered.

[0198] "Pharmaceutically acceptable carrier" refers to a component of a pharmaceutical composition other than the active ingredient that is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

[0199] The terms "package insert" or "instructions for use" are used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and / or warnings concerning the use of such therapeutic products.

[0200] The term "combination therapy" as indicated herein encompasses both combined administration (wherein two or more therapeutic agents are included in the same or separate formulations) and separate administration, in which case administration of the antibodies reported herein may be carried out before, simultaneously with and / or after administration of one or more additional therapeutic agents (preferably one or more antibodies).

[0201] The so-called "cross" Fab molecule (also referred to as "Crossfab") refers to the following Fab molecules: wherein the variable domains or constant domains of the Fab heavy chain and light chain are exchanged (ie, replaced with each other), i.e., the cross Fab molecule comprises a peptide chain (VL-CH1, in the N-terminal to C-terminal direction) consisting of a light chain variable domain VL and a heavy chain constant domain 1CH1, and a peptide chain (VH-CL, in the N-terminal to C-terminal direction) consisting of a heavy chain variable domain VH and a light chain constant domain CL. For clarity, in the cross Fab molecule in which the variable domains of the Fab light chain and the variable domains of the Fab heavy chain are exchanged, the peptide chain comprising the heavy chain constant domain 1CH1 is referred to herein as the "heavy chain" of the (cross) Fab molecule. On the contrary, in the cross Fab molecule in which the constant domains of the Fab light chain and the constant domains of the Fab heavy chain are exchanged, the peptide chain comprising the heavy chain variable domain VH is referred to herein as the "heavy chain" of the (cross) Fab molecule.

[0202] In contrast, by "conventional" Fab molecules we mean Fab molecules in their native form, i.e., comprising a heavy chain consisting of a heavy chain variable domain and a constant domain (VH-CH1, in N-terminal to C-terminal direction), and a light chain consisting of a light chain variable domain and a constant domain (VL-CL, in N-terminal to C-terminal direction).

[0203] The term "polynucleotide" refers to an isolated nucleic acid molecule or construct, such as messenger RNA (mRNA), virally derived RNA, or plasmid DNA (pDNA). A polynucleotide may contain conventional phosphodiester bonds or unconventional bonds (e.g., amide bonds, such as those present in peptide nucleic acids (PNA)). The term "nucleic acid molecule" refers to any one or more nucleic acid segments, such as DNA or RNA fragments, present in a polynucleotide.

[0204] "Isolated" nucleic acid molecules or polynucleotides mean nucleic acid molecules, DNA or RNA removed from their natural environment. For example, recombinant polynucleotides encoding polypeptides contained in vectors are considered to be isolated for the purposes of the present invention. Other examples of isolated polynucleotides include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially purified) polynucleotides in solution. Isolated polynucleotides include polynucleotide molecules that are contained in cells that usually contain polynucleotide molecules, but the polynucleotide molecules are present outside the chromosome or in a chromosomal position different from its natural chromosomal position. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the present invention, as well as positive and negative strand forms and double-stranded forms. Isolated polynucleotides or nucleic acids according to the present invention further include such molecules produced by synthesis. In addition, polynucleotides or nucleic acids may be or may include regulatory elements, such as promoters, ribosome binding sites or transcription terminators.

[0205] With respect to a nucleic acid or polynucleotide having a nucleotide sequence that is at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is meant that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include mutations at up to five points per 100 nucleotides of the reference nucleotide sequence. In other words, in order to obtain a polynucleotide having a nucleotide sequence that is at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These changes in the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, or may be interspersed individually among the residues of the reference sequence, or may be interspersed in one or more consecutive groups within the reference sequence. As a practical matter, whether any particular polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the invention can be routinely determined using known computer programs such as those discussed below for polypeptides (e.g., ALIGN-2).

[0206] The term "expression cassette" refers to a recombinant or synthetically produced polynucleotide, and a series of specified nucleic acid elements that allow a specific nucleic acid to be transcribed in a target cell. The recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus or nucleic acid fragment. Typically, the recombinant expression cassette portion of the expression vector includes, in addition to other sequences, a nucleic acid sequence to be transcribed and a promoter. In certain embodiments, the expression cassette of the present invention comprises a polynucleotide sequence encoding a bispecific antigen binding molecule of the present invention or a fragment thereof.

[0207] The term "vector" or "expression vector" is synonymous with "expression construct" and refers to a DNA molecule used to introduce a specific gene into a target cell operably associated therewith and to direct the expression of the gene. The term includes vectors that are self-replicating nucleic acid structures, as well as vectors that are incorporated into the genome of a host cell into which it has been introduced. The expression vector of the present invention comprises an expression cassette. The expression vector allows transcription of a large amount of stable mRNA. Once the expression vector is inside the target cell, a ribonucleic acid molecule or protein encoded by the gene is produced by cellular transcription and / or translation mechanisms. In one embodiment, the expression vector of the present invention comprises an expression cassette comprising a polynucleotide sequence encoding a bispecific antigen binding molecule of the present invention or a fragment thereof.

[0208] As used herein, the term "about" refers to the common error range of the corresponding value that is readily known to those skilled in the art. References herein to "about" values ​​or parameters include (and describe) embodiments involving the value or parameter itself.

[0209] "B cell proliferative disorder" means a disease in which the number of B cells in a patient is increased compared to the number of B cells in healthy subjects, particularly wherein the increase in the number of B cells is a cause or hallmark of the disease. A "CD20-positive B cell proliferative disorder" is a B cell proliferative disorder in which B cells, particularly malignant B cells (in addition to normal B cells), express CD20.

[0210] Exemplary B-cell proliferative disorders include non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL; e.g., relapsed or refractory DLBCL not otherwise specified (NOS), high-grade B-cell lymphoma (HGBCL; e.g., HGBCL NOS, double-hit HGBCL, and triple-hit HGBCL), primary mediastinal large B-cell lymphoma (PMBCL), and DLBCL arising from FL (transformed FL; trFL)); follicular lymphoma (FL), including grade 1-3b FL; mantle cell lymphoma (MCL); and marginal zone lymphoma (MZL), including splenic, lymph node, or extranodal MZL. In one embodiment, the CD20-positive B-cell proliferative disorder is relapsed or refractory NHL (e.g., relapsed or refractory DLBCL, relapsed or refractory FL, or relapsed or refractory MCL).

[0211] "Refractory disease" is defined as incomplete remission to first-line therapy. In one embodiment, refractory disease is defined as no response to previous therapy or relapse within 6 months. In one embodiment, refractory disease is characterized by one or more of the following: progressive disease (PD) is the best response to first-line therapy, stable disease (SD) is the best response after at least 4 cycles of first-line therapy (e.g., 4 cycles of rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin) and prednisone (also abbreviated as R-CHOP)), or partial remission (PR) is the best response after at least 6 cycles, and residual disease or disease progression confirmed by biopsy after partial response. "Relapsed disease" is defined as complete remission to first-line therapy. In one embodiment, disease relapse is confirmed by biopsy. In one embodiment, the patient relapses or does not respond to at least two previous systemic treatment regimens (including at least one previous regimen containing anthracyclines and at least one anti-CD20 directed therapy).

[0212] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). Preferably, the individual or subject is a human. In one instance, each subject in a population of subjects is a human. In one instance, each subject in a reference population of subjects is a human.

[0213] As used herein, "treatment" (and grammatical variants thereof such as treat or treat) refers to an attempt to alter the natural course of the disease of the individual being treated, and may be performed for prevention or clinical interventions that may be performed during clinical pathology. The desired effects of treatment include, but are not limited to, preventing the occurrence or recurrence of the disease, alleviating symptoms, weakening any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, improving or alleviating the disease state, and alleviating or improving prognosis. In some embodiments, the methods of the present invention are used to delay the development of a disease or slow down the progression of a disease.

[0214] As used herein, "delaying progression" of a disorder or disease means delaying, hindering, slowing, delaying, stabilizing and / or postponing the development of a disease or disorder (e.g., a CD20-positive B-cell proliferative disorder, e.g., NHL, e.g., DLBCL). Such delays may be of varying lengths of time, depending on the medical history and / or the individual to be treated. It will be apparent to one skilled in the art that a substantial or significant delay may actually encompass prevention, as the individual will not develop the disease. For example, in advanced cancer, the development of central nervous system (CNS) metastases may be delayed.

[0215] "Reduce or inhibit" means to cause an overall reduction of, for example, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or more. For clarity, the term also includes reduction to zero (or below the detection limit of the analytical method), i.e., complete removal or elimination. In certain embodiments, reduction or inhibition may refer to the reduction or inhibition of undesirable events, such as cytokine-driven toxicity (e.g., cytokine release syndrome (CRS)), infusion-related reactions (IRR), macrophage activation syndrome (MAS), neurotoxicity, severe tumor lysis syndrome (TLS), neutropenia, thrombocytopenia, elevated liver enzymes and / or central nervous system (CNS) toxicity after treatment with an anti-CD20 / anti-CD3 bispecific antibody using the escalating dose regimen of the present invention, relative to the unchanged target dose preset administration of the bispecific antibody. In other embodiments, reduction or inhibition may refer to the effector functions of antibodies mediated by the Fc region of the antibody, such effector functions specifically including complement dependent cytotoxicity (CDC), antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). In other embodiments, reduction or inhibition may refer to the symptoms of the CD20 positive B cell proliferative disorder being treated (e.g., NHL (e.g., DLBCL), FL (e.g., relapsed and / or refractory FL or transformed FL), MCL, high grade B cell lymphoma or PMLBCL), the presence or size of metastases or the size of the primary tumor.

[0216] As used herein, "administering" means a method of giving a dose of a pharmaceutical composition of an anti-CD20 / anti-CD3 bispecific antibody to a subject. The pharmaceutical compositions described herein can be administered intravenously (eg, by intravenous infusion).

[0217] As used herein, "buffer" refers to a buffered solution that resists pH changes through the action of its acid-base conjugate components (also referred to herein as "buffers"). In some embodiments, the buffer of the present invention has a pH in the range of about 5 to about 6. Exemplary buffers for use in the present invention include, but are not limited to, histidine (e.g., histidine HCl), acetate, phosphate, succinate, or a combination thereof. In some embodiments, histidine is histidine hydrochloride (histidine HCl), histidine acetate, sodium dihydrogen phosphate, disodium hydrogen phosphate, trisodium phosphate, potassium monohydrogen phosphate, potassium dihydrogen phosphate, tripotassium phosphate, or a mixture thereof.

[0218] The pharmaceutical composition according to the present invention may also include one or more tonicity agents. The term "tonicity agent" refers to a pharmaceutical excipient for adjusting the tonicity of a preparation. The preparation may be a hypotonic, isotonic or hypertonic preparation. Isotonicity is generally associated with the osmotic pressure of a solution, which is generally relative to the osmotic pressure of human serum (about 250mOsmol / kg to 350mOsmol / kg). The preparation according to the present invention may be a hypotonic, isotonic or hypertonic preparation, but is preferably an isotonic preparation. An isotonic preparation is a liquid or a liquid reconstituted from a solid form (e.g., from a lyophilized form), and represents a solution having the same tonicity as a certain other solution such as a physiological saline solution and serum compared thereto. Suitable tonicity agents include, but are not limited to, salts such as sodium chloride or potassium chloride, glycerol, and any component selected from the group of amino acids or sugars, particularly glucose. Tonicity agents are generally used in an amount of about ≥200mM.

[0219] Among stabilizers and tonicity agents, there is a group of compounds that can act in two ways, i.e. they can be stabilizers and tonicity agents at the same time. Examples of such compounds can be found in the group consisting of sugars, amino acids, polyols, cyclodextrins, polyethylene glycols and salts. An example of a sugar that can act as both a stabilizer and a tonicity agent is trehalose.

[0220] As used herein, "surfactant" refers to a surfactant, preferably a nonionic surfactant. Examples of surfactants herein include polysorbates (e.g., polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 85); poloxamers (e.g., poloxamer 188); Sodium octyl glucoside; lauryl, myristyl, linoleyl, or stearoyl sulfobetaine; lauryl, myristyl, linoleyl, or stearoyl sarcosine; linoleyl, myristyl, or cetyl betaine; lauramidopropyl, cocamidopropyl, linoleamidopropyl, myristylpropyl, palmitamidopropyl, or isostearamidopropyl betaine (e.g., lauroyl); myristylamidopropyl, palmitamidopropyl, or isostearamidopropyl-dimethylamine; sodium methyl cocoyl or disodium methyl oleyl-taurate; and MONAQUAT TM series (Mona Industries, Inc., Paterson, NJ); polyethylene glycol, polypropylene glycol, and copolymers of ethylene glycol and propylene glycol (e.g., Type block copolymers, such as F-68); etc. In one embodiment, the surfactant herein is polysorbate 20 (PS20). In another embodiment, the surfactant herein is poloxamer 188 (P188).

[0221] "Preservative" is a compound that can be optionally included in a formulation to substantially reduce bacterial action therein, thereby promoting the production of, for example, a multi-purpose formulation. Examples of potential preservatives include octadecyl dimethyl benzyl ammonium chloride, hexamethyl ammonium chloride, benzalkonium chloride (a mixture of alkyl benzyl dimethyl ammonium chlorides, wherein the alkyl group is a long-chain compound) and benzethonium chloride. Other types of preservatives include aromatic alcohols, such as phenol, butanol and benzyl alcohol; alkyl parabens, such as methyl paraben or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol and meta-cresol. In one embodiment, the preservative herein is benzyl alcohol. In some embodiments, the formulation does not include a preservative.

[0222] A "stable" pharmaceutical composition is a pharmaceutical formulation in which the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) substantially retains its physical stability and / or chemical stability and / or biological activity during storage. Preferably, the formulation substantially retains its physical and chemical stability and its biological activity during storage (e.g., frozen storage). The storage period is generally selected based on the expected shelf life of the formulation. Various analytical techniques for measuring protein stability are available in the art and are reviewed in, for example, the following literature: Peptide and Protein Drug Delivery, 247-301, Vincent Lee, ed., Marcel Dekker, Inc., New York, NY, Pubs. (1991) and Jones, A. Adv. Drug Delivery Rev. 10: 29-90 (1993). Stability over a selected time period can be measured at a selected exposure and / or temperature. Stability can be assessed qualitatively and / or quantitatively in a variety of different ways, including assessing aggregate formation (e.g., using size exclusion chromatography, by measuring turbidity, and / or by visual inspection); assessing ROS formation (e.g., by using a light stress assay or a 2,2'-azobis(2-amidinopropane) dihydrochloride (AAPH) stress assay); assessing the stability of the anti-CD20 / anti-CD3 bispecific antibody by evaluating the formation of specific amino acid residues (e.g., Met residues of the anti-CD20 / anti-CD3 bispecific antibody (e.g., TCB, such as Gefitumab)) oxidation; assessment of charge heterogeneity by using cation exchange chromatography, image capillary isoelectric focusing (icIEF) or capillary zone electrophoresis; amino-terminal or carboxyl-terminal sequence analysis; mass spectrometry analysis; SDS-PAGE analysis to compare reduced and intact anti-CD20 / anti-CD3 bispecific antibodies; peptide mapping (e.g., trypsin or LYS-C) analysis; evaluation of the biological activity or target binding function (e.g., binding to T cells and / or B cells) of the anti-CD20 / anti-CD3 bispecific antibodies; etc. Instability may involve any one or more of the following: aggregation, deamidation (e.g., Asn deamidation), oxidation (e.g., Met oxidation and / or Trp oxidation), isomerization (e.g., Asp isomerization), cleavage / hydrolysis / fragmentation (e.g., hinge region fragmentation), succinimide formation, unpaired cysteine, N-terminal extension, C-terminal processing, glycosylation differences, etc.

[0223] The term "liquid" as used herein in connection with a formulation according to the present invention refers to a formulation that is liquid at a temperature of at least about 2°C to about 8°C at atmospheric pressure.

[0224] In this application, unless otherwise indicated, the techniques used can be found in several well-known references, such as: Molecular Cloning: A Laboratory Manual (Sambrook et al., 1989, Cold Spring Harbor Laboratory Press), PCR Protocols: A Guide to Methods and Applications (Innis et al. 1990. Academic Press, San Diego, CA) and Harlow and Lane (1988) Antibodies: A Laboratory Manual Chapter 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).

[0225] Suitably, procedures involving the use of commercially available kits and reagents are generally performed according to protocols and / or parameters defined by the manufacturer unless otherwise indicated. Therefore, before describing the methods and uses of the present invention, it should be understood that the present invention is not limited to the specific methods, protocols, cell lines, animal species or genera, constructs and reagents described, as these may of course vary. It should also be understood that the terms used herein are only for the purpose of describing specific embodiments and are not intended to limit the scope of the present invention, which will only be limited by the appended claims.

[0226] III. Pharmaceutical Compositions

[0227] The present invention provides pharmaceutical compositions comprising low concentrations of anti-CD20 / anti-CD3 bispecific antibodies (e.g., anti-CD20 / anti-CD3 TCBs, such as Gefituzumab) and uses thereof, for example, for the treatment of B cell proliferative disorders (e.g., non-Hodgkin's lymphoma NHL). The pharmaceutical compositions of the present invention can be formulated to support low concentrations of anti-CD20 / anti-CD3 bispecific antibodies (e.g., anti-CD20 / anti-CD3 TCBs, such as Gefituzumab), and are stable during storage and clinical administration without loss of protein due to adsorption. For low antibody concentrations that require further dilution and processing before clinical administration, adsorption may be an important issue and may result in low potency values. The dosage of Gefituzumab is 2.5 mg and 10 mg (step-by-step doses) and a 30 mg maintenance dose (target dose, fixed dose). Gefituzumab is intended to be administered IV after dilution in 0.9% or 0.45% sodium chloride via IV bag infusion. Dosing in the IV bag is achieved with dosing solution concentrations ranging from 0.05 mg / ml to 0.6 mg / ml.

[0228] In one embodiment, a liquid pharmaceutical composition is provided, comprising:

[0229] about 1 mg / ml to 25 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB such as gefuzumab);

[0230] about 10 mM to 50 mM buffer;

[0231] Tonicity agent of about ≥200 mM;

[0232] about 0 mM to 15 mM methionine; and

[0233] About ≥ 0.2 mg / ml of surfactant;

[0234] The pH is in the range of about 5.0 to about 6.0.

[0235] In one embodiment, a liquid pharmaceutical composition is provided, comprising:

[0236] about 5 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB such as gefuzumab);

[0237] about 10 mM to 50 mM buffer;

[0238] Tonicity agent of about ≥200 mM;

[0239] about 0 mM to 15 mM methionine; and

[0240] About ≥ 0.2 mg / ml of surfactant;

[0241] The pH is in the range of about 5.0 to about 6.0.

[0242] In one embodiment, a liquid pharmaceutical composition is provided, comprising:

[0243] about 0.9 mg / ml to 1.1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB such as gefuzumab);

[0244] about 10 mM to 50 mM buffer;

[0245] Tonicity agent of about ≥200 mM;

[0246] about 0 mM to 15 mM methionine; and

[0247] About ≥ 0.2 mg / ml of surfactant;

[0248] The pH is in the range of about 5.0 to about 6.0.

[0249] In one embodiment, a liquid pharmaceutical composition is provided, comprising:

[0250] about 1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB such as gefuzumab);

[0251] about 10 mM to 50 mM buffer;

[0252] Tonicity agent of about ≥200 mM;

[0253] about 0 mM to 15 mM methionine; and

[0254] About ≥ 0.2 mg / ml of surfactant;

[0255] The pH is in the range of about 5.0 to about 6.0.

[0256] In one embodiment, the concentration of the anti-CD20 / anti-CD3 bispecific antibody is in the range of about 1 mg / ml to 5 mg / ml. In one embodiment, the concentration of the anti-CD20 / anti-CD3 bispecific antibody is about 0.5 mg / ml, about 0.6 mg / ml, about 0.7 mg / ml, about 0.8 mg / ml, about 0.9 mg / ml, about 1 mg / ml, about 1.1 mg / ml, about 1.5 mg / ml, about 2 mg / ml, about 3 mg / ml, about 4 mg / ml, or about 5 mg / ml. In one embodiment, the concentration of the anti-CD20 / anti-CD3 bispecific antibody is about 6 mg / ml, about 7 mg / ml, about 8 mg / ml, about 9 mg / ml, about 10 mg / ml, about 11 mg / ml, about 12 mg / ml, about 13 mg / ml, about 14 mg / ml, about 15 mg / ml, about 16 mg / ml, about 17 mg / ml, about 18 mg / ml, about 19 mg / ml, about 20 mg / ml, about 21 mg / ml, about 22 mg / ml, about 23 mg / ml, about 24 mg / ml, about 25 mg / ml, about 26 mg / ml, about 27 mg / ml, about 28 mg / ml, about 29 mg / ml or about 30 mg / ml.

[0257] In one embodiment, the concentration of the anti-CD20 / anti-CD3 bispecific antibody is in the range of about 0.9 mg / ml to 1.1 mg / ml. In one embodiment, the concentration of the anti-CD20 / anti-CD3 bispecific antibody is about 1 mg / ml.

[0258] In one embodiment, the liquid pharmaceutical composition comprises an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprising at least one antigen binding domain that specifically binds to CD20, comprising: a heavy chain variable region comprising:

[0259] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;

[0260] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and

[0261] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO:3;

[0262] and a light chain variable region comprising:

[0263] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4;

[0264] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and

[0265] (iii) HVR-L3, which comprises the amino acid sequence shown in SEQ ID NO:6.

[0266] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) of the liquid pharmaceutical composition comprises at least one antigen binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 7, and a light chain variable region sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 8. In yet another embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprises at least one antigen binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8.

[0267] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, e.g., Gefituzumab) of the liquid pharmaceutical composition comprises at least one antigen binding domain that specifically binds to CD3, comprising:

[0268] A heavy chain variable region comprising:

[0269] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9;

[0270] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and

[0271] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO:11;

[0272] and a light chain variable region comprising:

[0273] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;

[0274] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and

[0275] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14.

[0276] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) of the liquid pharmaceutical composition comprises at least one antigen binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 15, and a light chain variable region sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 16. In yet another embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprises at least one antigen binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence of SEQ ID NO: 15 and a light chain variable region sequence of SEQ ID NO: 16.

[0277] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) of the liquid pharmaceutical composition comprises:

[0278] a) at least one antigen binding domain that specifically binds to CD20,

[0279] It comprises: a heavy chain variable region comprising:

[0280] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;

[0281] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and

[0282] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO:3;

[0283] and a light chain variable region comprising:

[0284] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4;

[0285] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and

[0286] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and

[0287] b) at least one antigen binding domain that specifically binds to CD3,

[0288] It comprises: a heavy chain variable region comprising:

[0289] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9;

[0290] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and

[0291] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO: 11; and a light chain variable region comprising:

[0292] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;

[0293] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and

[0294] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14.

[0295] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) of the liquid pharmaceutical composition comprises:

[0296] (i) at least one antigen binding domain that specifically binds to CD20, comprising SEQ ID

[0297] The heavy chain variable region sequence of SEQ ID NO:7 and the light chain variable region sequence of SEQ ID NO:8; and

[0298] (ii) at least one antigen binding domain that specifically binds to CD3, comprising SEQ ID NO:

[0299] The heavy chain variable region sequence of SEQ ID NO: 15 and the light chain variable region sequence of SEQ ID NO: 16.

[0300] In one embodiment, the antigen binding domain that specifically binds to CD3 of an anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) is an antibody fragment, particularly a Fab molecule or a scFv molecule, more particularly a Fab molecule. In a specific embodiment, the antigen binding domain that specifically binds to CD3 of an anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) is a crossover Fab molecule in which the variable domains or constant domains of the Fab heavy and light chains are exchanged (i.e., replaced with each other).

[0301] In one embodiment, the antigen binding domain that specifically binds to CD20 of an anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) is an antibody fragment, particularly a Fab molecule or a scFv molecule, more particularly a Fab molecule. In a specific embodiment, the antigen binding domain that specifically binds to CD20 of an anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) is a conventional Fab molecule.

[0302] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) of the liquid pharmaceutical composition comprises at least one antigen binding domain that specifically binds to CD20 and one antigen binding domain that specifically binds to CD3. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody of the liquid pharmaceutical composition comprises a first antigen binding domain that specifically binds to CD3 and a second and third antigen binding domain that specifically binds to CD20. In one embodiment, the first antigen binding domain is a cross Fab molecule, and the second and third antigen binding domains are each conventional Fab molecules. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) further comprises an Fc domain. The anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) of the liquid pharmaceutical composition may comprise modifications in the Fc region and / or antigen binding domain as described herein. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) of the liquid pharmaceutical composition comprises an IgG1 Fc domain comprising one or more amino acid substitutions that reduce binding to an Fc receptor and / or effector function. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) of the liquid pharmaceutical composition comprises an IgG1 Fc domain comprising amino acid substitutions L234A, L235A, and P329G (EU numbering).

[0303] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) of the liquid pharmaceutical composition comprises:

[0304] (i) an antigen binding domain that specifically binds to CD3, which is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain;

[0305] (ii) a first antigen binding domain that specifically binds to CD20, which is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of an antigen binding domain that specifically binds to CD3; and

[0306] (iii) a second antigen binding domain that specifically binds to CD20, which is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain.

[0307] In certain embodiments, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) of the liquid pharmaceutical composition comprises:

[0308] a) a first Fab molecule, which specifically binds to CD3, in particular CD3ε; and wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced with each other;

[0309] b) a second Fab molecule and a third Fab molecule, which specifically binds to CD20, wherein in the constant domain CL of the second Fab molecule and the third Fab molecule, the amino acid at position 124 is substituted by lysine (K) (according to Kabat numbering), and the amino acid at position 123 is substituted by lysine (K) or arginine (R), in particular by arginine (R) (according to Kabat numbering), and wherein in the constant domain CH1 of the second Fab molecule and the third Fab molecule, the amino acid at position 147 is substituted by glutamic acid (E) (EU numbering), and the amino acid at position 213 is substituted by glutamic acid (E) (EU numbering); and

[0310] c) The Fc domain is composed of a first subunit and a second subunit that are capable of stable association.

[0311] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) of the liquid pharmaceutical composition comprises two antigen binding domains that specifically bind to CD20 and one antigen binding domain that specifically binds to CD3.

[0312] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (eg, anti-CD20 / anti-CD3 TCB, such as Gefituzumab) of the liquid pharmaceutical composition is bivalent for CD20 and monovalent for CD3.

[0313] In one embodiment, the first Fab molecule under a) is fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain under c), the second Fab molecule under b) is fused at the C-terminus of the Fab heavy chain to the N-terminus of the heavy chain of the first Fab molecule under a), and the third Fab molecule under b) is fused at the C-terminus of the Fab heavy chain to the N-terminus of another subunit of the Fc domain under c). In one embodiment, the first Fab molecule under a) comprises a heavy chain variable region that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 15, and a light chain variable region that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 16.

[0314] In yet another embodiment, the first Fab molecule under a) comprises the heavy chain variable region sequence of SEQ ID NO:15 and the light chain variable region sequence of SEQ ID NO:16.

[0315] In one embodiment, the second Fab molecule and the third Fab molecule under b) each comprise a heavy chain variable region that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO:7, and a light chain variable region that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO:8.

[0316] In one embodiment, the second Fab molecule and the third Fab molecule under b) each comprise a heavy chain variable region sequence of SEQ ID NO:7 and a light chain variable region sequence of SEQ ID NO:8.

[0317] In specific embodiments, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) of the liquid pharmaceutical composition comprises a polypeptide at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 17, a polypeptide at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 18, a polypeptide at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 19, and a polypeptide at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 20. In yet another specific embodiment, the bispecific antibody comprises the polypeptide sequence of SEQ ID NO: 17, the polypeptide sequence of SEQ ID NO: 18, the polypeptide sequence of SEQ ID NO: 19, and the polypeptide sequence of SEQ ID NO: 20. In another specific embodiment, the bispecific antibody comprises one polypeptide chain comprising the amino acid sequence of SEQ ID NO: 17, one polypeptide chain comprising the amino acid sequence of SEQ ID NO: 18, one polypeptide chain comprising the amino acid sequence of SEQ ID NO: 19, and two polypeptide chains each comprising the amino acid sequence of SEQ ID NO: 20.

[0318] Specific anti-CD20 / anti-CD3 bispecific antibodies are described in PCT Publication No. WO 2016 / 020309 and European Patent Application Nos. EP15188093 and EP16169160 (each of which is herein incorporated by reference in its entirety).

[0319] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (eg, anti-CD20 / anti-CD3 TCB, such as Gefituzumab) of the liquid pharmaceutical composition specifically binds to CD3ε.

[0320] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody of the liquid pharmaceutical composition can be combined with antibody H2C (PCT Publication No. WO2008 / 119567), antibody V9 (Rodrigues et al., Int J Cancer Suppl. 7, 45-50 (1992) and U.S. Pat. No. 6,054,297), antibody FN18 (Nooij et al., Eur J Immunol. 19, 981-984 (1986)), antibody SP34 (Pessano et al., EMBO J. 4, 337-340 (1985)), antibody OKT3 (Kung et al., Science 206, 347-349 (1979)), antibody WT31 (Spits et al., J Immunol. 135, 1922 (1985)), antibody UCHT1 (Burns et al., J Immunol. 136, 1922 (1985)). Immunol. 129, 1451-1457 (1982)), antibody 7D6 (Coulie et al., Eur J Immunol. 21, 1703-1709 (1991)) or antibody Leu-4 compete for binding. In some embodiments, the anti-CD20 / anti-CD3 bispecific antibody of the liquid pharmaceutical composition may further comprise an antigen binding portion that specifically binds to CD3, such as WO 2005 / 040220, WO 2005 / 118635, WO 2007 / 042261, WO 2008 / 119567, WO 2008 / 119565, WO 2012 / 162067, WO 2013 / 158856, WO 2013 / 188693, WO 2013 / 186613, WO 2014 / 110601, WO 2014 / 145806, WO 2014 / 191113, WO 2014 / 047231, WO 2015 / 095392, WO 2015 / 181098, WO 2015 / 001085, WO 2015 / 104346, WO 2015 / 172800, WO 2016 / 020444 or WO 2016 / 014974.

[0321] In some embodiments, the anti-CD20 / anti-CD3 bispecific antibody of the liquid pharmaceutical composition may comprise an antibody or antigen-binding portion from rituximab, obinutuzumab, ocrelizumab, ofatumumab, okatuzumab, veltuzumab, and urituximab.

[0322] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody is Gefituzumab.

[0323] In some embodiments, the anti-CD20 / anti-CD3 bispecific antibodies may comprise generic, biosimilar, or incomparable biological versions of the antibodies named herein.

[0324] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody of the liquid pharmaceutical composition provided herein is Gefituzumab. Gefituzumab (WHO drug information (International Nonproprietary Name of the drug), recommended INN: List 83, 2020, Vol. 34, No. 1, p. 39, also referred to as CD20-TCB, RO7082859 or RG6026; CAS No.: 2229047-91-8) is a novel T cell binding bispecific (TCB) full-length antibody with a 2:1 molecular configuration, which can bind to CD20 on B cells bivalently and to CD3 on T cells, particularly CD3ε chain (CD3e) monovalently. Its CD3 binding region is fused to one of the CD20 binding regions in a head-to-tail form via a flexible linker. This structure gives Gefituzumab excellent in vitro efficacy relative to CD20-CD3 bispecific antibodies with other 1:1 configurations, and produces important anti-tumor efficacy in preclinical DLBCL models. CD20 Bivalent retains this potency in the presence of competing anti-CD20 antibodies, providing the opportunity for pre-treatment or combination therapy with these agents. Gefituzumab contains an engineered heterodimeric Fc region that completely removes binding to FcgR and C1q. By simultaneously binding to human CD20-expressing tumor cells and CD3e of the T cell receptor (TCR) complex on T cells, it induces tumor cell lysis in addition to T cell activation, proliferation, and cytokine release. Gefituzumab-mediated B cell lysis is CD20-specific and does not occur in the absence of CD20 expression or simultaneous binding (cross-linking) of T cells to CD20-expressing cells. In addition to killing, T cells are activated by CD3 cross-linking, which can be detected by increases in T cell activation markers (CD25 and CD69), cytokine release (IFNγ, TNFα, IL-2, IL-6, IL-10), cytotoxic granule release (granzyme B), and T cell proliferation. A schematic diagram of the molecular structure of Gefituzumab is shown in Figure 2 The sequence of Gefituzumab is summarized in Table 2.

[0325] Table 2. Sequence ID of Gefituzumab

[0326]

[0327] In certain embodiments, the buffer is histidine, acetate, phosphate, succinate, citrate or a combination thereof. In certain embodiments, histidine is histidine acetate. Alternative buffers include sodium dihydrogen phosphate, disodium hydrogen phosphate, trisodium phosphate, potassium monohydrogen phosphate, potassium dihydrogen phosphate, tripotassium phosphate or a mixture thereof. In a particular embodiment, the liquid pharmaceutical composition comprises a histidine buffer, i.e. a buffer having histidine (generally L-histidine) as a buffer. In a particular embodiment, the buffer comprises L-histidine HCl, i.e. a buffer comprising a mixture of L-histidine or L-histidine and L-histidine HCl, and pH adjustment is achieved with hydrochloric acid. L-histidine HCl buffer can be prepared by dissolving an appropriate amount of L-histidine and L-histidine hydrochloride in water, or dissolving an appropriate amount of L-histidine in water and adjusting pH to a desired value by adding hydrochloric acid.

[0328] In some cases, the concentration of the buffer (e.g., histidine, such as L-histidine HCl) is 10mM to 50mM. For example, the buffer can be 10mM to 15mM or 15mM to 20mM, such as 6mM to 18mM, 7mM to 16mM, 8mM to 15mM, or 9mM to 12mM, such as about 10mM, about 11mM, about 12mM, about 13mM, about 14mM, about 15mM, about 16mM, about 17mM, about 18mM, about 19mM or about 20mM. In particular cases, the concentration of the buffer (e.g., histidine, such as L-histidine HCl) is about 15mM to 25mM. In one embodiment, the concentration of the buffer (e.g., histidine, such as L-histidine HCl) is about 20mM.

[0329] Regardless of the buffer used, the pH can be adjusted to a value in the range of about 5.0 to about 6.0, particularly pH about 5.2 to about 5.8, with acids or bases known in the art, such as hydrochloric, acetic, phosphoric, sulfuric and citric acids, sodium hydroxide and potassium hydroxide.

[0330] The inventors of the present invention have discovered that an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprises:

[0331] a) at least one antigen binding domain that specifically binds to CD20,

[0332] It comprises: a heavy chain variable region comprising:

[0333] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;

[0334] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and

[0335] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO:3;

[0336] and a light chain variable region comprising:

[0337] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4;

[0338] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and

[0339] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and

[0340] b) at least one antigen binding domain that specifically binds to CD3,

[0341] It comprises: a heavy chain variable region comprising:

[0342] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9;

[0343] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and

[0344] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO: 11; and a light chain variable region comprising:

[0345] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;

[0346] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and

[0347] (iii) HVR-L3, which comprises the amino acid sequence of SEQ ID NO: 14, is particularly stable in a composition having a pH of about 5.2 to about 5.8. In one embodiment, the buffer provides a pH of about 5.2 to about 5.8, particularly about 5.5.

[0348] In some embodiments, the pharmaceutical composition includes a tonicity agent, such as a sugar, an amino acid, or a salt. In embodiments where the tonicity agent is a sugar, the sugar can be, for example, sucrose, glucose, glycerol, or trehalose. In particular embodiments, the sugar is sucrose, optionally D-sucrose. In some embodiments, the tonicity agent is sucrose or sodium chloride. The concentration of the tonicity agent (e.g., sugar, such as sucrose) can be at least about ≥200 mM. For example, the concentration of the tonicity agent (e.g., a sugar, such as sucrose) can be, for example, 200 mM to 220 mM, 220 mM to 240 mM, 240 mM to 260 mM, 260 mM to 280 mM, 280 mM to 300 mM, 300 mM to 320 mM, 320 mM to 340 mM, 340 mM to 360 mM, 360 mM to 380 mM, 380 mM to 400 mM, 400 mM to 420 mM, 420 mM to 4 In some embodiments, the tonicity agent is present in an amount of about 200 mM to 280 mM. In some embodiments, the tonicity agent is present in an amount of about 240 mM to 500 mM, such as 200 mM to 300 mM, such as about 200 mM, about 210 mM, about 220 mM, about 230 mM, about 240 mM, about 250 mM, about 260 mM, about 270 mM, about 280 mM, about 290 mM, about 300 mM, about 350 mM, about 400 mM, about 450 mM, or about 500 mM. In some embodiments, the tonicity agent is present in an amount of about 200 mM to 280 mM. In some embodiments, the tonicity agent is present in an amount of about 240 mM. In a specific embodiment, the tonicity agent is sucrose and is present in a concentration of at least about 200 mM, i.e., present in a concentration of about ≥ 200 mM. In other specific embodiments, the tonicity agent is sucrose (e.g., D-sucrose) and is present at a concentration of about 200 mM to 280 mM. In a specific embodiment, the tonicity agent is sucrose (e.g., D-sucrose) and is present at a concentration of about 240 mM.

[0349] In some embodiments, the liquid pharmaceutical composition comprises methionine as a stabilizer.

[0350] Any suitable concentration of the stabilizer methionine can be used. For example, in some embodiments of any of the aforementioned pharmaceutical compositions, the concentration of the stabilizer (e.g., methionine) is about 0.01 mM to about 15 mM, such as about 0.01 mM, about 0.05 mM, about 0.1 mM, about 0.2 mM, about 0.3 mM, about 0.4 mM, about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, or about 15 mM.

[0351] In certain embodiments, the concentration of methionine is about 5 mM to 15 mM. In certain embodiments, the concentration of methionine is about 10 mM.

[0352] Any pharmaceutical composition described herein may include a surfactant. Any suitable surfactant may be used. In some embodiments, the surfactant is a nonionic surfactant (e.g., polysorbate (polyoxyethylene (n) sorbitan monolaurate), poloxamer, polyoxyethylene alkyl ether, alkylphenyl polyoxyethylene ether, or a combination thereof). In some embodiments, the nonionic surfactant is a polysorbate (e.g., polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate (PS20), TWEEN For example, ultra-pure PS20 (PS20 that has been subjected to a proprietary flash chromatography process to obtain a higher purity and is available from Avantor Performance Materials, LLC (Center Valley, PA, US)) or polysorbate 80 (polyoxyethylene (20) sorbitan monooleate (PS80), such as TWEEN ; e.g., super refined PS80 (Avantor)). In certain embodiments, the polysorbate is polysorbate 20. In other embodiments, the nonionic surfactant is a poloxamer (e.g., poloxamer 188, poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol)).

[0353] The concentration of the pharmaceutical surfactant may be at least about ≥ 0.2 mg / ml, ie, a concentration of at least about ≥ 0.02% (w / v).

[0354] In some embodiments of any of the pharmaceutical compositions described herein, the concentration of the surfactant (e.g., PS20 or P188) is about 0.01% (w / v) to about 2% (w / v), for example, about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, about 0.15%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, or about 2% (w / v).

[0355] In some embodiments, the concentration of the surfactant (e.g., PS20 or P188) is about 0.1 mg / ml to 1 mg / ml, i.e., 0.01% (w / v) to about 0.1% (w / v). In some embodiments, the concentration of the surfactant (e.g., PS20 or P188) is about 0.2 mg / ml to 1 mg / ml, i.e., 0.02% (w / v) to about 0.1% (w / v). In some embodiments, the concentration of the surfactant (e.g., PS20 or P188) is about 0.2 mg / ml to 0.8 mg / ml, i.e., 0.02% (w / v) to about 0.08% (w / v). In some embodiments, the concentration of the surfactant (e.g., PS20 or P188) is about 0.5 mg / ml, i.e., 0.05% (w / v).

[0356] In certain embodiments, the surfactant is P188, and the concentration of P188 is about 0.05% (w / v), 0.07% (w / v), or 0.1% (w / v).

[0357] In certain embodiments, the surfactant is PS20, and the concentration of PS20 is at least about ≥ 0.2 mg / ml, ie, at least about ≥ 0.02% (w / v) PS20.

[0358] In a particular embodiment, the surfactant is PS20, and the concentration of PS20 is about 0.2 mg / ml to 0.8 mg / ml, i.e., about 0.02% (w / v) to about 0.08% (w / v). In a particular embodiment, the surfactant is PS20, and the concentration of PS20 is about 0.5 mg / ml, i.e., 0.05% (w / v). In a particular embodiment, the surfactant is PS20, and the concentration of PS20 is at least about ≥ 0.02% (w / v) PS20. In a particular embodiment, the surfactant is PS20, and the concentration of PS20 is about 0.02% (w / v) to about 0.08% (w / v). In a particular embodiment, the surfactant is PS20, and the concentration of PS20 is about 0.05% (w / v).

[0359] In one embodiment, the liquid pharmaceutical composition according to the present invention comprises:

[0360] About 1 mg / ml to 5 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprising:

[0361] a) at least one antigen binding domain that specifically binds to CD20,

[0362] It comprises: a heavy chain variable region comprising:

[0363] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;

[0364] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and

[0365] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO:3;

[0366] and a light chain variable region comprising:

[0367] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4;

[0368] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and

[0369] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and

[0370] b) at least one antigen binding domain that specifically binds to CD3,

[0371] It comprises: a heavy chain variable region comprising:

[0372] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9;

[0373] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and

[0374] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO: 11; and

[0375] A light chain variable region comprising:

[0376] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;

[0377] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and

[0378] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14;

[0379] About 15 mM to 25 mM histidine buffer;

[0380] about 200mM to 280mM sucrose;

[0381] about 0 mM to 15 mM methionine; and

[0382] About 0.2mg / ml to 0.8mg / ml of PS20,

[0383] The pH is from about 5 to about 6.

[0384] In one embodiment, the liquid pharmaceutical composition according to the present invention comprises:

[0385] About 1 mg / ml to 5 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprising:

[0386] a) at least one antigen binding domain that specifically binds to CD20,

[0387] It comprises: a heavy chain variable region comprising:

[0388] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;

[0389] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and

[0390] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO:3;

[0391] and a light chain variable region comprising:

[0392] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4;

[0393] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and

[0394] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and

[0395] b) at least one antigen binding domain that specifically binds to CD3,

[0396] It comprises: a heavy chain variable region comprising:

[0397] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9;

[0398] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and

[0399] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO: 11; and

[0400] A light chain variable region comprising:

[0401] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;

[0402] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and

[0403] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14;

[0404] About 15 mM to 25 mM histidine buffer;

[0405] about 200mM to 280mM sucrose;

[0406] about 0 mM to 15 mM methionine; and

[0407] About 0.2mg / ml to 0.8mg / ml of PS20,

[0408] The pH is from about 5.2 to about 5.8.

[0409] In one embodiment, the liquid pharmaceutical composition according to the present invention comprises:

[0410] About 0.9 mg / ml to 1.1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab), comprising:

[0411] a) at least one antigen binding domain that specifically binds to CD20,

[0412] It comprises: a heavy chain variable region comprising:

[0413] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;

[0414] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and

[0415] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO:3;

[0416] and a light chain variable region comprising:

[0417] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4;

[0418] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and

[0419] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and

[0420] b) at least one antigen binding domain that specifically binds to CD3,

[0421] It comprises: a heavy chain variable region comprising:

[0422] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9;

[0423] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and

[0424] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO: 11; and

[0425] A light chain variable region comprising:

[0426] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;

[0427] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and

[0428] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14;

[0429] About 15 mM to 25 mM histidine buffer;

[0430] about 200mM to 280mM sucrose;

[0431] about 0 mM to 15 mM methionine; and

[0432] About 0.2mg / ml to 0.8mg / ml of PS20,

[0433] The pH is from about 5.2 to about 5.8.

[0434] In one embodiment, the liquid pharmaceutical composition comprises:

[0435] About 1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab), comprising:

[0436] a) at least one antigen binding domain that specifically binds to CD20,

[0437] It comprises: a heavy chain variable region comprising:

[0438] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;

[0439] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and

[0440] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO:3;

[0441] and a light chain variable region comprising:

[0442] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4;

[0443] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and

[0444] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and

[0445] b) at least one antigen binding domain that specifically binds to CD3,

[0446] It comprises: a heavy chain variable region comprising:

[0447] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9;

[0448] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and

[0449] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO: 11; and

[0450] A light chain variable region comprising:

[0451] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;

[0452] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and

[0453] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14;

[0454] About 15 mM to 25 mM histidine buffer;

[0455] about 200mM to 280mM sucrose;

[0456] about 0 mM to 15 mM methionine; and

[0457] About 0.2mg / ml to 0.8mg / ml of PS20,

[0458] The pH is from about 5.2 to about 5.8.

[0459] In one embodiment, the liquid pharmaceutical composition comprises:

[0460] About 1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab), comprising:

[0461] a) at least one antigen binding domain that specifically binds to CD20,

[0462] It comprises: a heavy chain variable region comprising:

[0463] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;

[0464] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and

[0465] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO:3;

[0466] and a light chain variable region comprising:

[0467] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4;

[0468] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and

[0469] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and

[0470] b) at least one antigen binding domain that specifically binds to CD3,

[0471] It comprises: a heavy chain variable region comprising:

[0472] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9;

[0473] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and

[0474] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO: 11; and

[0475] A light chain variable region comprising:

[0476] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;

[0477] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and

[0478] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14;

[0479] About 20 mM histidine buffer;

[0480] About 240 mM sucrose;

[0481] about 10 mM methionine; and

[0482] About 0.5mg / ml of PS20,

[0483] The pH was about 5.5.

[0484] In one embodiment, the liquid pharmaceutical composition according to the present invention comprises:

[0485] About 1 mg / ml to 5 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprising:

[0486] (i) at least one antigen binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8; and

[0487] (ii) at least one antigen binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence of SEQ ID NO: 15 and a light chain variable region sequence of SEQ ID NO: 16;

[0488] About 15 mM to 25 mM histidine buffer;

[0489] about 200mM to 280mM sucrose;

[0490] about 0 mM to 15 mM methionine; and

[0491] About 0.2mg / ml to 0.8mg / ml of PS20,

[0492] The pH is from about 5.2 to about 5.8.

[0493] In one embodiment, the liquid pharmaceutical composition according to the present invention comprises:

[0494] About 0.9 mg / ml to about 1.1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody comprising:

[0495] (i) at least one antigen binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8; and

[0496] (ii) at least one antigen binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence of SEQ ID NO: 15 and a light chain variable region sequence of SEQ ID NO: 16;

[0497] About 15 mM to 25 mM histidine buffer;

[0498] about 200mM to 280mM sucrose;

[0499] about 0 mM to 15 mM methionine; and

[0500] About 0.2mg / ml to 0.8mg / ml of PS20,

[0501] The pH is from about 5.2 to about 5.8.

[0502] In one embodiment, the liquid pharmaceutical composition according to the present invention comprises:

[0503] About 1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab), comprising:

[0504] (i) at least one antigen binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8; and

[0505] (ii) at least one antigen binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence of SEQ ID NO: 15 and a light chain variable region sequence of SEQ ID NO: 16;

[0506] About 15 mM to 25 mM histidine buffer;

[0507] about 200mM to 280mM sucrose;

[0508] about 0 mM to 15 mM methionine; and

[0509] About 0.2mg / ml to 0.8mg / ml of PS20,

[0510] The pH is from about 5.2 to about 5.8.

[0511] In one embodiment, the liquid pharmaceutical composition according to the present invention comprises:

[0512] About 1 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab), comprising:

[0513] (i) at least one antigen binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8; and

[0514] (ii) at least one antigen binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence of SEQ ID NO: 15 and a light chain variable region sequence of SEQ ID NO: 16;

[0515] About 20 mM histidine buffer;

[0516] About 240 mM sucrose;

[0517] about 10 mM methionine; and

[0518] About 0.5mg / ml of PS20,

[0519] The pH was about 5.5.

[0520] In one embodiment, the liquid pharmaceutical composition according to the present invention comprises:

[0521] About 1 mg / ml to 5 mg / ml of Gefituzumab,

[0522] About 15 mM to 25 mM histidine buffer;

[0523] about 200mM to 280mM sucrose;

[0524] about 0 mM to 15 mM methionine; and

[0525] About 0.2mg / ml to 0.8mg / ml of PS20,

[0526] The pH is from about 5.2 to about 5.8.

[0527] In one embodiment, the liquid pharmaceutical composition according to the present invention comprises:

[0528] About 0.9 mg / ml to 1.1 mg / ml of Gefituzumab,

[0529] About 15 mM to 25 mM histidine buffer;

[0530] about 200mM to 280mM sucrose;

[0531] about 0 mM to 15 mM methionine; and

[0532] About 0.2mg / ml to 0.8mg / ml of PS20,

[0533] The pH is from about 5.2 to about 5.8.

[0534] In one embodiment, the liquid pharmaceutical composition according to the present invention comprises:

[0535] About 1 mg / ml of Gefituzumab;

[0536] About 15 mM to 25 mM histidine buffer;

[0537] about 200mM to 280mM sucrose;

[0538] about 0 mM to 15 mM methionine; and

[0539] About 0.2mg / ml to 0.8mg / ml of PS20,

[0540] The pH is from about 5.2 to about 5.8.

[0541] In one embodiment, the liquid pharmaceutical composition according to the present invention comprises:

[0542] About 1 mg / ml of Gefituzumab;

[0543] About 20 mM histidine buffer;

[0544] About 240 mM sucrose;

[0545] about 10 mM methionine; and

[0546] About 0.5mg / ml of PS20,

[0547] The pH was about 5.5.

[0548] The preparation may also contain adjuvants, such as preservatives, wetting agents, emulsifiers and dispersants. The presence of microorganisms can be ensured by sterilization procedures and by adding various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, sorbic acid, etc.). Preservatives are usually used in an amount of about 0.001% (w / v) to about 2% (w / v). Preservatives include, but are not limited to, ethanol, benzyl alcohol, phenol, metacresol, parachlorometacresol, methylparahydroxybenzoate or propylparahydroxybenzoate and benzalkonium chloride.

[0549] IV. Therapeutic Agents Used in the Pharmaceutical Compositions of the Invention

[0550] A. Anti-CD20 / anti-CD3 bispecific antibodies

[0551] The present invention provides novel pharmaceutical compositions of anti-CD20 / anti-CD3 bispecific antibodies (e.g., anti-CD20 / anti-CD3 T cell engaging bispecific antibodies (TCBs), such as Gefituzumab). In one embodiment, the antibody is a monoclonal antibody. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody is a polyclonal antibody. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody is a human antibody. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCBs, such as Gefituzumab) is a humanized antibody. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody is a chimeric antibody. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody is a full-length antibody. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCBs, such as Gefituzumab) is an IgG class antibody, particularly an IgG1 subclass antibody. In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (eg, anti-CD20 / anti-CD3 TCB, such as Gefituzumab) is a recombinant antibody.

[0552] In certain embodiments, the anti-CD20 / anti-CD3 bispecific antibody comprises an antibody fragment. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv and scFv fragments, as well as other fragments described below. For a review of certain antibody fragments, see Hudson et al. Nat. Med. 9:129-134 (2003). For a review of scFv fragments, see, for example, Plückthun, The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore, ed., (Springer-Verlag, New York), pp. 269-315 (1994); see also WO 93 / 16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For a discussion of Fab fragments and F(ab')2 fragments comprising salvage receptor binding epitope residues and having extended in vivo half-lives, see U.S. Pat. No. 5,869,046. In one embodiment, the antibody fragment is a Fab fragment or a scFv fragment.

[0553] Diabodies are antibody fragments with two antigen binding sites that can be bivalent or bispecific. See, e.g., EP 404,097; WO 1993 / 01161; Hudson et al., Nat. Med. 9:129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-134 (2003).

[0554] Single domain antibodies are antibody fragments that contain all or part of the heavy chain variable domain or all or part of the light chain variable domain of an antibody.In certain embodiments, the single domain antibody is a human single domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Pat. No. 6,248,516 Bl).

[0555] Antibody fragments can be prepared by a variety of techniques, including, but not limited to, proteolytic digestion of intact antibodies and production by recombinant host cells (eg, E. coli or phage), as described herein.

[0556] In certain embodiments, the anti-CD20 / anti-CD3 bispecific antibody is a chimeric antibody. Certain chimeric antibodies are described in, for example, U.S. Patent No. 4,816,567 and Morrison et al., Proc. Natl. Acad. Sci. USA, 81: 6851-6855 (1984). In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate (such as a monkey)) and a human constant region. In another example, a chimeric antibody is a "class-switched" antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.

[0557] In certain embodiments, anti-CD20 / anti-CD3 bispecific antibodies are humanized antibodies. Typically, non-human antibodies are humanized to reduce immunogenicity to humans while retaining the specificity and affinity of the parent non-human antibody. Typically, humanized antibodies include one or more variable domains, wherein HVR, such as CDR (or a portion thereof) is derived from a non-human antibody, and FR (or a portion thereof) is derived from a human antibody sequence. Humanized antibodies will optionally also include at least a portion of a human constant region. In certain embodiments, some FR residues in humanized antibodies are replaced by corresponding residues from non-human antibodies (e.g., antibodies from which HVR residues are derived), for example to restore or improve antibody specificity or affinity.

[0558] Humanized antibodies and methods for their preparation are reviewed, e.g., in Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008), and further described, e.g., in Riechmann et al., Nature 332:323-329 (1988); Queen et al., Proc. Nat'l Acad. Sci. USA 86:10029-10033 (1989); U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri et al., Methods 36:25-34 (2005) (describing specificity determining region (SDR) grafting); Padlan, Mol. Immunol. 28:489-498 (1991) (describing "resurfacing"); Dall'Acqua et al., Methods 36:25-34 (2005) (describing specificity determining region (SDR) grafting); Padlan, Mol. Immunol. 28:489-498 (1991) (describing "resurfacing"); Dall'Acqua et al., Methods 36:25-34 (2005) (describing specificity determining region (SDR) grafting); 36:43-60 (2005) (describing "FR shuffling"); and Osbourn et al., Methods 36:61-68 (2005) and Klimka et al., Br. J. Cancer, 83:252-260 (2000) (describing the "guided selection" method for FR shuffling).

[0559] Human framework regions that can be used for humanization include, but are not limited to, framework regions selected using the "best match" method (see, e.g., Sims et al. J. Immunol. 151:2296 (1993)); framework regions derived from the consensus sequence of human antibodies having a particular subgroup of light or heavy chain variable regions (see, e.g., Carter et al. Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta et al. J. Immunol., 151:2623 (1993)). 93)); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci. 13: 1619-1633 (2008)); and framework regions derived from screening FR libraries (see, e.g., Baca et al., J. Biol. Chem. 272: 10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271: 22611-22618 (1996)).

[0560] In certain embodiments, the anti-CD20 / anti-CD3 bispecific antibody is a human antibody. Human antibodies can be produced using various techniques known in the art. Human antibodies are generally described in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5: 368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20: 450-459 (2008).

[0561] Human antibodies can be prepared by administering an immunogen to a transgenic animal that has been modified to produce complete human antibodies or complete antibodies with human variable regions in response to antigenic stimulation. Such animals typically contain all or part of a human immunoglobulin locus that replaces an endogenous immunoglobulin locus, or exists outside the chromosome of the animal or is randomly integrated into the chromosome of the animal. In such transgenic mice, the endogenous immunoglobulin locus is typically inactivated. For a review of methods for obtaining human antibodies from transgenic animals, see Lonberg, Nat. Biotech. 23: 1117-1125 (2005). See also, for example, description of XENOMOUSE TM US Patent Nos. 6,075,181 and 6,150,584 for the technology; description US Patent No. 5,770,429 for technology; describes KM US Patent No. 7,041,870, and describes The human variable regions from intact antibodies produced by such animals can be further modified, for example by combining with different human constant regions.

[0562] Human antibodies can also be prepared by hybridoma-based methods. Human myeloma and mouse-human hybrid myeloma cell lines for producing human monoclonal antibodies have been described. (See, for example, Kozbor J. Immunol., 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol., 147: 86 (1991).) Human antibodies generated via human B cell hybridoma technology are also described in Li et al., Proc. Natl. Acad. Sci. USA, 103: 3557-3562 (2006). Additional methods include, for example, those described in U.S. Pat. No. 7,189,826 (describing the production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26 (4): 265-268 (2006) (describing human-human hybridomas). Human hybridoma technology (Trioma technology) is also described in Vollmers and Brandlein, Histology and Histopathology, 20 (3): 927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, 27 (3): 185-91 (2005).

[0563] Human antibodies can also be produced by isolating the Fv clone variable domain sequence selected from the human phage display library. Such variable domain sequences can then be combined with the expected human constant domains. The technology of selecting human antibodies from the antibody library is described below.

[0564] The binding domain contained in the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) can be isolated by screening the combinatorial library of binding moieties with the desired activity. For example, various methods are known in the art for generating phage display libraries and screening such libraries to obtain antibodies with the desired binding characteristics. Such methods are reviewed in, e.g., Hoogenboom et al., Methods in Molecular Biology 178:1-37 (O'Brien et al., eds., Human Press, Totowa, NJ, 2001) and further described in, e.g., McCafferty et al., Nature 348:552-554; Clackson et al., Nature 352:624-628 (1991); Marks et al., J. Mol. Biol. 222:581-597 (1992); Marks and Bradbury, Methods in Molecular Biology 248:161-175 (Lo eds., Human Press, Totowa, NJ, 2003); Sidhu et al., J. Mol. Biol. 338(2):299-310 (2004); Lee et al., J. Mol. Biol. 340(5):1073-1093 (2004); Fellouse, Proc. Natl. Acad. Sci. USA 101(34);12467-12472 (2004); and Lee et al., J. Immunol. Methods 284(1-2):119-132 (2004).

[0565] In certain phage display methods, the repertoire of VH and VL genes is cloned individually by polymerase chain reaction (PCR) and randomly recombined in a phage library, which can then be screened for antigen-binding phage, as described in Winter et al., Ann. Rev. Immunol., 12: 433-455 (1994). Phage typically display antibody fragments as single-chain Fv (scFv) fragments or Fab fragments. Libraries from immunized sources provide high-affinity antibodies to immunogens without the need to construct hybridomas. Alternatively, all natural repertoires (e.g., all natural repertoires from humans) can be cloned to provide a single source of antibodies to a wide range of non-self-antigens and self-antigens without any immunization, as described in Griffiths et al., EMBO J, 12: 725-734 (1993). Finally, natural libraries can also be made by cloning unrearranged V gene segments from stem cells; and using PCR primers containing random sequences to encode highly variable CDR3 regions and perform in vitro rearrangement, as described by Hoogenboom and Winter, J. Mol. Biol., 227:381-388 (1992). Patent publications describing human antibody phage libraries include, for example: U.S. Pat. No. 5,750,373, and U.S. Publication Nos. 2005 / 0079574, 2005 / 0119455, 2005 / 0266000, 2007 / 0117126, 2007 / 0160598, 2007 / 0237764, 2007 / 0292936, and 2009 / 0002360.

[0566] Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments herein.

[0567] Techniques for preparing bispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs with different specificities (see, Milstein and Cuello, Nature 305:537 (1983), WO 93 / 08829 and Traunecker et al., EMBO J. 10:3655 (1991)) and "knob-in-hole" engineering (see, e.g., U.S. Pat. No. 5,731,168). Multispecific antibodies can also be prepared by the following techniques: engineering electrostatic manipulation effects to prepare antibody Fc-heterodimer molecules (WO 2009 / 089004A1); cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980 and Brennan et al., Science 229:81 (1985)); using leucine zippers to generate bispecific antibodies (see, e.g., Kostelny et al., J. Immunol. 148(5):1547-1553 (1992)); using "diabody" technology to prepare bispecific antibody fragments (see, e.g., Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); and using single-chain Fv (scFv) dimers (see, e.g., Gruber et al., J. Immunol. 152:5368 (1994)); and preparing trispecific antibodies as described, e.g., in Tutt et al., J. Immunol. 147:60 (1991).

[0568] Engineered antibodies with three or more functional antigen binding sites, including "octopus antibodies," are also included herein (see, e.g., US 2006 / 0025576 A1).

[0569] The anti-CD20 / anti-CD3 bispecific antibodies herein also include "dual-acting FAbs" or "DAFs," which comprise antigen binding sites that bind to two different antigens (see, e.g., US 2008 / 0069820).

[0570] The "Crossmab" antibody is also included herein (see, e.g., WO2009080251, WO2009080252, WO2009080253, WO2009080254).

[0571] Another technology used to prepare bispecific antibody fragments is "bispecific T cell engager" or Method (see, e.g., WO2004 / 106381, WO2005 / 061547, WO2007 / 042261, and WO2008 / 119567). The method utilizes two antibody variable domains arranged on a single polypeptide. For example, a single polypeptide chain includes two single-chain Fv (scFv) fragments, each of which has a variable heavy chain (VH) and a variable light chain (VL) domain separated by a polypeptide linker, and the length of the polypeptide linker is sufficient to allow intramolecular association between the two domains. The single polypeptide further includes a polypeptide spacer sequence between the two scFv fragments. Each scFv recognizes a different epitope, and these epitopes can be specific to different cell types, so that when each scFv engages with its cognate epitope, cells of two different cell types will approach or be bound together. One specific embodiment of the method comprises a scFv that recognizes a cell surface antigen expressed by an immune cell (e.g., a CD3 polypeptide on a T cell) linked to another scFv that recognizes a cell surface antigen expressed by a target cell (such as a malignant or tumor cell).

[0572] Since it is a single polypeptide, the bispecific T cell adaptor can be expressed using any prokaryotic or eukaryotic cell expression system known in the art (e.g., CHO cell line). However, specific purification techniques (see, e.g., EP1691833) may be required to separate the monomeric bispecific T cell adaptor from other polymeric species, which may have biological activities different from the expected activity of the monomer. In an exemplary purification scheme, a solution containing the secreted polypeptide is first subjected to metal affinity chromatography, and the polypeptide is eluted with an imidazole concentration gradient. The eluent is further purified using anion exchange chromatography, and the polypeptide is eluted using a sodium chloride concentration gradient. Finally, the eluent is subjected to size exclusion chromatography to separate the monomer from the polymer.

[0573] In certain embodiments, the anti-CD20 / anti-CD3 bispecific antibody can be further modified to include additional non-proteinaceous moieties known in the art and readily available. Suitable derivatized moieties for anti-CD20 / anti-CD3 bispecific antibodies (e.g., anti-CD20 / anti-CD3 TCBs, such as Gefituzumab) include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol / propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (homopolymers or random copolymers) and dextran or poly (n-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide / ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Due to its stability in water, polyethylene glycol propionaldehyde may have advantages in manufacturing. The polymer may be of any molecular weight and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymer is attached, they may be the same or different molecules. Generally, the number and / or type of polymers used for derivatization may be determined based on considerations including, but not limited to, the specific property or function of the antibody to be improved, whether the antibody derivative will be used for therapy under defined conditions, etc.

[0574] The anti-CD20 / anti-CD3 bispecific antibodies can also be conjugated to one or more cytotoxic agents, such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g., protein toxins of bacterial, fungal, plant or animal origin, enzymatically active toxins, or fragments thereof), or radioactive isotopes.

[0575] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody comprises an antibody-drug conjugate (ADC) in which the antibody is conjugated to one or more drugs, including but not limited to maytansine alkaloids (see U.S. Pat. Nos. 5,208,020, 5,416,064 and European Patent EP 0425235 B1); auristatins, such as monomethyl auristatin drug moieties DE and DF (MMAE and MMAF) (see U.S. Pat. Nos. 5,635,483 and 5,780,588 and 7,498,298); dolastatin; calicheamicin or a derivative thereof (see U.S. Pat. Nos. 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001 and 5,877,296; Hinman et al., Cancer Res. 53:3336-3342 (1993); and Lode et al., Cancer Res. 58:2925-2928 (1998)); anthracyclines such as daunorubicin or doxorubicin (see Kratz et al., Current Med. Chem. 13:477-523 (2006); Jeffrey et al., Bioorganic & Med. Chem. Letters 16:358-362 (2006); Torgov et al., Bioconj. Chem. 16:717-721 (2005); Nagy et al., Proc. Natl. Acad. Sci. USA 97:829-834 (2000); Dubowchik et al., Bioorg. & Med. Chem. Letters 12:1529-1532 (2002); King et al., J. Med. Chem. 45:4336-4343 (2002); and U.S. Pat. No. 6,630,579); methotrexate; vinblastine; taxanes, such as docetaxel, paclitaxel, larotaxel, tesetaxel, and octataxel; trichothecenes; and CC1065.

[0576] In another embodiment, the anti-CD20 / anti-CD3 bispecific antibody is conjugated to an enzymatically active toxin or fragment thereof, including but not limited to diphtheria A chain, a non-binding active fragment of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana antiviral proteins (PAPI, PAPII and PAP-S), Momordica charantia inhibitor, curcin, crotin, Saponaria officinalis toxin, scutellaria baicalensis ... officinalis inhibitors, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and tricothecenes.

[0577] In another embodiment, the anti-CD20 / anti-CD3 bispecific antibody is conjugated to a radioactive atom to form a radioconjugate. A variety of radioisotopes can be used to produce radioconjugates. Examples include At 211 ,I 131 ,I 125 , Y 90 、Re 186 、Re 188 、Sm 153 、Bi 212 , P 32 , Pb 212 When the radioconjugate is used for detection, it may contain a radioactive atom such as Tc for scintigraphic studies. 99m or I 123 , or spin labels for nuclear magnetic resonance (NMR) imaging (also called magnetic resonance imaging, MRI), such as iodine-123, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.

[0578] Conjugates of the anti-CD20 / anti-CD3 bispecific antibody and a cytotoxic agent can be prepared using a variety of bifunctional protein coupling agents, such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipate hydrochloride), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, ricin immunotoxins can be prepared as described in Vitetta et al., Science 238: 1098 (1987). Carbon-14 labeled 1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugating radionucleotides to antibodies. See WO94 / 11026. The linker can be a "cleavable linker" that promotes the release of cytotoxic drugs in cells. For example, acid-labile linkers, peptidase-sensitive linkers, photolabile linkers, dimethyl linkers, or disulfide-containing linkers can be used (Chari et al., Cancer Res. 52: 127-131 (1992); U.S. Pat. No. 5,208,020).

[0579] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) is indicated for the treatment of a cell proliferative disorder (e.g., cancer). In one embodiment, the cell proliferative disorder is cancer. In one embodiment, the cancer is a B-cell proliferative disorder. In one embodiment, the cancer is a CD20-positive B-cell proliferative disorder. In one embodiment, the cancer is non-Hodgkin's lymphoma (NHL). In one embodiment, the NHL is diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), DLBCL caused by follicular lymphoma (FL) [transformed FL; trFL], primary mediastinal large B-cell lymphoma (PMBCL), or marginal zone lymphoma (MZL). MZL can be divided into splenic MZL, lymph node MZL, and extranodal MZL. In one embodiment, the NHL is mantle cell lymphoma (MCL). In one embodiment, the NHL is grade 1-3a follicular lymphoma (FL). In one embodiment, the CD20-positive B-cell proliferative disorder is a relapsed or refractory B-cell proliferative disorder. In one embodiment, the relapsed or refractory B-cell proliferative disorder is a relapsed or refractory NHL (e.g., relapsed or refractory DLBCL, relapsed or refractory FL or relapsed or refractory MCL).

[0580] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (eg, anti-CD20 / anti-CD3 TCB, such as Gefituzumab) specifically binds to CD3ε.

[0581] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody can be combined with antibody H2C (PCT Publication No. WO2008 / 119567), antibody V9 (Rodrigues et al., Int J Cancer Suppl. 7, 45-50 (1992) and U.S. Pat. No. 6,054,297), antibody FN18 (Nooij et al., Eur J Immunol. 19, 981-984 (1986)), antibody SP34 (Pessano et al., EMBO J. 4, 337-340 (1985)), antibody OKT3 (Kung et al., Science 206, 347-349 (1979)), antibody WT31 (Spits et al., J Immunol. 19, 347-349 (1986)). Immunol. 135, 1922 (1985)), antibody UCHT1 (Burns et al., J Immunol. 129, 1451-1457 (1982)), antibody 7D6 (Coulie et al., Eur J Immunol. 21, 1703-1709 (1991)) or antibody Leu-4 compete for binding. In some embodiments, the anti-CD20 / anti-CD3 bispecific antibody may further comprise an antigen binding portion that specifically binds to CD3, such as WO 2005 / 040220, WO 2005 / 118635, WO 2007 / 042261, WO 2008 / 119567, WO 2008 / 119565, WO 2012 / 162067, WO 2013 / 158856, WO 2013 / 188693, WO 2013 / 186613, WO 2014 / 110601, WO 2014 / 145806, WO 2014 / 191113, WO 2014 / 047231, WO 2015 / 095392, WO 2015 / 181098, WO 2015 / 001085, WO 2015 / 104346, WO 2015 / 172800, WO 2016 / 020444 or WO 2016 / 014974.

[0582] In some embodiments, the anti-CD20 / anti-CD3 bispecific antibody may comprise an antibody or antigen-binding portion from rituximab, obinutuzumab, ocrelizumab, ofatumumab, okatuzumab, veltuzumab, and urituximab.

[0583] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody is Gefituzumab.

[0584] In some embodiments, the anti-CD20 / anti-CD3 bispecific antibodies may comprise generic, biosimilar, or incomparable biological versions of the antibodies named herein.

[0585] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., Gefituzumab) comprises at least one antigen binding domain that specifically binds to CD20, comprising:

[0586] A heavy chain variable region comprising:

[0587] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;

[0588] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and

[0589] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO:3;

[0590] and a light chain variable region comprising:

[0591] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4;

[0592] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and

[0593] (iii) HVR-L3, which comprises the amino acid sequence shown in SEQ ID NO:6.

[0594] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprises at least one antigen binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 7, and a light chain variable region sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 8. In yet another embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprises at least one antigen binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8.

[0595] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, e.g., Gefituzumab) comprises at least one antigen binding domain that specifically binds to CD3, comprising:

[0596] A heavy chain variable region comprising:

[0597] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9;

[0598] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and

[0599] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO: 11; and

[0600] and a light chain variable region comprising:

[0601] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;

[0602] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and

[0603] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14.

[0604] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprises at least one antigen binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 15, and a light chain variable region sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 16. In yet another embodiment, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprises at least one antigen binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence of SEQ ID NO: 15 and a light chain variable region sequence of SEQ ID NO: 16.

[0605] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprises:

[0606] a) at least one antigen binding domain that specifically binds to CD20, comprising: a heavy chain variable region comprising:

[0607] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;

[0608] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and

[0609] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO:3;

[0610] and a light chain variable region comprising:

[0611] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4;

[0612] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and

[0613] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and

[0614] b) at least one antigen binding domain that specifically binds to CD3, comprising: a heavy chain variable region comprising:

[0615] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9;

[0616] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and

[0617] (iii) HVR-H3 comprising the amino acid sequence shown in SEQ ID NO: 11; and

[0618] A light chain variable region comprising:

[0619] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;

[0620] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and

[0621] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14.

[0622] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprises:

[0623] (i) at least one antigen binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8; and

[0624] (ii) at least one antigen-binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence of SEQ ID NO: 15 and a light chain variable region sequence of SEQ ID NO: 16.

[0625] In one embodiment, the antigen binding domain that specifically binds to CD3 of the anti-CD20 / anti-CD3 bispecific antibody is an antibody fragment, particularly a Fab molecule or a scFv molecule, more particularly a Fab molecule. In a specific embodiment, the antigen binding domain that specifically binds to CD3 of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) is a crossover Fab molecule in which the variable domains or constant domains of the Fab heavy and light chains are exchanged (i.e., replaced with each other).

[0626] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprises at least one antigen binding domain that specifically binds to CD20 and one antigen binding domain that specifically binds to CD3. In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprises a first antigen binding domain that specifically binds to CD3, and a second and third antigen binding domain that specifically binds to CD20. In one embodiment, the first antigen binding domain is a cross-Fab molecule, and the second and third antigen binding domains are each conventional Fab molecules. In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) further comprises an Fc domain. The anti-CD20 / anti-CD3 bispecific antibody may comprise modifications in the Fc region and / or antigen binding domain as described herein. In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprises an IgG1 Fc domain comprising one or more amino acid substitutions that reduce binding to an Fc receptor and / or effector function. In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprises an IgG1 Fc domain comprising amino acid substitutions L234A, L235A, and P329G (EU numbering).

[0627] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprises:

[0628] (i) an antigen binding domain that specifically binds to CD3, which is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain;

[0629] (ii) a first antigen binding domain that specifically binds to CD20, which is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of an antigen binding domain that specifically binds to CD3; and

[0630] (iii) a second antigen binding domain that specifically binds to CD20, which is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain.

[0631] In certain embodiments, an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprises:

[0632] a) a first Fab molecule, which specifically binds to CD3, in particular CD3ε; and wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced with each other;

[0633] b) a second Fab molecule and a third Fab molecule, which specifically binds to CD20, wherein in the constant domain CL of the second Fab molecule and the third Fab molecule, the amino acid at position 124 is substituted by lysine (K) (according to Kabat numbering), and the amino acid at position 123 is substituted by lysine (K) or arginine (R), in particular by arginine (R) (according to Kabat numbering), and wherein in the constant domain CH1 of the second Fab molecule and the third Fab molecule, the amino acid at position 147 is substituted by glutamic acid (E) (EU numbering), and the amino acid at position 213 is substituted by glutamic acid (E) (EU numbering); and

[0634] c) The Fc domain is composed of a first subunit and a second subunit that are capable of stable association.

[0635] In one embodiment, an anti-CD20 / anti-CD3 bispecific antibody (eg, an anti-CD20 / anti-CD3 TCB, such as Gefituzumab) comprises two antigen binding domains that specifically bind to CD20 and one antigen binding domain that specifically binds to CD3.

[0636] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody (eg, anti-CD20 / anti-CD3 TCB, such as Gefituzumab) is bivalent for CD20 and monovalent for CD3.

[0637] In one embodiment, the first Fab molecule under a) is fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain under c), the second Fab molecule under b) is fused at the C-terminus of the Fab heavy chain to the N-terminus of the heavy chain of the first Fab molecule under a), and the third Fab molecule under b) is fused at the C-terminus of the Fab heavy chain to the N-terminus of another subunit of the Fc domain under c). In one embodiment, the first Fab molecule under a) comprises a heavy chain variable region that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 15, and a light chain variable region that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 16.

[0638] In yet another embodiment, the first Fab molecule under a) comprises the heavy chain variable region sequence of SEQ ID NO:15 and the light chain variable region sequence of SEQ ID NO:16.

[0639] In one embodiment, the second Fab molecule and the third Fab molecule under b) each comprise a heavy chain variable region that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO:7, and a light chain variable region that is at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO:8.

[0640] In one embodiment, the second Fab molecules under the third Fab molecule under b) each comprise a heavy chain variable region sequence of SEQ ID NO:7 and a light chain variable region sequence of SEQ ID NO:8.

[0641] In a specific embodiment, the anti-CD20 / anti-CD3 bispecific antibody comprises a polypeptide at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 17, a polypeptide at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 18, a polypeptide at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 19, and a polypeptide at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 20. In yet another specific embodiment, the bispecific antibody comprises the polypeptide sequence of SEQ ID NO: 17, the polypeptide sequence of SEQ ID NO: 18, the polypeptide sequence of SEQ ID NO: 19, and the polypeptide sequence of SEQ ID NO: 20. In another specific embodiment, the bispecific antibody comprises one polypeptide chain comprising the amino acid sequence of SEQ ID NO: 17, one polypeptide chain comprising the amino acid sequence of SEQ ID NO: 18, one polypeptide chain comprising the amino acid sequence of SEQ ID NO: 19, and two polypeptide chains each comprising the amino acid sequence of SEQ ID NO: 20.

[0642] Specific anti-CD20 / anti-CD3 bispecific antibodies are described in PCT Publication No. WO 2016 / 020309 and European Patent Application Nos. EP15188093 and EP16169160 (each incorporated herein by reference in its entirety). In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody of the pharmaceutical composition of the present invention is Gefituzumab.

[0643] B. Antibody Format

[0644] 1. Configuration of anti-CD20 / anti-CD3 bispecific antibodies

[0645] The components of the anti-CD20 / anti-CD3 bispecific antibody can be fused to each other in a variety of configurations. Exemplary configurations are Figure 1 Described in.

[0646] In certain embodiments, the antigen binding moiety contained in the anti-CD20 / anti-CD3 bispecific antibody is a Fab molecule. In such embodiments, the first, second, third antigen binding moiety, etc. may be referred to herein as the first, second, third Fab molecule, etc., respectively. In addition, in certain embodiments, the anti-CD20 / anti-CD3 bispecific antibody comprises an Fc domain, which is composed of a first subunit and a second subunit capable of stably associating.

[0647] In some embodiments, the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain.

[0648] In one such embodiment, the second Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first Fab molecule. In a specific such embodiment, the anti-CD20 / anti-CD3 bispecific antibody consists essentially of a first Fab molecule and a second Fab molecule, an Fc domain consisting of a first subunit and a second subunit, and optionally one or more peptide linkers, wherein the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit or the second subunit of the Fc domain, and the second Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first Fab molecule. This configuration is Figure 1 G and 1 K. Optionally, the Fab light chain of the first Fab molecule and the Fab light chain of the second Fab molecule may additionally be fused to each other.

[0649] In another embodiment, the second Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain. In a specific such embodiment, the antibody consists essentially of a first Fab molecule and a second Fab molecule, an Fc domain consisting of the first subunit and the second subunit, and optionally one or more peptide linkers, wherein the first Fab molecule and the second Fab molecule are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain. This configuration is Figure 1 A and 1D schematically depicted. The first Fab molecule and the second Fab molecule can be fused to the Fc domain directly or through a peptide linker. In a specific embodiment, the first Fab molecule and the second Fab molecule are each fused to the Fc domain through an immunoglobulin hinge region. In a specific embodiment, the immunoglobulin hinge region is a human IgG1 hinge region, particularly when the Fc domain is an IgG1 Fc domain.

[0650] In other embodiments, the second Fab molecule is fused to the N-terminus of the first or second subunit of the Fc domain at the C-terminus of the Fab heavy chain. In one such embodiment, the first Fab molecule is fused to the N-terminus of the Fab heavy chain of the second Fab molecule at the C-terminus of the Fab heavy chain. In specific such embodiments, the antibody consists essentially of the first and second Fab molecules, the Fc domain consisting of the first and second subunits, and optionally one or more peptide linkers, wherein the first Fab molecule is fused to the N-terminus of the Fab heavy chain of the second Fab molecule at the C-terminus of the Fab heavy chain, and the second Fab molecule is fused to the N-terminus of the first or second subunit of the Fc domain at the C-terminus of the Fab heavy chain. This configuration is Figure 1H and 1 L. Optionally, the Fab light chain of the first Fab molecule and the Fab light chain of the second Fab molecule may additionally be fused to each other.

[0651] The Fab molecule can be fused to the Fc domain directly or via a peptide linker comprising one or more amino acids, typically about 2-20 amino acids. Peptide linkers are known in the art and described herein. Suitable non-immunogenic peptide linkers include, for example, (G4S) n (SEQ ID NO:21), (SG4) n (SEQ ID NO: 22) or G4 (SG4) n (SEQ ID NO: 23) peptide linker. "n" is generally an integer from 1 to 10, and is generally from 2 to 4. In one embodiment, the peptide linker is at least 5 amino acids long, in one embodiment 5 to 100 amino acids long, and in another embodiment 10 to 50 amino acids long. In one embodiment, the peptide linker is (GxS) n or (GxS) n G m , wherein G=glycine, S=serine, and (x=3, n=3, 4, 5 or 6, and m=0, 1, 2 or 3) or (x=4, n=2, 3, 4 or 5 and m=0, 1, 2 or 3) (SEQ ID NOs: 27-58), in one embodiment, x=4 and n=2 or 3, in another embodiment, x=4 and n=2. In one embodiment, the peptide linker is (G4S)2 (SEQ ID NO: 24). A particularly suitable peptide linker for fusing the Fab light chains of the first Fab molecule and the second Fab molecule to each other is (G4S)2 (SEQ ID NO: 24). An exemplary peptide linker suitable for connecting the Fab heavy chains of the first Fab fragment and the second Fab fragment comprises the sequence (D)-(G4S)2 (SEQ ID NO: 24 and SEQ ID NO: 25). Another suitable such linker comprises the sequence (G4S)4 (SEQ ID NO: 26). In addition, the linker may comprise (a portion of) an immunoglobulin hinge region. In particular, in case of fusion of a Fab molecule to the N-terminus of an Fc domain subunit, the fusion may be via an immunoglobulin hinge region or a portion thereof, with or without an additional peptide linker.

[0652] has the ability to specifically bind to target cell antigens (e.g. Figure 1Antibodies that contain a single antigen-binding portion (such as a Fab molecule) of the target cell antigen are useful, particularly when internalization of the target cell antigen is expected following binding of the high-affinity antigen-binding portion. In this case, the presence of more than one antigen-binding portion specific for the target cell antigen may enhance internalization of the target cell antigen, thereby reducing its availability.

[0653] However, in many other cases it would be advantageous to have an antibody comprising two or more antigen binding portions (such as Fab molecules) specific for a target cell antigen (see Figure 1 B, 1C, 1E, 1F, 1I, 1J, 1M or 1N), for example to optimize targeting to a target site or to allow cross-linking of target cell antigens.

[0654] Thus, in certain embodiments, the anti-CD20 / anti-CD3 bispecific antibody comprises two anti-CD20 binding moieties, e.g., two Fab molecules targeting CD20. In one embodiment, the two Fab molecules targeting CD20 are conventional Fab molecules. In one embodiment, the two Fab molecules targeting CD20 comprise the same heavy and light chain amino acid sequences and have the same domain arrangement (i.e., conventional or crossover).

[0655] In alternative embodiments, the anti-CD20 / anti-CD3 bispecific antibody comprises two anti-CD3 binding moieties, such as two Fab molecules targeting CD3. In one such embodiment, both Fab molecules targeting CD3 are crossover Fab molecules (Fab molecules in which the variable domains VH and VL or the constant domains CL and CH1 of the Fab heavy and light chains are exchanged / replaced with each other). In one such embodiment, the two Fab molecules targeting CD3 comprise the same heavy and light chain amino acid sequences and have the same domain arrangement (i.e., conventional or crossover).

[0656] In one embodiment, the third Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain.

[0657] In a specific embodiment, the second and third Fab molecules are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain, and the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second Fab molecule. In a specific such embodiment, the antibody consists essentially of the first Fab molecule, the second Fab molecule and the third Fab molecule, an Fc domain consisting of the first subunit and the second subunit, and optionally one or more peptide linkers, wherein the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second Fab molecule, and the second Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, and wherein the third Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain. This configuration is Figure 1 B and Figure 1 E (embodiment, wherein the third Fab molecule is a conventional Fab molecule and is identical to the second Fab molecule) and Figure 1 I and Figure 1 M (embodiment, wherein the third Fab molecule is a cross Fab molecule and is preferably identical to the first Fab molecule). The second and third Fab molecules can be fused to the Fc domain directly or through a peptide linker. In a specific embodiment, the second and third Fab molecules are each fused to the Fc domain through an immunoglobulin hinge region. In a specific embodiment, the immunoglobulin hinge region is a human IgG1 hinge region, particularly when the Fc domain is an IgG1 Fc domain. Optionally, the Fab light chain of the first Fab molecule and the Fab light chain of the second Fab molecule can additionally fuse to each other.

[0658] In another embodiment, the second Fab molecule and the third Fab molecule are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain, and the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second Fab molecule. In a specific embodiment of this type, the antibody consists essentially of the first Fab molecule, the second Fab molecule and the third Fab molecule, an Fc domain consisting of the first subunit and the second subunit, and optionally one or more peptide linkers, wherein the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second Fab molecule, and the second Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, and wherein the third Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain. This configuration is Figure 1 C and Figure 1 F (embodiment, wherein the third Fab molecule is a conventional Fab molecule and is identical to the second Fab molecule) and Figure 1 J and Figure 1 N (embodiment, wherein the third Fab molecule is a cross Fab molecule and is identical to the first Fab molecule) is schematically depicted. The first and third Fab molecules can be fused to the Fc domain directly or through a peptide linker. In a specific embodiment, the second and third Fab molecules are each fused to the Fc domain through an immunoglobulin hinge region. In a specific embodiment, the immunoglobulin hinge region is a human IgG1 hinge region, particularly when the Fc domain is an IgG1 Fc domain. Optionally, the Fab light chain of the first Fab molecule and the Fab light chain of the second Fab molecule can additionally be fused to each other.

[0659] In the configuration of the antibody, wherein the Fab molecule is fused to the N-terminus of each subunit in the subunit of the Fc domain through an immunoglobulin hinge region at the C-terminus of the Fab heavy chain, the two Fab molecules, the hinge region and the Fc domain essentially form an immunoglobulin molecule. In a specific embodiment, the immunoglobulin molecule is an IgG class immunoglobulin. In an even more specific embodiment, the immunoglobulin is an IgG1 subclass immunoglobulin. In another embodiment, the immunoglobulin is an IgG4 subclass immunoglobulin. In another specific embodiment, the immunoglobulin is a human immunoglobulin. In other embodiments, the immunoglobulin is a chimeric immunoglobulin or a humanized immunoglobulin.

[0660] In some antibodies, the Fab light chain of the first Fab molecule and the Fab light chain of the second Fab molecule are fused to each other, optionally via a peptide linker. According to the configuration of the first Fab molecule and the second Fab molecule, the Fab light chain of the first Fab molecule can be fused to the N-terminus of the Fab light chain of the second Fab molecule at its C-terminus, or the Fab light chain of the second Fab molecule can be fused to the N-terminus of the Fab light chain of the first Fab molecule at its C-terminus. The fusion of the Fab light chain of the first Fab molecule and the second Fab molecule further reduces the mispairing of unmatched Fab heavy chains and light chains, and also reduces the number of plasmids required to express some antibodies.

[0661] In certain embodiments, the antibody comprises a polypeptide wherein the Fab light chain variable region of a first Fab molecule shares a carboxyl-terminal peptide bond with the Fab heavy chain constant region of a first Fab molecule (i.e., the first Fab molecule comprises a crossover Fab heavy chain in which the heavy chain variable region is replaced by a light chain variable region), which Fab heavy chain constant region in turn shares a carboxyl-terminal peptide bond with an Fc domain subunit (VL (1) -CH1 (1) -CH2-CH3(-CH4)), and a polypeptide in which the Fab heavy chain of the second Fab molecule shares a carboxyl-terminal peptide bond (VH (2) -CH1 (2)In some embodiments, the antibody further comprises a polypeptide wherein the Fab heavy chain variable region of the first Fab molecule shares a carboxyl-terminal peptide bond (VH (1) -CL (1) ) and shares a carboxyl-terminal peptide bond (VL (2) -CL (2) ). In certain embodiments, the polypeptides are covalently linked, for example, via a disulfide bond.

[0662] In certain embodiments, the antibody comprises a polypeptide wherein the Fab heavy chain variable region of a first Fab molecule shares a carboxyl-terminal peptide bond with the Fab light chain constant region of a first Fab molecule (i.e., the first Fab molecule comprises a crossover Fab heavy chain in which the heavy chain constant region is replaced by a light chain constant region), which in turn shares a carboxyl-terminal peptide bond with an Fc domain subunit (VH (1) -CL (1) -CH2-CH3(-CH4)), and a polypeptide in which the Fab heavy chain of the second Fab molecule shares a carboxyl-terminal peptide bond (VH (2) -CH1 (2) In some embodiments, the antibody further comprises a polypeptide wherein the Fab light chain variable region of the first Fab molecule shares a carboxyl-terminal peptide bond (VL (1) -CH1 (1) ) and shares a carboxyl-terminal peptide bond (VL (2) -CL (2) ). In certain embodiments, the polypeptides are covalently linked, for example, via a disulfide bond.

[0663] In some embodiments, the antibody comprises a polypeptide wherein the Fab light chain variable region of a first Fab molecule shares a carboxyl-terminal peptide bond with the Fab heavy chain constant region of the first Fab molecule (i.e., the first Fab molecule comprises a crossover Fab heavy chain in which the heavy chain variable region is replaced by a light chain variable region), which Fab heavy chain constant region in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain of a second Fab molecule, which in turn shares a carboxyl-terminal peptide bond with an Fc domain subunit (VL (1) -CH1 (1) -VH (2) -CH1 (2)-CH2-CH3(-CH4)). In other embodiments, the antibody comprises a polypeptide wherein the Fab heavy chain of the second Fab molecule shares a carboxyl-terminal peptide bond with the Fab light chain variable region of the first Fab molecule, which in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain constant region of the first Fab molecule (i.e., the first Fab molecule comprises a crossover Fab heavy chain in which the heavy chain variable region is replaced by the light chain variable region), which in turn shares a carboxyl-terminal peptide bond with the Fc domain subunit (VH (2) -CH1 (2) -VL (1) -CH1 (1) -CH2-CH3(-CH4)).

[0664] In some of these embodiments, the antibody further comprises a crossover Fab light chain polypeptide of the first Fab molecule, wherein the Fab heavy chain variable region of the first Fab molecule shares a carboxyl-terminal peptide bond (VH (1) -CL (1) ) and shares a carboxyl-terminal peptide bond (VL (2) -CL (2) In other embodiments of these embodiments, the antibody further comprises a polypeptide wherein the Fab heavy chain variable region of a first Fab molecule shares a carboxyl-terminal peptide bond with the Fab light chain constant region of a first Fab molecule, which in turn shares a carboxyl-terminal peptide bond (VH (1) -CL (1) -VL (2) -CL (2) ), or a polypeptide wherein the Fab light chain polypeptide of the second Fab molecule shares a carboxyl-terminal peptide bond with the Fab heavy chain variable region of the first Fab molecule, which in turn shares a carboxyl-terminal peptide bond (VL (2) -CL (2) -VH (1) -CL (1) ), as the case may be.

[0665] The antibody according to these embodiments may further comprise (i) an Fc domain subunit polypeptide (CH2-CH3(-CH4)), or (ii) a polypeptide in which the Fab heavy chain of the third Fab molecule shares a carboxyl-terminal peptide bond with the Fc domain subunit (VH (3) -CH1 (3) -CH2-CH3(-CH4)), and the Fab light chain polypeptide (VL(3) -CL (3) ). In certain embodiments, the polypeptides are covalently linked, for example, via a disulfide bond.

[0666] In some embodiments, the antibody comprises a polypeptide wherein the Fab heavy chain variable region of the second Fab molecule shares a carboxyl-terminal peptide bond with the Fab light chain constant region of the first Fab molecule (i.e., the first Fab molecule comprises a crossover Fab heavy chain in which the heavy chain constant region is replaced by a light chain constant region), which in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain of the second Fab molecule, which in turn shares a carboxyl-terminal peptide bond with an Fc domain subunit (VH (1) -CL (1) -VH (2) -CH1 (2) -CH2-CH3(-CH4)). In other embodiments, the antibody comprises a polypeptide wherein the Fab heavy chain of the second Fab molecule shares a carboxyl-terminal peptide bond with the Fab heavy chain variable region of the first Fab molecule, which in turn shares a carboxyl-terminal peptide bond with the Fab light chain constant region of the first Fab molecule (i.e., the first Fab molecule comprises a crossover Fab heavy chain in which the heavy chain constant region is replaced by the light chain constant region), which in turn shares a carboxyl-terminal peptide bond with the Fc domain subunit (VH (2) -CH1 (2) -VH (1) -CL (1) -CH2-CH3(-CH4)).

[0667] In some of these embodiments, the antibody further comprises a crossover Fab light chain polypeptide of the first Fab molecule, wherein the Fab light chain variable region of the first Fab molecule shares a carboxyl-terminal peptide bond (VL (1) -CH1 (1) ) and shares a carboxyl-terminal peptide bond (VL (2) -CL (2) In other embodiments of these embodiments, the antibody further comprises a polypeptide wherein the Fab light chain variable region of a first Fab molecule shares a carboxyl-terminal peptide bond with the Fab heavy chain constant region of a first Fab molecule, which in turn shares a carboxyl-terminal peptide bond (VL (1) -CH1 (1) -VL (2) -CL (2)), or a polypeptide wherein the Fab light chain polypeptide of the second Fab molecule shares a carboxyl-terminal peptide bond with the Fab heavy chain variable region of the first Fab molecule, which in turn shares a carboxyl-terminal peptide bond (VL (2) -CL (2) -VH (1) -CL (1) ), as the case may be.

[0668] The antibodies according to these embodiments may further comprise (i) an Fc domain subunit polypeptide (CH2-CH3(-CH4)), or (ii) a polypeptide in which the Fab heavy chain of the third Fab molecule shares a carboxyl-terminal peptide bond with the Fc domain subunit (VH (3) -CH1 (3) -CH2-CH3(-CH4)), and the Fab light chain polypeptide (VL (3) -CL (3) ). In certain embodiments, the polypeptides are covalently linked, for example, via a disulfide bond.

[0669] In certain embodiments, the antibody comprises a polypeptide wherein the Fab heavy chain of a first Fab molecule shares a carboxyl-terminal peptide bond with the Fab light chain variable region of a second Fab molecule, which in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain constant region of a second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain in which the heavy chain variable region is replaced by a light chain variable region) (VH (1) -CH1 (1) -VL (2) -CH1 (2) In some embodiments, the antibody further comprises a polypeptide wherein the Fab heavy chain variable region of the second Fab molecule shares a carboxyl-terminal peptide bond (VH (2) -CL (2) ) and shares a carboxyl-terminal peptide bond (VL (1) -CL (1) ).

[0670] In certain embodiments, the antibody comprises a polypeptide wherein the Fab light chain variable region of the second Fab molecule shares a carboxyl-terminal peptide bond with the Fab heavy chain constant region of the second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain in which the heavy chain variable region is replaced by a light chain variable region), which in turn shares a carboxyl-terminal peptide bond (VL ) with the Fab heavy chain of the first Fab molecule. (2) -CH1 (2) -VH (1) -CH1(1) In some embodiments, the antibody further comprises a polypeptide wherein the Fab heavy chain variable region of the second Fab molecule shares a carboxyl-terminal peptide bond (VH (2) -CL (2) ) and shares a carboxyl-terminal peptide bond (VL (1) -CL (1) ).

[0671] In certain embodiments, the antibody comprises a polypeptide wherein the Fab heavy chain variable region of the second Fab molecule shares a carboxyl-terminal peptide bond with the Fab light chain constant region of the second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain in which the heavy chain constant region is replaced by a light chain constant region), which in turn shares a carboxyl-terminal peptide bond (VH) with the Fab heavy chain of the first Fab molecule. (2) -CL (2) -VH (1) -CH1 (1) In some embodiments, the antibody further comprises a polypeptide wherein the Fab light chain variable region of the second Fab molecule shares a carboxyl-terminal peptide bond (VL (2) -CH1 (2) ) and shares a carboxyl-terminal peptide bond (VL (1) -CL (1) ).

[0672] In certain embodiments, the antibody comprises a polypeptide wherein the Fab heavy chain of the third Fab molecule shares a carboxyl-terminal peptide bond with the Fab heavy chain of the first Fab molecule, which in turn shares a carboxyl-terminal peptide bond with the Fab light chain variable region of the second Fab molecule, which in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain constant region of the second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain in which the heavy chain variable region is replaced by a light chain variable region) (VH (3) -CH1 (3) -VH (1) -CH1 (1) -VL (2) -CH1 (2) In some embodiments, the antibody further comprises a polypeptide wherein the Fab heavy chain variable region of the second Fab molecule shares a carboxyl-terminal peptide bond (VH (2) -CL (2) ) and shares a carboxyl-terminal peptide bond (VL (1) -CL(1) In some embodiments, the antibody further comprises a Fab light chain polypeptide (VL (3) -CL (3) ).

[0673] In certain embodiments, the antibody comprises a polypeptide wherein the Fab heavy chain of the third Fab molecule shares a carboxyl-terminal peptide bond with the Fab heavy chain of the first Fab molecule, which in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain variable region of the second Fab molecule, which in turn shares a carboxyl-terminal peptide bond with the Fab light chain constant region of the second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain in which the heavy chain constant region is replaced by the light chain constant region) (VH (3) -CH1 (3) -VH (1) -CH1 (1) -VH (2) -CL (2) In some embodiments, the antibody further comprises a polypeptide wherein the Fab light chain variable region of the second Fab molecule shares a carboxyl-terminal peptide bond (VL (2) -CH1 (2) ) and shares a carboxyl-terminal peptide bond (VL (1) -CL (1) In some embodiments, the antibody further comprises a Fab light chain polypeptide (VL (3) -CL (3) ).

[0674] In certain embodiments, the antibody comprises a polypeptide wherein the Fab light chain variable region of a second Fab molecule shares a carboxyl-terminal peptide bond with the Fab heavy chain constant region of a second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain in which the heavy chain variable region is replaced by a light chain variable region), which in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain of the first Fab molecule, which in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain of a third Fab molecule (VL (2) -CH1 (2) -VH (1) -CH1 (1) -VH (3) -CH1 (3) In some embodiments, the antibody further comprises a polypeptide wherein the Fab heavy chain variable region of the second Fab molecule shares a carboxyl-terminal peptide bond (VH (2) -CL (2)) and shares a carboxyl-terminal peptide bond (VL (1) -CL (1) In some embodiments, the antibody further comprises a Fab light chain polypeptide (VL (3) -CL (3) ).

[0675] In certain embodiments, the antibody comprises a polypeptide wherein the Fab heavy chain variable region of a second Fab molecule shares a carboxyl-terminal peptide bond with the Fab light chain constant region of a second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain in which the heavy chain constant region is replaced by a light chain constant region), which in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain of the first Fab molecule, which in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain of a third Fab molecule (VH (2) -CL (2) -VH (1) -CH1 (1) -VH (3) -CH1 (3) In some embodiments, the antibody further comprises a polypeptide wherein the Fab light chain variable region of the second Fab molecule shares a carboxyl-terminal peptide bond (VL (2) -CH1 (2) ) and shares a carboxyl-terminal peptide bond (VL (1) -CL (1) In some embodiments, the antibody further comprises a Fab light chain polypeptide (VL (3) -CL (3) ).

[0676] In certain embodiments, the antibody comprises a polypeptide wherein the Fab heavy chain of a first Fab molecule shares a carboxyl-terminal peptide bond with the Fab light chain variable region of a second Fab molecule, the Fab light chain variable region of the second Fab molecule in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain constant region of the second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain, wherein the heavy chain variable region is replaced by a light chain variable region), the Fab heavy chain constant region of the second Fab molecule in turn shares a carboxyl-terminal peptide bond with the Fab light chain variable region of a third Fab molecule, the Fab light chain variable region of the third Fab molecule in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain constant region of the third Fab molecule (i.e., the third Fab molecule comprises a crossover Fab heavy chain, wherein the heavy chain variable region is replaced by a light chain variable region) (VH (1) -CH1 (1) -VL (2) -CH1(2) -VL (3) -CH1 (3) In some embodiments, the antibody further comprises a polypeptide wherein the Fab heavy chain variable region of the second Fab molecule shares a carboxyl-terminal peptide bond (VH (2) -CL (2) ) and shares a carboxyl-terminal peptide bond (VL (1) -CL (1) In some embodiments, the antibody further comprises a polypeptide wherein the Fab heavy chain variable region of the third Fab molecule shares a carboxyl-terminal peptide bond (VH (3) -CL (3) ).

[0677] In certain embodiments, the antibody comprises a polypeptide wherein the Fab heavy chain of a first Fab molecule shares a carboxyl-terminal peptide bond with the Fab heavy chain variable region of a second Fab molecule, which in turn shares a carboxyl-terminal peptide bond with the Fab light chain constant region of a second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain, wherein the heavy chain constant region is replaced by the light chain constant region), which in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain variable region of a third Fab molecule, which in turn shares a carboxyl-terminal peptide bond with the Fab light chain constant region of the third Fab molecule (i.e., the third Fab molecule comprises a crossover Fab heavy chain, wherein the heavy chain constant region is replaced by the light chain constant region) (VH (1) -CH1 (1) -VH (2) -CL (2) -VH (3) -CL (3) In some embodiments, the antibody further comprises a polypeptide wherein the Fab light chain variable region of the second Fab molecule shares a carboxyl-terminal peptide bond (VL (2) -CH1 (2) ) and shares a carboxyl-terminal peptide bond (VL (1) -CL (1) In some embodiments, the antibody further comprises a polypeptide wherein the Fab light chain variable region of the third Fab molecule shares a carboxyl-terminal peptide bond (VL (3) -CH1 (3) ).

[0678] In certain embodiments, the antibody comprises a polypeptide wherein the Fab light chain variable region of the third Fab molecule shares a carboxyl-terminal peptide bond with the Fab heavy chain constant region of the third Fab molecule (i.e., the third Fab molecule comprises a crossover Fab heavy chain in which the heavy chain variable region is replaced by a light chain variable region), which in turn shares a carboxyl-terminal peptide bond with the Fab light chain variable region of the second Fab molecule, which in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain constant region of the second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain in which the heavy chain variable region is replaced by a light chain variable region), which in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain of the first Fab molecule (VL (3) -CH1 (3) -VL (2) -CH1 (2) -VH (1) -CH1 (1) In some embodiments, the antibody further comprises a polypeptide wherein the Fab heavy chain variable region of the second Fab molecule shares a carboxyl-terminal peptide bond (VH (2) -CL (2) ) and shares a carboxyl-terminal peptide bond (VL (1) -CL (1) In some embodiments, the antibody further comprises a polypeptide wherein the Fab heavy chain variable region of the third Fab molecule shares a carboxyl-terminal peptide bond (VH (3) -CL (3) ).

[0679] In certain embodiments, the antibody comprises a polypeptide wherein the Fab heavy chain variable region of the third Fab molecule shares a carboxyl-terminal peptide bond with the Fab light chain constant region of the third Fab molecule (i.e., the third Fab molecule comprises a crossover Fab heavy chain in which the heavy chain constant region is replaced by a light chain constant region), which in turn shares a carboxyl-terminal peptide bond with the Fab heavy chain variable region of the second Fab molecule, which in turn shares a carboxyl-terminal peptide bond with the Fab light chain constant region of the second Fab molecule (i.e., the second Fab molecule comprises a crossover Fab heavy chain in which the heavy chain constant region is replaced by a light chain constant region), which in turn shares a carboxyl-terminal peptide bond (VH) with the Fab heavy chain of the first Fab molecule. (3) -CL (3) -VH (2) -CL (2) -VH (1) -CH1(1) In some embodiments, the antibody further comprises a polypeptide wherein the Fab light chain variable region of the second Fab molecule shares a carboxyl-terminal peptide bond (VL (2) -CH1 (2) ) and shares a carboxyl-terminal peptide bond (VL (1) -CL (1) In some embodiments, the antibody further comprises a polypeptide wherein the Fab light chain variable region of the third Fab molecule shares a carboxyl-terminal peptide bond (VL (3) -CH1 (3) ).

[0680] According to any of the above embodiments, the components of the antibody (e.g., Fab molecules, Fc domains) can be fused directly or through various linkers, particularly peptide linkers comprising one or more amino acids, usually about 2 to 20 amino acids, which are described herein or known in the art. Suitable non-immunogenic peptide linkers include, for example, (G4S) n (SEQ ID NO:21), (SG4) n (SEQ ID NO: 22) or G4 (SG4) n (SEQ ID NO: 23) a peptide linker, wherein n is typically an integer from 1 to 10, typically from 2 to 4.

[0681] 2. Fc domain

[0682] The anti-CD20 / anti-CD3 bispecific antibody may comprise an Fc domain consisting of a pair of polypeptide chains comprising the heavy chain domain of an antibody molecule. For example, the Fc domain of an immunoglobulin G (IgG) molecule is a dimer, each subunit of which comprises a CH2 and CH3 IgG heavy chain constant domain. The two subunits of the Fc domain are capable of stably associating with each other.

[0683] In one embodiment, the Fc domain is an IgG Fc domain. In a specific embodiment, the Fc domain is an IgG1 Fc domain. In another embodiment, the Fc domain is an IgG4 Fc domain. In a more specific embodiment, the Fc domain is an IgG4 Fc domain, which comprises an amino acid substitution (Kabat numbering) at position S228, particularly an amino acid substitution S228P. The amino acid substitution reduces the in vivo Fab arm exchange of IgG4 antibodies (see Stubenrauch et al., Drug Metabolism and Disposition 38, 84-91 (2010)). In another specific embodiment, the Fc domain is human.

[0684] (i) Fc domain modifications that promote heterodimerization

[0685] Anti-CD20 / anti-CD3 bispecific antibodies may comprise different components (e.g., antigen binding domains) fused to one or the other of the two subunits of the Fc domain, which are therefore typically contained in two different polypeptide chains. Recombinant co-expression of these polypeptides and subsequent dimerization results in several possible combinations of the two polypeptides. In order to increase the yield and purity of such antibodies in recombinant production, it would therefore be advantageous to introduce modifications in the Fc domain of the antibody that promote the association of the desired polypeptide.

[0686] Thus, in a specific embodiment, the Fc domain comprises a modification that promotes the association of the first subunit and the second subunit of the Fc domain. The most extensive protein-protein interaction site between the two subunits of the human IgG Fc domain is in the CH3 domain of the Fc domain. Thus, in one embodiment, the modification is located in the CH3 domain of the Fc domain.

[0687] Several methods for modifying the CH3 domain of the Fc domain to implement heterodimerization are fully described in, for example, WO 96 / 27011, WO 98 / 050431, EP 1870459, WO 2007 / 110205, WO 2007 / 147901, WO 2009 / 089004, WO2010 / 129304, WO 2011 / 90754, WO 2011 / 143545, WO 2012058768, WO 2013157954, WO2013096291. Generally, in all such methods, the CH3 domain of the first subunit of the Fc domain and the CH3 domain of the second subunit of the Fc domain are engineered in a complementary manner so that each CH3 domain (or a heavy chain comprising it) can no longer homodimerize with itself, but is forced to heterodimerize with the other complementary engineered CH3 domain (so that the first and second CH3 domains heterodimerize and no homodimer is formed between the two first or two second CH3 domains). These different methods for improved heavy chain heterodimerization are considered to be different replacement schemes combined with heavy-light chain modifications (e.g., variable or constant region exchange / replacement in the Fab arm, or introduction of oppositely charged charged amino acids in the CH1 / CL interface), which reduce light chain mispairing and Bence Jones type side products.

[0688] In a specific embodiment, the modification that promotes the association of the first subunit and the second subunit of the Fc domain is a so-called "protrusion into hole" modification, which comprises a "protrusion" modification in one of the two subunits of the Fc domain and a "hole" modification in the other of the two subunits of the Fc domain.

[0689] The knob-and-hole technique is described in, for example, US 5,731,168; US 7,695,936; Ridgway et al., Prot Eng. 9, 617-621 (1996) and Carter, J Immunol Meth. 248, 7-15 (2001). Typically, the method involves introducing a protrusion ("knob") at the interface of a first polypeptide and introducing a corresponding cavity ("hole") in the interface of a second polypeptide so that the protrusion can be positioned in the cavity to promote the formation of heterodimers and hinder the formation of homodimers. The protrusion is constructed by replacing a small amino acid side chain from the interface of the first polypeptide with a larger side chain (e.g., tyrosine or tryptophan). A compensating cavity having the same or similar size as the protrusion is created in the interface of the second polypeptide by replacing a large amino acid side chain with a smaller amino acid side chain (e.g., alanine or threonine).

[0690] Therefore, in a specific embodiment, in the CH3 domain of the first subunit of the Fc domain, the amino acid residue is replaced by an amino acid residue having a larger side chain volume, thereby generating a protrusion in the CH3 domain of the first subunit, and the protrusion can be positioned in the cavity in the CH3 domain of the second subunit; and in the CH3 domain of the second subunit of the Fc domain, the amino acid residue is replaced by an amino acid residue having a smaller side chain volume, thereby generating a cavity in the CH3 domain of the second subunit, and the protrusion in the CH3 domain of the first subunit can be positioned in the cavity.

[0691] Preferably, the amino acid residue having a larger side chain volume is selected from the group consisting of arginine (R), phenylalanine (F), tyrosine (Y) and tryptophan (W).

[0692] Preferably, the amino acid residue having a smaller side chain volume is selected from the group consisting of alanine (A), serine (S), threonine (T) and valine (V).

[0693] Protrusions and cavities can be produced by altering the nucleic acid encoding the polypeptide (eg, by site-specific mutagenesis or by peptide synthesis).

[0694] In a specific embodiment, in the CH3 domain of the first subunit ("knob" subunit) of the Fc domain, the threonine residue at position 366 is replaced by a tryptophan residue (T366W), and in the CH3 domain of the second subunit ("hole" subunit) of the Fc domain, the tyrosine residue at position 407 is replaced by a valine residue (Y407V). In one embodiment, in addition, in the second subunit of the Fc domain, the threonine residue at position 366 is replaced by a serine residue (T366S), and the leucine residue at position 368 is replaced by an alanine residue (L368A) (EU numbering).

[0695] In a further embodiment, in addition in the first subunit of the Fc domain, the serine residue at position 354 is replaced by a cysteine ​​residue (S354C) or the glutamic acid residue at position 356 is replaced by a cysteine ​​residue (E356C), and in addition in the second subunit of the Fc domain, the tyrosine residue at position 349 is replaced by a cysteine ​​residue (Y349C) (EU numbering). The introduction of these two cysteine ​​residues results in the formation of a disulfide bridge between the two subunits of the Fc domain, thereby further stabilizing the dimer (Carter, J Immunol Methods 248, 7-15 (2001)).

[0696] In specific embodiments, the first subunit of the Fc domain comprises amino acid substitutions S354C and T366W, and the second subunit of the Fc domain comprises amino acid substitutions Y349C, T366S, L368A, and Y407V (EU numbering).

[0697] In a specific embodiment, the CD3 antigen binding moiety described herein is fused to the first subunit of the Fc domain (comprising a "knob" modification). Without wishing to be bound by theory, fusion of the CD3 antigen binding moiety to the knob-containing subunit of the Fc domain will (further) minimize the generation of bispecific antibodies comprising two CD3 antigen binding moieties (steric hindrance of the two knob-containing polypeptides).

[0698] Other CH3 modification techniques for implementing heterodimerization are contemplated as alternatives and are described, for example, in WO 96 / 27011, WO 98 / 050431, EP 1870459, WO 2007 / 110205, WO 2007 / 147901, WO 2009 / 089004, WO2010 / 129304, WO 2011 / 90754, WO 2011 / 143545, WO 2012 / 058768, WO 2013 / 157954, WO2013 / 096291.

[0699] In one embodiment, the heterodimerization method described in EP 1870459 A1 is used alternatively. The method is based on the introduction of charged amino acids with opposite charges at specific amino acid positions in the CH3 / CH3 domain interface between the two subunits of the Fc domain. A preferred embodiment is the amino acid mutations R409D and K370E in one of the two CH3 domains (of the Fc domain) and the amino acid mutations D399K and E357K (EU numbering) in the other of the CH3 domains of the Fc domain.

[0700] In another embodiment, the anti-CD20 / anti-CD3 bispecific antibody may comprise the amino acid mutation T366W in the CH3 domain of the first subunit of the Fc domain and the amino acid mutations T366S, L368A and Y407V in the CH3 domain of the second subunit of the Fc domain, and additionally the amino acid mutations R409D and K370E in the CH3 domain of the first subunit of the Fc domain and the amino acid mutations D399K and E357K in the CH3 domain of the second subunit of the Fc domain (EU numbering).

[0701] In another embodiment, the anti-CD20 / anti-CD3 bispecific antibody may comprise the amino acid mutations S354C and T366W in the CH3 domain of the first subunit of the Fc domain and the amino acid mutations Y349C, T366S, L368A, and Y407V in the CH3 domain of the second subunit of the Fc domain, or the antibody comprises the amino acid mutations Y349C and T366W in the CH3 domain of the first subunit of the Fc domain and the amino acid mutations S354C, T366S, L368A, and Y407V in the CH3 domain of the second subunit of the Fc domain, and additionally the amino acid mutations R409D and K370E in the CH3 domain of the first subunit of the Fc domain, and the amino acid mutations D399K and E357K in the CH3 domain of the second subunit of the Fc domain (all EU numbering).

[0702] In one embodiment, the heterodimerization method described in WO 2013 / 157953 is used instead. In one embodiment, the first CH3 domain comprises the amino acid mutation T366K, and the second CH3 domain comprises the amino acid mutation L351D (EU numbering). In another embodiment, the first CH3 domain comprises another amino acid mutation L351K. In another embodiment, the second CH3 domain further comprises an amino acid mutation (EU numbering) selected from Y349E, Y349D and L368E (preferably L368E).

[0703] In one embodiment, the heterodimerization method described in WO 2012 / 058768 is used instead. In one embodiment, the first CH3 domain comprises amino acid mutations L351Y, Y407A, and the second CH3 domain comprises amino acid mutations T366A and K409F. In another embodiment, the second CH3 domain comprises further amino acid mutations at positions T411, D399, S400, F405, N390 or K392, for example selected from: (a) T411N, T411R, T411Q, T411K, T411D, T411E or T411W; (b) D399R, D399W, D399Y or D39 9K; (c) S400E, S400D, S400R or S400K; (d) F405I, F405M, F405T, F405S, F405V or F405W; (e) N390R, N390K or N390D; or (f) K392V, K392M, K392R, K392L, K392F or K392E (EU numbering). In another embodiment, the first CH3 domain comprises amino acid mutations L351Y and Y407A, and the second CH3 domain comprises amino acid mutations T366V and K409F. In another embodiment, the first CH3 domain comprises amino acid mutations Y407A, and the second CH3 domain comprises amino acid mutations T366A and K409F. In another embodiment, the second CH3 domain further comprises amino acid mutations K392E, T411E, D399R and S400R (EU numbering).

[0704] In one embodiment, the heterodimerization method described in WO 2011 / 143545 is used instead, for example, an amino acid modification is made at a position selected from the group consisting of 368 and 409 (EU numbering).

[0705] In one embodiment, the heterodimerization method described in WO 2011 / 090762 is used instead, which also uses the above-mentioned protrusion-into-hole technology. In one embodiment, the first CH3 domain comprises the amino acid mutation T366W, and the second CH3 domain comprises the amino acid mutation Y407A. In one embodiment, the first CH3 domain comprises the amino acid mutation T366Y, and the second CH3 domain comprises the amino acid mutation Y407T (EU numbering).

[0706] In one embodiment, the anti-CD20 / anti-CD3 bispecific antibody or the Fc domain of the anti-CD20 / anti-CD3 bispecific antibody is of the IgG2 subclass and the heterodimerization method described in WO 2010 / 129304 is used.

[0707] In alternative embodiments, modifications that promote association of the first and second subunits of the Fc domain include modifications that mediate an electrostatic steering effect, such as described in PCT Publication WO 2009 / 089004. Typically, the method involves replacing one or more amino acid residues at the interface of the two Fc domain subunits with charged amino acid residues such that homodimer formation becomes electrostatically unfavorable, but heterodimerization is electrostatically favorable. In one such embodiment, the first CH3 domain comprises an amino acid substitution of K392 or N392 with a negatively charged amino acid (e.g., glutamic acid (E) or aspartic acid (D), preferably K392D or N392D), and the second CH3 domain comprises an amino acid substitution of D399, E356, D356 or E357 with a positively charged amino acid (e.g., lysine (K) or arginine (R), preferably D399K, E356K, D356K or E357K, and more preferably D399K and E356K). In another embodiment, the first CH3 domain further comprises an amino acid substitution of K409 or R409 with a negatively charged amino acid (e.g., glutamic acid (E) or aspartic acid (D), preferably K409D or R409D). In another embodiment, the first CH3 domain further or alternatively comprises an amino acid substitution (EU numbering) of K439 and / or K370 with a negatively charged amino acid, such as glutamic acid (E) or aspartic acid (D).

[0708] In yet another embodiment, the heterodimerization method described in WO 2007 / 147901 is used instead.In one embodiment, the first CH3 domain comprises the amino acid mutations K253E, D282K and K322D, and the second CH3 domain comprises the amino acid mutations D239K, E240K and K292D (EU numbering).

[0709] In yet another embodiment, the heterodimerization method described in WO 2007 / 110205 is used.

[0710] In one embodiment, the first subunit of the Fc domain comprises amino acid substitutions K392D and K409D, and the second subunit of the Fc domain comprises amino acid substitutions D356K and D399K (EU numbering).

[0711] (ii) Fc domain modifications that reduce Fc receptor binding and / or effector function

[0712] The Fc domain confers favorable pharmacokinetic properties to antibodies such as anti-CD20 / anti-CD3 bispecific antibodies, including a long serum half-life and a favorable tissue-blood distribution ratio that contribute to good accumulation in target tissues. However, at the same time, it may cause the antibody to undesirably target cells expressing Fc receptors rather than preferred antigen-bearing cells. In addition, co-activation of Fc receptor signaling pathways can lead to cytokine release, which, combined with other immunostimulatory properties that antibodies may have and the long half-life of antibodies, leads to overactivation of cytokine receptors and severe side effects after systemic administration.

[0713] Thus, in specific embodiments, the Fc domain of the anti-CD20 / anti-CD3 bispecific antibody exhibits reduced binding affinity to an Fc receptor and / or reduced effector function compared to a native IgG1 Fc domain. In one such embodiment, the Fc domain (or a molecule comprising the Fc domain, such as an antibody) exhibits less than 50% binding affinity to an Fc receptor, preferably less than 20%, more preferably less than 10%, and most preferably less than 5%, compared to a native IgG1 Fc domain (or a corresponding molecule comprising a native IgG1 Fc domain), and / or less than 50%, preferably less than 20%, more preferably less than 10%, and most preferably less than 5% of the effector function compared to a native IgG1 Fc domain (or a corresponding molecule comprising a native IgG1 Fc domain). In one embodiment, the Fc domain (or a molecule comprising the Fc domain, such as an antibody) does not substantially bind to an Fc receptor and / or induce effector function. In a specific embodiment, the Fc receptor is an Fcγ receptor. In one embodiment, the Fc receptor is a human Fc receptor. In one embodiment, the Fc receptor is an activated Fc receptor. In a specific embodiment, the Fc receptor is an activated human Fcγ receptor, more particularly human FcγRIIIa, FcγRI or FcγRIIa, most particularly human FcγRIIIa. In one embodiment, the effector function is one or more effector functions selected from the group of CDC, ADCC, ADCP and cytokine secretion. In a specific embodiment, the effector function is ADCC. In one embodiment, compared with the natural IgG1 Fc domain, the Fc domain exhibits substantially similar binding affinity to the neonatal Fc receptor (FcRn). When the Fc domain (or a molecule comprising the Fc domain, such as an antibody) exhibits a binding affinity of the natural IgG1 Fc domain (or a corresponding molecule comprising the natural IgG1 Fc domain) to FcRn greater than about 70%, particularly greater than about 80%, more particularly greater than about 90%, substantially similar binding to FcRn is achieved.

[0714] In certain embodiments, the Fc domain is engineered to have a reduced binding affinity to Fc receptors and / or reduced effector functions compared to a non-engineered Fc domain. In a specific embodiment, the Fc domain comprises one or more amino acid mutations that reduce the binding affinity of the Fc domain to the Fc receptor and / or the effector functions. Typically, the same one or more amino acid mutations are present in each of the two subunits of the Fc domain. In one embodiment, the amino acid mutation reduces the binding affinity of the Fc domain to the Fc receptor. In one embodiment, the amino acid mutation reduces the binding affinity of the Fc domain to the Fc receptor by at least 2 times, at least 5 times, or at least 10 times. In the embodiment where there is more than one amino acid mutation that reduces the binding affinity of the Fc domain to the Fc receptor, the combination of these amino acid mutations can reduce the binding affinity of the Fc domain to the Fc receptor by at least 10 times, at least 20 times, or even at least 50 times. In one embodiment, compared with the corresponding molecule comprising a non-engineered Fc domain, the molecule (e.g., antibody) comprising an engineered Fc domain exhibits a binding affinity to an Fc receptor of less than 20%, particularly less than 10%, and more particularly less than 5%. In a specific embodiment, the Fc receptor is an Fcγ receptor. In some embodiments, the Fc receptor is a human Fc receptor. In some embodiments, the Fc receptor is an activated Fc receptor. In a specific embodiment, the Fc receptor is an activated human Fcγ receptor, more particularly human FcγRIIIa, FcγRI or FcγRIIa, most particularly human FcγRIIIa. Preferably, the binding to each of these receptors is reduced. In some embodiments, the binding affinity to complement components, particularly the binding affinity to C1q, is also reduced. In one embodiment, the binding affinity to the neonatal Fc receptor (FcRn) is not reduced. When the Fc domain (or a molecule comprising the Fc domain, such as an antibody) exhibits greater than about 70% of the binding affinity of the non-engineered form of the Fc domain (or the corresponding molecule comprising the non-engineered form of the Fc domain) to FcRn, substantially similar binding to FcRn is achieved, i.e., the binding affinity of the Fc domain to the receptor is maintained. The Fc domain or a molecule comprising the Fc domain (e.g., an antibody) may exhibit greater than about 80%, and even greater than about 90% of such affinity. In certain embodiments, the Fc domain is engineered to have reduced effector function compared to a non-engineered Fc domain.The effector function of reduction may include but is not limited to one or more of the following items: reduced complement dependent cytotoxicity (CDC), reduced antibody dependent cell-mediated cytotoxicity (ADCC), reduced antibody dependent cellular phagocytosis (ADCP), reduced cytokine secretion, reduced immune complex-mediated antigen presenting cells to antigen uptake, reduced binding to NK cells, reduced binding to macrophages, reduced binding to monocytes, reduced binding to polymorphonuclear cells, reduced direct signaling induced apoptosis, reduced cross-linking of target binding antibodies, reduced dendritic cell maturation, or reduced T cell sensitization. In one embodiment, the effector function of reduction is selected from the group of reduced CDC, reduced ADCC, reduced ADCP and reduced cytokine secretion. In a specific embodiment, the effector function of reduction is reduced ADCC. In one embodiment, the reduced ADCC is less than 20% of the ADCC induced by non-engineered Fc domains (or corresponding molecules comprising non-engineered Fc domains).

[0715] In one embodiment, the amino acid mutation that reduces the binding affinity of the Fc domain to Fc receptors and / or effector function is an amino acid substitution. In one embodiment, the Fc domain is included in the amino acid substitution (EU numbering) at the position of the group selected from E233, L234, L235, N297, P331 and P329. In a more specific embodiment, the Fc domain is included in the amino acid substitution (EU numbering) at the position of the group selected from L234, L235 and P329. In certain embodiments, the Fc domain includes amino acid substitutions L234A and L235A (EU numbering). In one such embodiment, the Fc domain is an IgG1 Fc domain, particularly a human IgG1 Fc domain. In one embodiment, the Fc domain is included in the amino acid substitution at the P329 position. In a more specific embodiment, the amino acid substitution is P329A or P329G, particularly P329G (EU numbering). In one embodiment, the Fc domain includes an amino acid replacement at position P329, and a further amino acid replacement (EU numbering) at a position selected from E233, L234, L235, N297 and P331. In a more specific embodiment, the further amino acid replacement is E233P, L234A, L235A, L235E, N297A, N297D or P331S. In a specific embodiment, the Fc domain includes an amino acid replacement (EU numbering) at position P329, L234 and L235. In a more specific embodiment, the Fc domain includes amino acid mutations L234A, L235A and P329G ("P329GLALA"). In one such embodiment, the Fc domain is an IgG1 Fc domain, particularly a human IgG1 Fc domain. The amino acid substitution "P329G LALA" combination almost completely abolished Fcγ receptor (and complement) binding of human IgG1 Fc domains, as described in PCT Publication No. WO 2012 / 130831, which is incorporated herein by reference in its entirety. WO 2012 / 130831 also describes methods for preparing such mutant Fc domains and methods for determining their properties (such as Fc receptor binding or effector function).

[0716] Compared with IgG1 antibody, IgG4 antibody shows reduced binding affinity to Fc receptors and reduced effector function.Therefore, in some embodiments, Fc domain is IgG4 Fc domain, particularly human IgG4 Fc domain.In one embodiment, IgG4 Fc domain is included in the amino acid replacement at position S228, specifically amino acid replacement S228P (EU numbering).In order to further reduce its binding affinity to Fc receptors and / or its effector function, in one embodiment, IgG4 Fc domain is included in the amino acid replacement at position L235, specifically amino acid replacement L235E (EU numbering).In another embodiment, IgG4 Fc domain is included in the amino acid replacement at position P329, particularly amino acid replacement P329G (EU numbering).In a specific embodiment, IgG4 Fc domain is included in the amino acid replacement at position S228, L235 and P329, particularly amino acid replacement S228P, L235E and P329G (EU numbering). Such IgG4 Fc domain mutants and their Fcγ receptor binding properties are described in PCT Publication No. WO 2012 / 130831, which is incorporated herein by reference in its entirety.

[0717] In specific embodiments, the Fc domain that exhibits reduced binding affinity to an Fc receptor and / or reduced effector function compared to a native IgG1 Fc domain is a human IgG1 Fc domain comprising amino acid substitutions L234A, L235A, and optionally P329G, or a human IgG4 Fc domain comprising amino acid substitutions S228P, L235E, and optionally P329G (EU numbering).

[0718] In certain embodiments, N-glycosylation of the Fc domain has been eliminated. In one such embodiment, the Fc domain comprises an amino acid mutation at position N297, in particular an amino acid substitution replacing asparagine with alanine (N297A) or aspartic acid (N297D) or glycine (N297G) (EU numbering).

[0719] In addition to the Fc domains described above and in PCT Publication No. WO 2012 / 130831, Fc domains with reduced Fc receptor binding and / or reduced effector function also include those with substitutions to one or more of Fc domain residues 238, 265, 269, 270, 297, 327, and 329 (U.S. Pat. No. 6,737,056) (EU numbering). Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297, and 327, including the so-called "DANA" Fc mutants, in which residues 265 and 297 are substituted with alanine (U.S. Pat. No. 7,332,581).

[0720] Mutant Fc domains can be prepared by amino acid deletion, substitution, insertion or modification using genetic or chemical methods well known in the art. Genetic methods can include site-specific mutagenesis of the encoding DNA sequence, PCR, gene synthesis, etc. The correct nucleotide changes can be verified, for example, by sequencing.

[0721] Binding to Fc receptors can be measured, for example, by ELISA or by surface plasmon resonance (SPR) using standard instrumentation such as Instrument (GE Healthcare)), and Fc receptors such as can be obtained by recombinant expression. Alternatively, cell lines known to express specific Fc receptors (such as human NK cells expressing FcγIIIa receptors) can be used to assess the binding affinity of Fc domains or molecules comprising Fc domains to Fc receptors.

[0722] The effector function of the Fc domain or a molecule (e.g., an antibody) comprising the Fc domain can be measured by methods known in the art. Suitable assays for measuring ADCC are described herein. Other examples of in vitro assays for assessing the ADCC activity of target molecules are described in U.S. Patent No. 5,500,362; Hellstrom et al. Proc Natl Acad Sci USA.83,7059-7063 (1986) and Hellstrom et al., Proc Natl Acad Sci USA.82,1499-1502 (1985); U.S. Patent No. 5,821,337; Bruggemann et al., J Exp Med 166,1351-1361 (1987). Alternatively, non-radioactive assays can be used (see, e.g., ACTI for flow cytometry). TM Nonradioactive cytotoxicity assay (Cell Technology, Inc. Mountain View, CA); and CytoTox Non-radioactive cytotoxicity assay (Promega, Madison, WI). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively or additionally, ADCC activity of the target molecule can be assessed in vivo, for example, in an animal model such as that disclosed in Clynes et al., Proc Natl Acad Sci USA 95, 652-656 (1998).

[0723] In some embodiments, the binding of the Fc domain to complement components, particularly C1q, is reduced. Thus, in some embodiments, wherein the Fc domain is engineered to have reduced effector function, the reduced effector function includes reduced CDC. A C1q binding assay can be performed to determine whether the Fc domain or a molecule (e.g., an antibody) comprising the Fc domain is able to bind to C1q and therefore has CDC activity. See, e.g., C1q and C3c binding ELISA in WO 2006 / 029879 and WO 2005 / 100402. To assess complement activation, a CDC assay can be performed (see, e.g., Gazzano-Santoro et al., J Immunol Methods 202, 163 (1996); Cragg et al., Blood 101, 1045-1052 (2003); and Cragg and Glennie, Blood 103, 2738-2743 (2004)).

[0724] 3. Substitutions, insertions, and deletions

[0725] In some cases, the anti-CD20 / anti-CD3 bispecific antibody variants of the pharmaceutical compositions provided herein have one or more amino acid substitutions. The target sites for substitution mutations include HVR and FR. Conservative substitutions are shown under the heading "preferred substitutions" in Table 3. More substantial changes are provided under the heading "exemplary substitutions" in Table 3, and are further described below with reference to the amino acid side chain categories. Amino acid substitutions can be introduced into the target antibody, and the product can be screened for desired activity (e.g., retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC).

[0726] Table 3. Exemplary and preferred amino acid substitutions

[0727]

[0728]

[0729] Amino acids can be grouped according to common side chain properties:

[0730] (1) Hydrophobicity: norleucine, Met, Ala, Val, Leu, Ile;

[0731] (2) Neutral hydrophilicity: Cys, Ser, Thr, Asn, Gln;

[0732] (3) Acidic: Asp, Glu;

[0733] (4) Basic: His, Lys, Arg;

[0734] (5) Residues that affect chain orientation: Gly, Pro;

[0735] (6) Aromatic: Trp, Tyr, Phe.

[0736] Non-conservative substitutions will entail exchanging a member of one of these classes for another class.

[0737] One type of substitution variant involves replacing one or more hypervariable region residues of a parent antibody (e.g., a humanized antibody or a human antibody). Typically, relative to the parent antibody, one or more resulting variants selected for further study will have changes (e.g., improvements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) and / or will substantially retain certain biological properties of the parent antibody. Exemplary substitution variants are affinity matured antibodies, which can be conveniently generated, for example, using affinity maturation techniques based on phage display such as those described herein. In short, one or more HVR residues are mutated and the variant antibodies are displayed on phage and screened for specific biological activities (e.g., binding affinity).

[0738] For example, HVR can be changed (e.g., substituted) to improve antibody affinity. Such changes can be made in HVR "hot spots", i.e., residues encoded by codons that undergo high-frequency mutations during somatic maturation (see, e.g., Chowdhury, Methods Mol. Biol. 207: 179-196 (2008)) and / or residues in contact with the antigen, and the resulting variant VH or VL binding affinity is tested. Affinity maturation achieved by construction and reselection from a secondary library has been described, for example, by Hoogenboom et al. in Methods in Molecular Biology 178: 1-37 (O'Brien et al., Human Press, Totowa, NJ, (2001)). In some examples of affinity maturation, diversity is introduced into variable genes selected for maturation purposes by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then created. The library is subsequently screened to identify any antibody variants with the desired affinity. Another method to introduce diversity involves an HVR-directed approach in which several HVR residues (e.g., 4 to 6 residues at a time) are randomized. HVR residues involved in antigen binding can be specifically identified, for example, using alanine scanning mutagenesis or modeling. In particular, CDR-H3 and CDR-L3 are often targeted.

[0739] In some instances, substitutions, insertions or deletions may occur within one or more HVRs, as long as such changes do not substantially reduce the ability of the antibody to bind to antigen. For example, conservative changes (e.g., conservative substitutions as described herein) that do not substantially reduce binding affinity may be made in HVRs. Such changes may be outside the antigen contact residues of HVRs. In some cases of the variant VH and VL sequences described above, each HVR remains unchanged or includes no more than one, two or three amino acid substitutions.

[0740] The method that can be used to identify antibody residues or regions that can be targeted for mutagenesis is called "alanine scanning mutagenesis", as described in Cunningham and Wells (1989) Science, 244: 1081-1085. In this method, a residue or a group of target residues (e.g., charged residues such as Arg, Asp, His, Lys and Glu) are identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with the antigen is affected. Other substitutions can be introduced at amino acid positions that exhibit functional sensitivity to the initial substitution. Alternatively or additionally, the contact points between the antibody and the antigen are identified using the crystal structure of the antigen-antibody complex. Such contact residues and adjacent residues that are candidates for substitution can be targeted or eliminated. Variants can be screened to determine whether they have the desired properties.

[0741] Amino acid sequence insertions include amino and / or carboxyl terminal fusions ranging in length from one residue to a polypeptide containing one hundred or more residues, and intrasequence insertions of one or more amino acid residues. Examples of terminal insertions include antibodies with an N-terminal methionyl residue. Other insertion variants of antibody molecules include fusions to the N-terminus or C-terminus of an antibody that increases the serum half-life of an antibody (e.g., for ADEPT) or a polypeptide.

[0742] 4. Glycosylation

[0743] In some cases, the anti-CD20 / anti-CD3 bispecific antibody contained in the pharmaceutical composition of the present invention can be changed to increase or decrease the degree of antibody glycosylation. The addition or deletion of glycosylation sites of the anti-CD20 / anti-CD3 bispecific antibody can be conveniently achieved by changing the amino acid sequence so that one or more glycosylation sites are generated or removed.

[0744] When antibody comprises Fc district, the carbohydrate attached thereto can be changed.Native antibodies produced by mammalian cells usually comprise the biantennary oligosaccharide of side chain, and this biantennary oligosaccharide is usually connected to the Asn297 of CH2 domain in Fc district by N-bonding.See, for example, Wright et al., TIBTECH 15:26-32 (1997).Oligosaccharide can include various carbohydrates, for example, mannose, N-acetylglucosamine (GlcNAc), galactose and sialic acid, and the fucose of GlcNAc in the " backbone " of biantennary oligosaccharide structure.In some cases, the oligosaccharide in antibody is modified, to produce antibody variants with some improved properties.

[0745] In one instance, the anti-CD20 / anti-CD3 bispecific antibody variant has a carbohydrate structure lacking fucose that is attached (directly or indirectly) to the Fc region. For example, the amount of fucose in such an antibody may be 1% to 80%, 1% to 65%, 5% to 65%, or 20% to 40%. For example, as described in WO 2008 / 077546, the amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297 relative to the sum of all sugar structures (e.g., complexes, hybrids, and high mannose structures) attached to Asn297 measured by MALDI-TOF mass spectrometry. Asn297 refers to an asparagine residue located at approximately position 297 in the Fc region (EU numbering of Fc region residues); however, due to minor sequence variations in antibodies, Asn297 may also be located approximately ±3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300. Such fucosylated variants may have improved ADCC function. See, for example, US Patent Publication Nos. US 2003 / 0157108 (Presta, L.); US 2004 / 0093621 (Kyowa Hakko Kogyo Co., Ltd). Related "defucosylated" or "fucose-deficient" antibody variants include: US 2003 / 0157108; WO 2000 / 61739; WO 2001 / 29246; US2003 / 0115614; US 2002 / 0164328; US2004 / 0093621; US2004 / 0132140; US2004 / 0110704; US2004 / 0110282; US2004 / 0109865; WO 2003 / 085119; WO 2003 / 084570; WO 2005 / 035586; WO 2005 / 035778; WO 2005 / 053742; WO 2002 / 031140; Okazaki et al., J. Mol. Biol. 336:1239-1249 (2004); Yamane-Ohnuki et al., Biotech. Bioeng. 87:614 (2004).Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells lacking protein fucosylation (Ripka et al., Arch. Biochem. Biophys. 249: 533-545 (1986); U.S. Patent Application No. US 2003 / 0157108A1, Presta, L; and WO 2004 / 056312 A1, Adams et al., especially in Example 11), and knockout cell lines, such as CHO cells in which the α-1,6-fucosyltransferase gene FUT8 is knocked out (see, e.g., Yamane-Ohnuki et al., Biotech. Bioeng. 87: 614 (2004); Kanda, Y. et al., Biotechnol. Bioeng., 94(4): 680-688 (2006); and WO 2003 / 085107).

[0746] In view of the above, in some cases, the pharmaceutical composition of the present invention comprises an anti-CD20 / anti-CD3 bispecific antibody variant comprising a non-glycosylation site mutation. In some cases, the deglycosylation site mutation reduces the effector function of the antibody. In some cases, the deglycosylation mutation is a substitution mutation. In some cases, the antibody comprises a substitution mutation in the Fc region that reduces the effector function. In some cases, the substitution mutation is at amino acid residues N297, L234, L235 and / or D265 (EU numbering). In some cases, the substitution mutation is selected from the group consisting of the following items: N297G, N297A, L234A, L235A, D265A and P329G. In some cases, the substitution mutation is at amino acid residue N297. In a preferred case, the substitution mutation is N297A.

[0747] Anti-CD20 / anti-CD3 bispecific antibody variants may comprise bisected oligosaccharides, for example, wherein the biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants may have reduced fucosylation and / or improved ADCC function. Examples of such antibody variants are described in, for example, WO 2003 / 011878; U.S. Patent No. 6,602,684; and US2005 / 0123546. Other antibody variants include at least one galactose residue in the oligosaccharide attached to the Fc region. Such antibody variants may have improved CDC function. Such antibody variants are described in, for example, WO 1997 / 30087, WO 1998 / 58964, and WO 1999 / 22764.

[0748] 5. Antibody derivatives

[0749] In some cases, the anti-CD20 / anti-CD3 bispecific antibody of the pharmaceutical composition provided herein is further modified to include other non-protein parts known in the art and easily available. Suitable parts for antibody derivatization include but are not limited to water-soluble polymers. Non-limiting examples of water-soluble polymers include but are not limited to polyethylene glycol (PEG), copolymers of ethylene glycol / propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymer, polyamino acid (homopolymer or random copolymer) and dextran or poly (n-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymer, polypropylene oxide / ethylene oxide copolymer, polyoxyethylene polyol (e.g., glycerol), polyvinyl alcohol and mixtures thereof. Due to its stability in water, polyethylene glycol propionaldehyde may have advantages in manufacturing. Polymers may have any molecular weight and may have side chains or may not have side chains. The number of polymers attached to the antibody can vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and / or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the specific property or function of the antibody to be improved, whether the antibody derivative will be used for therapy under defined conditions, etc.

[0750] In another case, the conjugate of the antibody and the non-protein moiety can be selectively heated by exposure to radiation. In one example, the non-protein moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102: 11600-11605 (2005)). The radiation can be of any wavelength, and includes, but is not limited to, wavelengths that are not harmful to normal cells, but heat the non-protein moiety to a temperature at which cells proximal to the antibody-non-protein moiety are killed.

[0751] C. Recombinant Production Methods

[0752] The anti-CD20 / anti-CD3 bispecific antibodies (e.g., anti-CD20 / anti-CD3 TCBs such as Gefituzumab) of the pharmaceutical compositions of the invention can be produced using recombinant methods and compositions, for example, as described in U.S. Pat. No. 4,816,567, which is incorporated herein by reference in its entirety.

[0753] For recombinant production of anti-CD20 / anti-CD3 bispecific antibodies, nucleic acids encoding the antibodies are isolated and inserted into one or more vectors for further cloning and / or expression in host cells. Such nucleic acids can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that specifically bind to genes encoding the heavy and light chains of the antibodies).

[0754] Suitable host cells for cloning or expressing vectors encoding antibodies include prokaryotic or eukaryotic cells as described herein. For example, antibodies can be produced in bacteria, particularly when glycosylation and Fc effector functions are not required. Regarding expressing antibody fragments and polypeptides in bacteria, see, for example, U.S. Patent Nos. 5,648,237, 5,789,199 and 5,840,523. (See also Charlton, Methods in Molecular Biology, Vol. 248 (BKCLo, Humana Press, Totowa, NJ, 2003), pp. 245-254, which describes the expression of antibody fragments in Escherichia coli.) Antibodies can be separated from bacterial cell paste in a soluble fraction after expression, and can be further purified.

[0755] In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are also suitable cloning or expression hosts for vectors encoding antibodies, including fungi and yeast strains whose glycosylation pathways have been "humanized" so that antibodies with partially or fully human glycosylation patterns are produced. See Gerngross, Nat. Biotech. 22: 1409-1414 (2004), and Li et al., Nat. Biotech. 24: 210-215 (2006).

[0756] Suitable host cells for expressing glycosylated antibodies also come from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant cells and insect cells. Many baculovirus strains have been identified that can be used with insect cells, particularly for transfecting Spodoptera frugiperda cells.

[0757] Plant cell cultures can also be used as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES for producing antibodies in transgenic plants). TM technology).

[0758] Vertebrate cells can also be used as hosts. For example, mammalian cell lines adapted to growth in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells, as described, e.g., in Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse Sertoli cells (TM4 cells, as described, e.g., in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK); Buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor cells (MMT 060562); TRI cells (as described, e.g., in Mather et al., Annals of NY Acad. Sci. 383: 44-68 (1982)); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, which include DHFR – CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines, such as Y0, NS0 and Sp2 / 0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKCLo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003).

[0759] V. Treatment Methods and Uses

[0760] Pharmaceutical compositions comprising the anti-CD20 / anti-CD3 bispecific antibodies described herein can be formulated for use as medicaments for treating various diseases and disorders. Accordingly, the invention features methods of intravenously administering a pharmaceutical composition to a subject in need thereof (e.g., a subject suffering from a disease or disorder such as cancer). The pharmaceutical compositions of the invention can be used to treat or delay the progression of a cell proliferative disorder in a subject in need thereof (e.g., a human subject in need thereof), or to enhance immune function in a subject suffering from a cell proliferative disorder (e.g., cancer).

[0761] In one aspect, the present invention provides a pharmaceutical composition as described herein for use in treating a cell proliferative disorder or delaying its progression. In one aspect, the present invention provides the use of a pharmaceutical composition as described herein in the manufacture of a medicament for treating a cell proliferative disorder or delaying its progression. In one aspect, the present invention provides a method of treating a cell proliferative disorder or delaying its progression in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition as described herein.

[0762] In some embodiments, the cell proliferative disorder is a cancer of non-Hodgkin lymphoma (NHL). In some embodiments, NHL is selected from the group consisting of non-Hodgkin lymphoma (NHL), chronic lymphatic leukemia (CLL), B-cell lymphoma, splenic diffuse red pulp small B-cell lymphoma, B-cell lymphoma with characteristics between diffuse large B-cell lymphoma and Burkitt's lymphoma, Burkitt-like lymphoma with 11q aberration, B-cell lymphoma with characteristics between diffuse large B-cell lymphoma and classical Hodgkin's lymphoma, germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL), Activated B-cell-like (ABC) DLBCL, primary cutaneous follicle center lymphoma, T-cell / histiocyte-rich large B-cell lymphoma, primary DLBCL of the central nervous system, primary cutaneous DLBCL (leg type), Epstein-Barr virus (EBV)-positive DLBCL in the elderly, DLBCL associated with chronic inflammation, primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, large B-cell lymphoma caused by HHV8-related multicentric Castleman disease B-cell lymphoma, B-cell leukemia, breast cancer, colorectal cancer, non-small cell lung cancer, multiple myeloma, kidney cancer, prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, mesothelioma, glioblastoma, follicular lymphoma (FL), follicular neoplasia in situ, mantle cell lymphoma (MCL), mantle cell neoplasia in situ, acute myeloid leukemia (AML), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), central nervous system lymphoma (CNSL), Burkitt lymphoma (BL), B-cell prolymphocytic leukemia, splenic marginal zone lymphoma, hairy cell leukemia, splenic lymphoma / leukemia, variant hairy cell leukemia, alpha heavy chain disease, gamma heavy chain disease, mu heavy chain disease, plasma cell myeloma, solitary plasmacytoma of bone, extraosseous plasmacytoma, extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), nodular marginal zone lymphoma, pediatric lymph node marginal zone lymphoma, pediatric follicular lymphoma, lymphomatoid granulomatosis, plasmablastic lymphoma, and primary effusion lymphoma. In specific embodiments, the cancer is germinal center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom's macroglobulinemia (WM), central nervous system lymphoma (CNSL), or Burkitt's lymphoma (BL).

[0763] In some embodiments, the cancer is selected from the group consisting of breast cancer, colorectal cancer, non-small cell lung cancer (NSCLC), multiple myeloma, renal cancer, prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, mesothelioma, and glioblastoma.

[0764] The anti-CD20 / anti-CD3 bispecific antibody can be formulated for administration to a subject at a dose of 0.5 mg, 2.5 mg, 10 mg, or 30 mg.

[0765] For all methods and pharmaceutical formulations described herein, the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) will be formulated, dosed, and administered in a manner consistent with good medical practice. Factors to be considered in this context include the specific disorder being treated, the specific mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the timing of administration, and other factors known to practitioners. The anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) need not be one or more agents currently used to prevent or treat the disorder in question, but is optionally formulated with these agents. The effective amount of such other agents depends on the amount of the anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab) present in the formulation, the type of disorder or treatment, and other factors discussed above. An anti-CD20 / anti-CD3 bispecific antibody (eg, an anti-CD20 / anti-CD3 TCB such as Gefituzumab) can be appropriately administered to a patient over a range of treatments.

[0766] VI. Products

[0767] In another aspect of the present invention, a product is provided, which contains a substance that can be used to treat, prevent and / or diagnose the above-mentioned diseases. The product includes a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, intravenous (IV) solution bags, etc. The container can be formed of a variety of materials such as glass or plastic. The container holds a pharmaceutical composition, which can effectively treat, prevent and / or diagnose the disease by itself or in combination with another composition, and the container can have a sterile access port (for example, the container can be an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic injection needle). As described herein, at least one active agent in the composition is an anti-CD20 / anti-CD3 bispecific antibody (e.g., anti-CD20 / anti-CD3 TCB, such as Gefituzumab). The label or package insert indicates that the composition is used to treat a selected disease (e.g., cancer), and further includes information related to at least one of the dosing regimens described herein.

[0768] The pharmaceutical composition can be supplied in a container having a volume of 1 ml to 100 ml, for example, 1 ml to 5 ml, 5 ml to 10 ml, 10 ml to 15 ml, 15 ml to 20 ml, 20 ml to 25 ml, 25 ml to 30 ml, 30 ml to 40 ml, 40 ml to 50 ml, 50 ml to 60 ml, 60 ml to 70 ml, 70 ml to 80 ml, 80 ml to 90 ml or 90 ml to 100 ml, for example about 5 ml, about 10 ml, about 15 ml, about 20 ml, about 25 ml, about 30 ml, about 40 ml, about 50 ml, about 60 ml, about 70 ml, about 80 ml, about 90 ml or about 100 ml.

[0769] In some embodiments, the container is a stainless steel container or a nickel steel alloy container (e.g., ), such as a box, a small box, a can, a jar, etc. In some cases, the pharmaceutical composition in such a container is a drug substance (DS), which can be further diluted before use, such as diluted into a drug product (DP) (e.g., in a final vial configuration). Alternatively, the pharmaceutical composition in the container is a DP. In some embodiments, the DP is in a container, such as an IV bag or a syringe (e.g., for delivery via a syringe pump).

[0770] In some embodiments, the article comprises a vial having a volume of about 1 ml or more, such as about 1 ml, about 2 ml, about 3 ml, about 4 ml, about 5 ml, about 6 ml, about 7 ml, about 8 ml, about 9 ml, about 10 ml, about 11 ml, about 12 ml, about 13 ml, about 14 ml, about 15 ml, about 16 ml, about 17 ml, about 18 ml, about 19 ml, about 20 ml, about 25 ml, about 30 ml, about 35 ml, about 40 ml, about 50 ml or more. In some embodiments, the container is a vial having a volume of about 10 ml. In some embodiments, the vial is disposable. In some embodiments, the vial contains about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg or more of an anti-CD20 / anti-CD3 bispecific antibody (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab). In some embodiments, the container closure system comprises one or more or all of a glass vial, a stopper, and a cap.

[0771] In addition, the article of manufacture may include (a) a first container containing a composition, wherein the pharmaceutical composition comprises an anti-CD20 / anti-CD3 bispecific antibody described herein (e.g., an anti-CD20 / anti-CD3 TCB, such as Gefituzumab); and (b) a second container containing a pharmaceutical composition, wherein the pharmaceutical composition comprises a further cytotoxic agent or other therapeutic agent. Alternatively or in addition, the article of manufacture may further include a second (or third) container containing a pharmaceutical buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution. It may also include other materials desired from a commercial and user perspective, including other buffers, diluents, filters, needles, and syringes.

[0772] Another aspect of the present invention relates to the invention as described above.

[0773] Example

[0774] Some embodiments of the technology described herein may be defined according to any of the following numbered embodiments:

[0775] 1. A liquid pharmaceutical composition comprising:

[0776] about 1 mg / ml to 25 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody;

[0777] about 10 mM to 50 mM buffer;

[0778] Tonicity agent of about ≥200 mM;

[0779] about 0 mM to 15 mM methionine; and

[0780] About ≥0.2mg / ml surfactant

[0781] The pH is in the range of about 5.0 to about 6.0,

[0782] Wherein the anti-CD20 / anti-CD3 bispecific antibody comprises:

[0783] a) at least one antigen binding domain that specifically binds to CD20, comprising:

[0784] A heavy chain variable region comprising:

[0785] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;

[0786] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and

[0787] (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3;

[0788] and a light chain variable region comprising:

[0789] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4;

[0790] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and

[0791] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and b) at least one antigen binding domain that specifically binds to CD3 comprising:

[0792] A heavy chain variable region comprising:

[0793] (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9;

[0794] (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and

[0795] (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 11; and a light chain variable region comprising:

[0796] (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;

[0797] (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and

[0798] (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14.

[0799] II. The liquid pharmaceutical composition according to embodiment I, wherein the concentration of the anti-CD20 / anti-CD3 bispecific antibody is in the range of about 1 mg / ml to 5 mg / ml.

[0800] III. The liquid pharmaceutical composition according to any one of the preceding embodiments, wherein the concentration of the anti-CD20 / anti-CD3 bispecific antibody is in the range of about 0.9 mg / ml to 1.1 mg / ml.

[0801] IV. The liquid pharmaceutical composition according to any one of the preceding embodiments, wherein the concentration of the anti-CD20 / anti-CD3 bispecific antibody is about 1 mg / ml.

[0802] V. A liquid pharmaceutical composition according to any one of the preceding embodiments, wherein the anti-CD20 /

[0803] Anti-CD3 bispecific antibodies include:

[0804] a) at least one antigen binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8; and

[0805] b) at least one antigen binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence of SEQ ID NO: 15 and a light chain variable region sequence of SEQ ID NO: 16.

[0806] VI. The liquid pharmaceutical composition according to any one of the preceding embodiments, wherein the anti-CD20 / anti-CD3 bispecific antibody comprises:

[0807] a) a first Fab molecule, which specifically binds to CD3, in particular CD3ε; and wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced with each other;

[0808] b) a second Fab molecule and a third Fab molecule, which specifically binds to CD20, wherein in the constant domain CL of the second Fab molecule and the third Fab molecule, the amino acid at position 124 is substituted by lysine (K) (according to Kabat numbering), and the amino acid at position 123 is substituted by lysine (K) or arginine (R), in particular by arginine (R) (according to Kabat numbering), and wherein in the constant domain CH1 of the second Fab molecule and the third Fab molecule, the amino acid at position 147 is substituted by glutamic acid (E) (EU numbering), and the amino acid at position 213 is substituted by glutamic acid (E) (EU numbering); and

[0809] c) c) an Fc domain, which is composed of a first subunit and a second subunit capable of stably associating. VII. The liquid pharmaceutical composition according to any one of the preceding embodiments, wherein the anti-CD20 / anti-CD3 bispecific antibody is Gefituzumab.

[0810] VIII. The liquid pharmaceutical composition according to any one of the preceding embodiments, wherein the buffer is a histidine buffer, optionally a histidine HCl buffer.

[0811] IX. The liquid pharmaceutical composition according to any one of the preceding embodiments, wherein the concentration of the buffer is about 15 mM to 25 mM.

[0812] X. The liquid pharmaceutical composition according to any one of the preceding embodiments, wherein the concentration of the buffer is about 20 mM.

[0813] XI. The liquid pharmaceutical composition according to any one of the preceding embodiments, wherein the buffer provides a pH of about 5.2 to about 5.8.

[0814] XII. The liquid pharmaceutical composition according to any one of the preceding embodiments, wherein the tonicity agent is selected from the group consisting of salts, sugars and amino acids.

[0815] XIII. The liquid pharmaceutical composition according to embodiment XII, wherein the tonicity agent is sucrose or sodium chloride.

[0816] XIV. The liquid pharmaceutical composition of embodiment XIII, wherein the tonicity agent is sucrose at a concentration of about 200 mM or greater.

[0817] XV. The liquid pharmaceutical composition of embodiment XIII or XIV, wherein the tonicity agent is sucrose at a concentration of about 200 mM to 280 mM.

[0818] XVI. The liquid pharmaceutical composition of any one of embodiments XIII to XV, wherein the tonicity agent is sucrose at a concentration of about 240 mM.

[0819] XVII. The liquid pharmaceutical composition according to any one of the preceding embodiments, wherein the concentration of methionine is about 5 mM to 15 mM.

[0820] XVIII. The liquid pharmaceutical composition according to embodiment XVII, wherein the concentration of methionine is about 10 mM.

[0821] XIX. The liquid pharmaceutical composition according to any one of the preceding embodiments, wherein the concentration of the surfactant is about 0.2 mg / ml to 0.8 mg / ml.

[0822] XX. The liquid pharmaceutical composition according to any one of the preceding embodiments, wherein the surfactant is polysorbate 20 or poloxamer 188.

[0823] XXI. The liquid pharmaceutical composition of embodiment XX, wherein the surfactant is polysorbate 20 at a concentration of 0.2 mg / ml to 0.8 mg / ml.

[0824] XXII. The liquid pharmaceutical composition of embodiment XXI, wherein the surfactant is polysorbate 20 at a concentration of about 0.5 mg / ml.

[0825] XXIII. A liquid pharmaceutical composition according to any one of the preceding embodiments, comprising:

[0826] about 1 mg / ml to 5 mg / ml of the anti-CD20 / anti-CD3 bispecific antibody;

[0827] About 15 mM to 25 mM histidine buffer;

[0828] about 200mM to 280mM sucrose;

[0829] about 0 mM to 15 mM methionine; and

[0830] About 0.2mg / ml to 0.8mg / ml of PS20,

[0831] The pH is from about 5 to about 6.

[0832] XXIV. A liquid pharmaceutical composition according to any one of the preceding embodiments, comprising:

[0833] About 1 mg / ml of Gefituzumab;

[0834] About 20 mM histidine buffer;

[0835] About 240 mM sucrose;

[0836] about 10 mM methionine; and

[0837] About 0.5mg / ml of PS20,

[0838] The pH was about 5.5.

[0839] XXV. Use of the liquid pharmaceutical composition according to any one of the preceding embodiments for the preparation of a medicament useful for treating a cell proliferative disorder.

[0840] XXVI. The pharmaceutical composition of any one of embodiments I to XXIV, for use in treating or delaying progression of a cell proliferative disorder in a subject in need thereof.

[0841] XXVII. A method of treating or delaying progression of a cell proliferative disorder in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of any one of Examples I to XXIV.

[0842] XXVIII. The use, liquid pharmaceutical composition for use, or method according to any one of embodiments XXV to XXVII, wherein the cell proliferative disorder is cancer.

[0843] XXIX. The present invention as hereinbefore described.

[0844] Examples

[0845] The following are examples of methods and compositions of the invention. It is understood that various other embodiments may be practiced given the general description provided above.

[0846] Example 1: Computer analysis of Gefituzumab

[0847] RO7082859 / gefitomab is a T cell bispecific humanized monoclonal antibody (TCB) that binds to human CD20 on tumor cells and to the human CD3ε subunit (CD3ε) of the T cell receptor complex (TCR) on T cells. It consists of two different heavy chains and two different light chains. Point mutations in the CH3 domain ("knob-in-hole structure") promote the assembly of two different heavy chains. The exchange of VH and VL domains in CD3-binding Fab ("CrossMab approach") and point mutations in the CH and CL domains in CD20-binding Fab ("charged variants") promote the correct assembly of two different light chains with the corresponding heavy chains. The "knob-in-hole structure" mutation consists of amino acid exchanges Y349C, T366S, L368A and Y407V in the heavy chain HC1 and amino acid exchanges S354C and T366W in the heavy chain HC2 (Kabat EU index numbering). The "charged variant" mutations consist of the amino acid exchanges E123R and Q124K (Kabat numbering) in the light chain LC2 and K147E and K213E (Kabat EU index numbering) in the heavy chains HC1 and HC2.

[0848] Binding to human CD20 occurs with high affinity and in a bivalent binding mode, while binding to CD3ε is monovalent and low affinity. RO7082859 is a human IgG1 with a modification ("PG LALA" mutation) in its Fc region that abolishes its binding to Fcγ receptors (FcγRs) in vitro and prevents FcγR-mediated co-activation of innate immune effector cells (including natural killer (NK) cells, monocytes / macrophages and neutrophils) without altering its functional binding to FcRn (neonatal Fc receptor). The "PG LALA" mutation consists of the amino acid exchanges P329G, L234A and L235A in the heavy chain HC1 and heavy chain HC2 ("PG LALA", Kabat EU index number).

[0849] The recombinant antibodies are produced in CHO cells and consist of two heavy chains (449 and 674 amino acid residues, respectively) and three light chains (232 and 219 (two copies) amino acid residues, respectively), arranged in an asymmetric configuration, e.g. Figure 2 shown.

[0850] Hot Events Summary

[0851] For the CD3-binding portion of the molecule, computer predictions indicated the presence of two degradation-prone Asn residues and one exposed Trp residue in the heavy chain CDR3. In stress experiments over 14 days, no major changes in target binding activity were observed after incubation at pH 6.0, but a strong loss of target binding activity was observed after incubation at physiological pH (PBS pH 7.4, data not shown).

[0852] Example 2: Gefituzumab formulation development GLP Tox and entry into human studies

[0853] Screening was performed according to the schedule shown in Table 4. During the screening period, the formulations were exposed to the following conditions: 3-week and 6-week storage (at 5°C, 25°C, and 40°C), 1 week of shaking at 5°C and 25°C, and freeze / thaw (F / T) stress (5 cycles). The designated formulations were then followed for up to 52 weeks.

[0854] Table 4: Adaptive platform screening study design with formulation code

[0855]

[0856] After 6 weeks of storage at 5°C, 25°C and 40°C, all formulations remained without significant changes in most of the physical properties tested (i.e., visible and microscopic particles, color, turbidity, pH and protein content). CE-SDS (capillary electrophoresis sodium dodecyl sulfate) data is not shown as it is not critical for the designation.

[0857] Visible particle analysis by the Seidenader method showed that no visible particles were formed by any of the formulations under all storage conditions. The microscopic particle counts were low (not shown). Under mechanical stress conditions, F2-F5 showed many particles at both 5°C and 25°C. F1 was particle free in both cases. Using EP and Optima, all compositions were virtually particle free (0 particles) except for F3 and F4 (both containing P188) which showed particles but below the limit (not shown). Under shaking at 5°C, the microscopic particles in F3 (P188+Met) were significantly worse than those in F4 (P188), with all other formulations having similar counts in each condition (not shown).

[0858] After 6 weeks, turbidity and color of all formulations showed no significant changes under all conditions. Surfactant content was stable at 5°C and 25°C, and for two formulations containing P188 (F3, F4), it was also stable at 40°C. For all active formulations containing PS20 (F1, F2 and F5), regardless of whether the formulation contained methionine or not, a loss of surfactant content was observed at 40°C.

[0859] The beneficial effect of methionine was only seen in the placebo formulation containing PS20, where only the PS content of P2 decreased at 40 °C ( Figure 3 ). Biochemical characterization revealed differences in the formulations only after storage at 40°C.

[0860] In size exclusion chromatography (SEC), the loss of monomers was more pronounced in F2 and F5, correlating with an increase in the HMW (high molecular weight) area. A new HMW species could be seen to emerge, only slightly larger in F3 and F4, stronger in F1, and predominant in F2 and F5. The LMW (low molecular weight) species was found to increase at approximately the same rate in all formulations ( Figure 4 A similar trend can be observed in ion exchange chromatography (IEC), with an overall increase in the basic peak area, and the increase in the acidic peak area is more obvious in F2 and F5 ( Figure 5 ).

[0861] Taken together, the data clearly exclude F2 and F5 and show that F1, F3, and F4 are equally stable, with no clear preference for any of the three. Designated F1 (5 mg / ml Gefitumab, 20 mM histidine / histidine HCl, pH 5.5, 240 mM sucrose, 10 mM methionine, 0.05% (w / v) PS20). A summary of all analytical results for F1 can be found at Figure 6 Found in.

[0862] Example 3: GLP Tox / Entry into Human Studies

[0863] pass Combination

[0864] The above purity results are also reflected in the loss of CD20 binding in F2 and F5 at 40°C, as well as the strong loss of CD3 binding in these preparations, up to 50%, compared to losses of between 10% and 20% in the remaining preparations ( Figure 7 A and Figure 7 B).

[0865] Example 4: Phase III and commercial formulation development studies

[0866] This example provides an overview of the drug development of a Gefituzumab formulation. As a result of this development, the Gefituzumab drug product is provided as a sterile liquid concentrate of a solution for IV infusion. The drug is composed of 1 mg / ml Gefituzumab dissolved in 20 mM L-histidine / L-histidine hydrochloride (HCl) buffer, 240 mM sucrose, 10 mM L-methionine, 0.5 mg / ml polysorbate 20 (pH 5.5). Gefituzumab is the only active ingredient in the drug substance and drug. Formulation development studies have confirmed that the dosage form and formulation are suitable for the intended use. The formulation is strong enough to ensure that the drug is stable during manufacture, storage, transportation and administration.

[0867] Formulations with higher protein concentrations (e.g., 5, 25, or 50 mg / ml Gefitumab) were tested but were not continued due to PS20 degradation leading to microscopic and visible particle formation. The release levels of free fatty acids (lauric and myristic acids) increased with increasing protein concentration, confirming that the underlying cause of microscopic and visible particle formation was due to hydrolytic PS20 degradation.

[0868] The liquid dosage form was chosen to allow for few handling steps while ensuring product quality during manufacturing and at the end of the drug product's shelf life.

[0869] The Gefituzumab drug product will be commercially available in two strengths provided in two vial configurations: 2.5 mg / vial in a 6-ml single-use glass vial and 10 mg / vial in a 15-ml single-use glass vial to match the required clinical doses of 2.5 mg, 10 mg and 30 mg while minimizing product waste. For the commercial drug product formulation, the concentration of Gefituzumab was reduced to 1 mg / ml while keeping the excipient composition unchanged.

[0870] Formulation development studies provide the basis for selecting the appropriate dosage form, protein concentration, surfactant concentration, buffer type, solution pH, stabilizers, tonicity agents, and vial configuration of the drug product. Drug substance formulations are optimized to account for facility formulation, dilution, and storage considerations.

[0871] Choice of dosage form

[0872] Liquid dosage forms are selected to provide a concentrate for solution for infusion that requires few processing steps while ensuring product quality during manufacturing and at the end of the drug product's shelf life.

[0873] Choice of protein concentration

[0874] A protein concentration of 5 mg / ml was selected for Phase I and retained through Phase III. A protein concentration of 1 mg / ml was subsequently selected as the commercial formulation based on formulation development studies and updated clinical dose requirements.

[0875] Formulations (pH 5.5) containing 20 mM L-histidine / L-histidine hydrochloride, 10 mM L-methionine, 240 mM D-sucrose and 0.5 mg / ml polysorbate 20 (PS20) were stability tested at 1 mg / ml, 5 mg / ml and 25 mg / ml of Gefituzumab concentrations to prepare protein concentrations to suit clinical needs. These formulations were evaluated by SE-HPLC and IE-HPLC for Gefituzumab purity, PS20 content and visible / microscopic particle formation at the initial time point (T0), several intermediate time points and at the end of the study after 104 weeks of storage at 2°C-8°C.

[0876] Purity by SE-HPLC and IE-HPLC was comparable between the 1 mg / ml and 5 mg / ml formulations throughout the study ( Figure 8 A and Figure 8 B). Microscopic particle counts were also comparable. In addition, the 1 mg / ml formulation showed no PS20 degradation beyond the method variability compared to the 5 mg / ml and 25 mg / ml formulations ( Fig.12 , see also below, Assessment of Polysorbate 20 Degradation). Based on these results and the updated clinical dosing regimen of 2.5 mg, 10 mg, and 30 mg, the 1 mg / ml formulation was selected as the commercial formulation.

[0877] A concentration range of 0.9 mg / ml to 1.1 mg / ml protein was further evaluated in a subsequent multivariate formulation robustness study (see Example 5, Formulation Robustness Study). This study demonstrated acceptable stability behavior within this concentration range.

[0878] Choice of pH, buffer, stabilizer and tonicity agent

[0879] Based on formulation development studies, a 20 mM L-histidine / L-histidine hydrochloride solution at pH 5.5 was selected as the buffer in combination with 10 mM L-methionine as a stabilizer and 240 mM D-sucrose as a tonicity agent for Phase I and reserved for Phase III and commercial formulations.

[0880] Studies were conducted at 5 mg / ml Gefitumab to test 20 mM L-histidine / L-histidine hydrochloride buffers at pH ranges from 5.5 to 6.0, and L-methionine levels of 0 mM and 10 mM. In addition, a comparison between 240 mM D-sucrose and 130 mM sodium chloride was performed.

[0881] The influence of pH and stabilizers was evaluated by SE-HPLC and IE-HPLC to assess the purity of Gefituzumab and visible / microscopic particle formation at the initial time point (T0) and after 6 weeks of storage at 40°C. The selection of tonicity agents was assessed by measuring SE-HPLC, IE-HPLC, and determining visible / microscopic particle formation at the initial time point (T0) and after 26 weeks of storage at 25°C. The combination of 20 mM L-histidine / L-histidine hydrochloride buffer at pH 5.5 and 10 mM L-methionine showed the lowest formation of high molecular weight substances (HMWS) compared to the corresponding formulation without added stabilizer or the combination of 20 mM L-histidine / L-histidine hydrochloride buffer at pH 6 / 10 mM L-methionine. Fig. 9 A) and changes in charge variants ( Fig. 9 B) A concentration of 20 mM L-histidine / L-histidine hydrochloride monohydrate was demonstrated to be sufficient to maintain formulation pH during manufacture of the drug product and during storage of the drug substance and drug product.

[0882] Based on the comparison between 240 mM D-sucrose and 130 mM sodium chloride, 240 mM D-sucrose was selected. Microscopic particle counts were comparable between formulations. No visible particle formation was observed for formulations containing D-sucrose after 26 weeks of storage at 25°C, while visible particles were observed for formulations containing NaCl ( Fig.10 ).

[0883] Choice of surfactant

[0884] Based on the results of the stability study, PS20 at a concentration of 0.5 mg / ml was selected for Phase I and retained for commercial preparation. A study was conducted with 50 mg / ml Gefitumab in a 20 mM L-histidine / L-histidine hydrochloride buffer at pH 5.5 containing 10 mM L-methionine and 240 mM D-sucrose to study the stabilizing effect of poloxamer 188 (P188) relative to PS20. P188 was tested at 0.5 mg / ml, 0.7 mg / ml, and 1.0 mg / ml levels; PS20 was tested at 0.1 mg / ml, 0.3 mg / ml, and 0.5 mg / ml levels.

[0885] The effect of added surfactant was evaluated by assessing the purity of Gefituzumab by SE-HPLC and IE-HPLC as well as visible / microscopic particle formation at the initial time point (T0) and after 7 days of shaking at 25°C.

[0886] Visible particle formation was observed for all P188 concentrations. Therefore, it was excluded as a suitable surfactant for Gefituzumab ( Fig.11After shaking at 25°C for 7 days, no visible particles were detected in the formulation containing PS20 ( Fig.11 A significant increase in HMWS and charge variants was observed for the formulation containing 0.1 mg / ml PS20, while a slight increase in the levels of HMWS and charge variants was observed for the formulation containing 0.3 mg / ml PS20 after 7 days of shaking at 25°C compared to the formulation containing 0.5 mg / ml PS20 ( Fig.11 ). The microscopic particle counts were comparable at different PS20 concentrations. A significant increase in HMWS and charge variants was observed for the formulation containing 0.1 mg / ml PS20, while a slight increase in the levels of HMWS and charge variants was observed for the formulation containing 0.3 mg / ml PS20 after 7 days of shaking at 25°C compared to the formulation containing 0.5 mg / ml PS20 ( Fig.11 ). Therefore, a formulation containing 0.5 mg / ml PS20 was selected. The polysorbate 20 level of 0.5 mg / ml was shown to be sufficient to protect Gefitumab from stresses that may occur during processing (e.g., stirring, freezing and thawing or shear stress), handling, storage and transportation. The concentration range of 0.2 mg / ml to 0.8 mg / ml PS20 was further evaluated in a subsequent multivariate formulation robustness study (see Example 5, formulation robustness study). The study confirmed acceptable stability behavior within this concentration range.

[0887] Example 5: Formulation Robustness Study

[0888] The composition of drug substances and drug products can vary within a range based on manufacturing factors such as weighing tolerances of buffer components. A multivariate formulation robustness study was performed and showed that the relevant quality attributes (QAs) of Gefituzumab were acceptable at the edges of these composition ranges. A two-level multivariate stability study was performed for three factors that were identified as having potential impact on the critical quality attributes (CQAs) during storage of the drug product. The following three formulation parameters were evaluated:

[0889] 1. Protein Concentration

[0890] 2. pH

[0891] 3.PS20 concentration

[0892] In addition, three formulation parameters were evaluated separately in the univariate stability study:

[0893] 4. Buffer strength

[0894] 5. L-methionine concentration

[0895] 6. D-sucrose concentration

[0896] The multivariate formulation robustness study demonstrated that the relevant CQAs of gefuzumab were acceptable across the entire range of claimed formulation compositions.

[0897] Study Design

[0898] A risk assessment was performed to identify formulation parameters in drug substances and drug products that are important to maintain product quality during shelf life. Multivariate and univariate studies were established accordingly.

[0899] Multivariate studies (F6 to F12)

[0900] A two-level fractional factorial design (resolution III) stability study was performed using the three identified formulation parameters protein concentration, pH and PS20 concentration as input factors.

[0901] Univariate studies (F13 to F20)

[0902] L-methionine and D-sucrose concentrations (low and high levels) as well as buffering strengths (low and high levels) were tested.

[0903] One formulation with low protein concentration, low pH and low PS20 concentration was evaluated as a direct comparison to a corresponding formulation with high pH, ​​high protein concentration and high PS20 concentration.

[0904] One formulation with a PS20 concentration of 0.3 mg / ml was included to support acceptance criteria setting.

[0905] The formulation parameter ranges tested were defined to cover the drug product specification acceptance criteria and / or manufacturing acceptable ranges as described in Table 5. Table 6 shows the design plan consisting of 15 experiments with 3 center points, where the 3 center points corresponded to the target commercial formulation compositions.

[0906] Table 5: Formulation robustness studies: target formulation and multivariate and univariate study ranges

[0907] Target Lower level upper layer Gefitumab concentration (mg / ml) Mab 1 0.9 1.1 L-Histidine / L-Histidine hydrochloride (mM) His 20 15 25 pH pH 5.5 5.0 6.0 PS20 concentration (mg / ml) PS20 0.5 0.2(0.3) 0.8 D-sucrose concentration (mM) sucrose 240 200 280 L-Methionine concentration (mM) Met 10 5 15

[0908] Table 6: Formulation robustness study design plan: Gefituzumab formulations evaluated

[0909]

[0910] The stability of Gefituzumab in the formulation compositions described in Table 6 was evaluated as follows:

[0911] Stability study:

[0912] oStorage conditions: real-time (2°C-8°C) and accelerated (25°C)

[0913] oTest frequency: 0, 4, 13, 26 (end of storage at 25°C), 39, 52, 78 and 104 weeks under the above storage conditions

[0914] Stress test:

[0915] o 5 freeze-thaw cycles,

[0916] o Oscillate at 2℃-8℃ for one week and at 25℃ for one week

[0917] Stability of DS supported: QA evaluated at 0, 26, 52 and 104 weeks storage at -40°C:

[0918] o HMWS (high molecular weight substances) and main peaks of SE-HPLC

[0919] o LMWS (low molecular weight substances) and main peaks of non-reduced CE-SDS,

[0920] o Acidic peaks 2 and 3, acidic region, basic region and main peak by IE-HPLC

[0921] o Protein content by UV-Vis spectroscopy

[0922] o Polysorbate 20 content by HPLC-ELSD

[0923] o L-methionine and L-histidine concentrations by RP-HPLC

[0924] ο Oxidation and isomerization by peptide mapping (LC-MS)

[0925] οBiological assay efficacy

[0926] οVisible particles

[0927] οParticles visible only under a microscope

[0928] οColor, clarity / opalescence

[0929] οpH

[0930] οOsmotic pressure

[0931] ο Density

[0932] Overall data analysis process

[0933] Collect data on all quality attributes of each formulation over time. Evaluate the relative change of each QA over time.

[0934] Multivariate studies:

[0935] Simple linear regressions were fitted to each quality attribute and each formulation over time. Therefore, the degradation rate of each quality attribute and each formulation was calculated. If not explicitly mentioned, the degradation rate was reported as weekly degradation. These degradation rates were evaluated as responses in the experimental design (DoE) study, and the effects of protein concentration, pH and PS20 concentration on these degradations of the three parameters were studied. If the quality attribute did not show meaningful changes over time compared to the target formulation, regression analysis and effect estimation were not performed. For quality attributes that show meaningful changes over time, linear regression was used to estimate the main effects of the three factors on the degradation rate. In addition, main effect plots were also shown to illustrate these effects graphically.

[0936] Univariate studies:

[0937] For parameters tested in univariate studies, results after 39 weeks of storage at 2°C-8°C were evaluated compared to T0 to identify potential changes. If changes were identified, degradation rates were calculated and compared to the degradation of the target formulation in order to estimate the impact of the formulation parameter studied at the margin. In some cases, weekly degradation rates were converted to observed degradation over 104 weeks by multiplying them by a factor of 104. Regression analysis was performed using SAS Institute (SAS Institute, Cary, NC, version 10.0 or higher).

[0938] Stability of robust formulations under recommended storage conditions (2°C-8°C):

[0939] An overview of the evaluation of relative changes compared to the target formulation after storage at 2°C-8°C for 39 weeks is provided in Table 7. For all formulations (F8, F9, F20) formulated at pH 6, increased acidic variant levels (acidic zone and acidic peak 2 by IE-HPLC) were observed. The corresponding reduction in the main IE-HPLC peak in the affected formulations reflects the observed increase in acidic variants. After storage at 2°C-8°C for 39 weeks, no changes were observed for all other CQAs for all other formulations. In summary, pH was identified as a key formulation parameter. All other formulation parameters protein content, PS20, L-methionine and D-sucrose concentrations, and buffer strength did not show an effect on the CQAs tested within the scope of the study.

[0940] Stability of robust formulations under accelerated storage conditions (25°C):

[0941] Compared to the 2°C-8°C data, increased levels of acidic variation due to deamidation (acidic zone and acidic peak 2 by IE-HPLC) were observed for all formulations (F8, F9, F20) formulated at pH 6, which was reflected in the reduction of the IE-HPLC main peak in the affected formulations. In addition, for F1 and F2 formulated at pH 5, increased levels of fragmentation were observed by increasing LMWS by CE-SDS. This increase was reflected in the reduction of the CE-SDS main peak. After 26 weeks of storage at 25°C, no changes were observed for any other CQA for all other formulations.

[0942] In summary, the 25°C data confirms that pH is a critical formulation parameter. All other formulation parameters showed no impact on CQAs.

[0943] Table 7: Relative changes of relevant CQAs after 39 weeks storage at 2°C-8°C

[0944]

[0945]

[0946] a Measurements were taken at t=0 and at the end of the study after 104 weeks.

[0947] b Measurements were performed only at t=0 and after 52 and 104 weeks of storage at 2°C-8°C.

[0948] Stability of the robust formulation at recommended drug substance storage conditions (-40°C):

[0949] To support the stability of the drug substance across the range of claimed formulation compositions, a stability study was conducted on a robust formulation of the drug product stored at -40°C. The study results demonstrated that no significant changes in the tested quality attributes were observed when the formulation was stored at the recommended drug substance storage condition of -40°C for 26 weeks.

[0950] Stability of robust formulations after shaking and freeze / thaw stress:

[0951] The formulations were shaken for one week at 2° C.-8° C. or 25° C. Additionally, the formulations were evaluated after five freeze / thaw cycles between -40° C. and 5° C. All samples contained almost no visible particles under shaking or freeze / thaw stress.

[0952] For all formulations, there was no change in microscopic particles upon shaking and freeze / thaw stress. Compared to all other formulations containing 0.3 mg / ml to 0.8 mg / ml PS20 levels, formulations with low PS20 content (0.2 mg / ml, F7, F8, F13) did not show any product quality impact after shaking and freeze / thaw stress.

[0953] The results confirm that polysorbate 20 levels of ≥ 0.2 mg / ml are sufficient to protect proteins from shaking and freezing / thawing stress. In contrast, compared with all other formulations containing 240-280 mM D-sucrose levels, formulations with low D-sucrose content (200 mM, F19) did not show any product quality impact after shaking and freezing / thawing stress. The results confirm that levels of ≥ 200 mM D-sucrose are sufficient to protect proteins from freezing / thawing stress. Compared with the control sample, no substantial changes in any other quality attributes were observed under shaking or freezing / thawing stress.

[0954] Linear regression analysis of identified CQAs based on data under recommended storage conditions (2°C-8°C):

[0955] A simple linear regression analysis was performed on the affected CQAs: solution pH, protein concentration and PS20 concentration. pH was identified as having a major effect. The degradation rates calculated weekly were extrapolated to the end of shelf life (EoS) by multiplying by 104 weeks (=24 months). The results of the extrapolation are summarized in Table 8.

[0956] Linear regression analysis showed that the pH range tested had no meaningful impact on the identified CQAs as all CQAs were within the stability acceptance criteria. However, to control for the increase in the acidic region, the pH acceptance criteria for drug product release were tightened to 5.2-5.8.

[0957] Table 8: Linear regression analysis results based on 2℃-8℃ data

[0958]

[0959] a All other parameters were set as the objectives of the linear regression analysis.

[0960] b Calculated as t=0 + degradation rate after 104 weeks (using the average t=0 of all formulations).

[0961] in conclusion:

[0962] Extrapolated data indicated the impact of a high pH of 6.0 on the levels of acidic variants after 24 months (the claimed shelf life of the drug product). Therefore, the pH acceptance criteria for drug product release were tightened to 5.2-5.8 to limit the formation of acidic forms during drug product stability.

[0963] The formulation is considered stable until the end of its shelf life because:

[0964] For all dosage forms at the edge of the dosage range, the CQAs met the release acceptance criteria at t=0 and after 9 months storage at 2°C-8°C

[0965] For all dosage forms at the edge of the dosage form range, the CQAs met the stability acceptance criteria when using the degradation rate extrapolated to the EoS.

[0966] Example 6: Assessment of Polysorbate 20 Degradation

[0967] Polysorbate 20 can degrade via oxidation or hydrolysis mechanisms. Hydrolytic degradation of polysorbate 20 results in the formation of free fatty acids (FFA), such as lauric acid. At certain high concentrations, FFA can form microscopic or visible particles. In addition, degradation of polysorbate 20 is also a problem if polysorbate 20 degradation results in less polysorbate in the formulation than is required to protect the protein from stirring stress.

[0968] Due to these issues, degradation of polysorbate 20 was monitored during formulation development. PS20 degradation was observed in the Gefitumab formulation during formulation development, and the extent of degradation depended on protein concentration. Significant PS20 degradation was observed for the 25 mg / ml formulation by observation of visible particles at 2°C-8°C ( Fig.12 ). For the 5mg / ml formulation, PS20 degradation was less evident, with visible particles observed after 20 months. The particle counts visible only under the microscope were not affected. Visible particles were isolated and characterized by Fourier transform infrared (FTIR) analysis, and were found to be FFA. The 1mg / ml formulation showed no PS20 degradation (beyond the method precision) and no visible particle formation throughout the 24-month study period. The particle counts visible only under the microscope were always low. Long-term stability data from nine drug product (DP) batches from four different drug substance (DS) batches confirmed the absence of visible particles. Fig.13 A visualization of the long-term stability data of an example DP batch is provided.

[0969] Example 7: Physical and chemical stability study

[0970] The Gefituzumab drug product is provided as a sterile liquid concentrate of a solution fo...

Claims

1. A liquid pharmaceutical composition comprising: about 1 mg / ml to 25 mg / ml of an anti-CD20 / anti-CD3 bispecific antibody; about 10 mM to 50 mM buffer; Tonicity agent of about ≥200 mM; about 0 mM to 15 mM methionine; and About ≥ 0.2 mg / ml of surfactant; The pH is in the range of about 5.0 to about 6.0, Wherein the anti-CD20 / anti-CD3 bispecific antibody comprises: a) at least one antigen binding domain that specifically binds to CD20, comprising: A heavy chain variable region comprising: (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and a light chain variable region comprising: (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and b) at least one antigen binding domain that specifically binds to CD3, comprising: A heavy chain variable region comprising: (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 11; and A light chain variable region comprising: (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:

14.

2. The liquid pharmaceutical composition according to claim 1, wherein the concentration of the anti-CD20 / anti-CD3 bispecific antibody is in the range of about 1 mg / ml to 5 mg / ml.

3. The liquid pharmaceutical composition according to claim 1 or 2, wherein the concentration of the anti-CD20 / anti-CD3 bispecific antibody is in the range of about 0.9 mg / ml to 1.1 mg / ml.

4. The liquid pharmaceutical composition according to any one of claims 1 to 3, wherein the concentration of the anti-CD20 / anti-CD3 bispecific antibody is about 1 mg / ml.

5. The liquid pharmaceutical composition according to any one of claims 1 to 4, wherein the anti-CD20 / anti-CD3 bispecific antibody comprises: a) at least one antigen binding domain that specifically binds to CD20, comprising a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8; and b) at least one antigen binding domain that specifically binds to CD3, comprising a heavy chain variable region sequence of SEQ ID NO: 15 and a light chain variable region sequence of SEQ ID NO:

16.

6. The liquid pharmaceutical composition according to any one of claims 1 to 5, wherein the anti-CD20 / anti-CD3 bispecific antibody comprises: a) a first Fab molecule, which specifically binds to CD3, in particular CD3ε; and wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced with each other; b) a second Fab molecule and a third Fab molecule, which specifically binds to CD20, wherein in the constant domain CL of the second Fab molecule and the third Fab molecule, the amino acid at position 124 is substituted by lysine (K) (according to Kabat numbering), and the amino acid at position 123 is substituted by lysine (K) or arginine (R), in particular by arginine (R) (according to Kabat numbering), and wherein in the constant domain CH1 of the second Fab molecule and the third Fab molecule, the amino acid at position 147 is substituted by glutamic acid (E) (EU numbering), and the amino acid at position 213 is substituted by glutamic acid (E) (EU numbering); and c) The Fc domain is composed of a first subunit and a second subunit that are capable of stable association. 7 . The liquid pharmaceutical composition according to any one of claims 1 to 6 , wherein the anti-CD20 / anti-CD3 bispecific antibody is Gefituzumab.

8. The liquid pharmaceutical composition according to any one of claims 1 to 7, wherein the buffer is a histidine buffer, optionally a histidine HCl buffer.

9. The liquid pharmaceutical composition according to any one of claims 1 to 8, wherein the concentration of the buffer is about 15 mM to 25 mM.

10. The liquid pharmaceutical composition according to any one of claims 1 to 9, wherein the concentration of the buffer is about 20 mM.

11. The liquid pharmaceutical composition according to any one of claims 1 to 10, wherein the buffer provides a pH of about 5.2 to about 5.

8.

12. The liquid pharmaceutical composition according to any one of claims 1 to 11, wherein the tonicity agent is selected from the group consisting of salts, sugars and amino acids.

13. The liquid pharmaceutical composition according to claim 12, wherein the tonicity agent is sucrose or sodium chloride.

14. The liquid pharmaceutical composition of claim 13, wherein the tonicity agent is sucrose at a concentration of about 200 mM or greater.

15. The liquid pharmaceutical composition of claim 13 or 14, wherein the tonicity agent is sucrose at a concentration of about 200 mM to 280 mM.

16. The liquid pharmaceutical composition according to any one of claims 13 to 15, wherein the tonicity agent is sucrose at a concentration of about 240 mM.

17. The liquid pharmaceutical composition according to any one of claims 1 to 16, wherein the concentration of methionine is about 5 mM to 15 mM.

18. The liquid pharmaceutical composition of claim 17, wherein the concentration of methionine is about 10 mM.

19. The liquid pharmaceutical composition according to any one of claims 1 to 18, wherein the concentration of the surfactant is about 0.2 mg / ml to 0.8 mg / ml.

20. The liquid pharmaceutical composition according to any one of claims 1 to 19, wherein the surfactant is polysorbate 20 or poloxamer 188.

21. The liquid pharmaceutical composition of claim 20, wherein the surfactant is polysorbate 20 at a concentration of 0.2 mg / ml to 0.8 mg / ml.

22. The liquid pharmaceutical composition of claim 21, wherein the surfactant is polysorbate 20 at a concentration of about 0.5 mg / ml.

23. A liquid pharmaceutical composition according to any one of claims 1 to 22, comprising: about 1 mg / ml to 5 mg / ml of the anti-CD20 / anti-CD3 bispecific antibody; About 15 mM to 25 mM histidine buffer; about 200mM to 280mM sucrose; about 0 mM to 15 mM methionine; and About 0.2mg / ml to 0.8mg / ml of PS20, The pH is from about 5 to about 6.

24. A liquid pharmaceutical composition according to any one of claims 1 to 23, comprising: About 1 mg / ml of Gefituzumab; About 20 mM histidine buffer; About 240 mM sucrose; about 10 mM methionine; and About 0.5mg / ml of PS20, The pH was about 5.

5.

25. The liquid pharmaceutical composition according to any one of claims 1 to 24, wherein the molar ratio of PS20 to the anti-CD20 / anti-CD3 bispecific antibody is less than 100.

26. The liquid pharmaceutical composition of claim 25, wherein the molar ratio of the PS20 to the anti-CD20 / anti-CD3 bispecific antibody is between 50 and 100.

27. The liquid pharmaceutical composition of claim 26, wherein the molar ratio of the PS20 to the anti-CD20 / anti-CD3 bispecific antibody is about 79.

28. Use of the liquid pharmaceutical composition according to any one of claims 1 to 27 in the preparation of a medicament useful for treating a cell proliferative disorder.

29. The liquid pharmaceutical composition according to any one of claims 1 to 27, for use in treating or delaying progression of a cell proliferative disorder in a subject in need thereof.

30. A method of treating or delaying progression of a cell proliferative disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of the liquid pharmaceutical composition of any one of claims 1 to 27.

31. The use, liquid pharmaceutical composition for use, or method according to any one of claims 28 to 30, wherein the cell proliferative disorder is cancer.

32. The invention as hereinbefore described.